Document:

EX-10.15

 Exhibit 10.15 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 PUBLIC
HEALTH SERVICE 
 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT 

FOR EXTRAMURAL-PHS CLINICAL RESEARCH 
 This
Agreement (“CRADA”) is based on the model Cooperative Research and Development Agreement (“Model CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the
National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human
Services (“HHS”). 
 This Cover Page identifies the Parties to this CRADA: 

The U.S. Department of Health and Human Services, as represented by 

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 

an Institute or Center (hereinafter referred to as the “IC”) of the 

National Institutes of Health (NIH) 

and 
 Lumena Pharmaceuticals,
Inc., 
 hereinafter referred to as the “Collaborator”, 

having offices at 2520 Meridian Parkway, Suite 400, Durham, NC 27713 

created and operating under the laws of Delaware.  
  

 
  

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 1 of 33	  	

 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT 

FOR EXTRAMURAL-PHS CLINICAL RESEARCH 
  

	Article 1.	Introduction 

 This CRADA between IC and Collaborator will be effective when signed by the Parties,
which are identified on both the Cover Page and the Signature Page. The official contacts for the Parties are identified on the Contacts Information Page. Publicly available information regarding this CRADA appears on the Summary Page. The research
and development activities that will be undertaken by IC, IC’s Grantees and Collaborator in the course of this CRADA are detailed in the Research Plan, attached as Appendix A. The staffing, funding, and materials contributions of the Parties
are set forth in Appendix B. 
  

	Article 2.	Definitions 

 The terms listed in this Article will carry the meanings indicated throughout the CRADA.
To the extent a definition of a term as provided in this Article is inconsistent with a corresponding definition in the applicable sections of either the United States Code (U.S.C.) or the Code of Federal Regulations (C.F.R.), the definition in the
U.S.C. or C.F.R. will control. 
 “Adverse Event” or “AE” means any untoward medical occurrence in a Human
Subject to whom the Test Article is administered, as defined under 21 CFR § 312.32. An AE does not necessarily have a causal relationship with the Test Article, that is, it can be any unfavorable and unintended sign (including an abnormal
laboratory finding), symptom, or disease temporally associated with the use of the Test Article, whether or not it is related to it. See FDA Good Clinical Practice Guideline (International Conference on Harmonisation (ICH) E6: “Good Clinical
Practice: Consolidated Guidance, 62 Federal Register 25, 691 (1997)). 
 “Affiliate” means any corporation or other
business entity controlled by, controlling, or under common control with Collaborator at any time during the term of the CRADA. For this purpose, “control” means direct or indirect beneficial ownership of at least fifty percent
(50%) of the voting stock or at least fifty percent (50%) interest in the income of the corporation or other business entity. 

“Annual Report” means the report of progress of an IND-associated investigation that the Sponsor must submit to the FDA
within sixty (60) days of the anniversary of the effective date of the IND (pursuant to 21 C.F.R. § 312.33). 

“Background Invention” means an Invention conceived and first actually reduced to practice before the Effective Date. 

“Clinical Investigator” means, in accordance with 21 C.F.R. § 312.3, an individual who actually conducts a clinical
investigation, that is, who directs the administration or dispensation of Test Article to a subject, and who assumes responsibility for studying 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 2 of 33	  	

 
Human Subjects, for recording and ensuring the integrity of research data, and for protecting the welfare and safety of Human Subjects. 

“Clinical Research Site(s)” means the site(s) at which the Protocol(s) described in the Research Plan will be performed. 

“Clinical Trial” means the clinical trial described in the Research Plan. 

“Collaborator Agreement” means a written agreement between the and a Grantee. In the event there is a conflict between the
terms of this CRADA and the Collaborator Agreement, the terms of the CRADA will control. 
 “Collaborator Materials” means
all tangible materials not first produced in the performance of this CRADA that are owned or controlled by Collaborator and which are provided to IC or IC’s grantees for use in the Clinical Trial. 

“Confidential Information” means confidential scientific, business, financial information, or Identifiable Private
Information provided that Confidential Information does not include: 
  

	 	(a)	information that is publicly known or that is available from public sources; 

	 	(b)	information that has been made available by its owner to others without a confidentiality obligation; 

	 	(c)	information that is already known by the receiving Party, or information that is independently created or compiled by the receiving Party without reference to or use of the provided information; or 

	 	(d)	information that relates to potential hazards or cautionary warnings associated with the production, handling, or use of the subject matter of the Research Plan. 

“Cooperative Agreement” means a Funding Agreement under the NIH Grant mechanism whereby the Federal funding agency intends to
be substantially involved in carrying out the research program and provides substantial scientific input. 
 “Cooperative Research
and Development Agreement” or “CRADA” means this Agreement, entered into pursuant to the Federal Technology Transfer Act of 1986, as amended (15 U.S.C. §§ 3710a et seq.), and Executive Order 12591 of
April 10, 1987. 
 “CRADA Data” means information developed by or on behalf of the Parties (including by Grantees) in
the performance of the Research Plan, excluding Raw Data and Source Data. CRADA Data includes both analyzed and unanalyzed Summary Data. 

“CRADA Materials” means all tangible materials first produced in the performance of the Research Plan other than CRADA Data.

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 3 of 33	  	

 “CRADA Collaborator Principal Investigator(s)” or “CRADA Collaborator
PI(s)” means the person(s) who will be responsible for the scientific and technical conduct of the Research Plan on behalf of the Collaborator. 

“CRADA Subject Invention” means any Invention of either or both Parties, conceived or first actually reduced to practice in
the performance of the Research Plan. 
 “Data Coordination Center” or “DCC” means the University of
Michigan. 
 “Drug Master File” or “DMF” as described in 21 C.F.R. Part 314.420, is a submission to the
FDA that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs. 

“Effective Date” means the date of the last signature of the Parties executing this Agreement. 

“Funding Agreement” means a contract, grant or Cooperative Agreement entered into between a Federal agency and another party
for the performance of the experimental, developmental or research work funded in whole or in part by the Federal Government. 

“Government” means the Government of the United States of America. 

“Grantees” mean the Clinical Investigators, the Clinical Research Sites, the Data Coordination Center, and any other grantees
of IC, that are funded by the NIDDK under a Cooperative Agreement and will perform activities under the Research Plan of this CRADA. 

“Human Subject” means, in accordance with the definition in 45 C.F.R. § 46.102(f), a living individual about whom an
investigator conducting research obtains: 

	 	(a)	data through intervention or interaction with the individual; or 

	 	(b)	Identifiable Private Information. 

 “IND” means an “Investigational
New Drug Application,” filed in accordance with 21 C.F.R. Part 312 under which clinical investigation of an experimental drug or biologic (Test Article) is performed in Human Subjects in the United States or intended to support a United
States licensing action. 
 “Identifiable Private Information” or “IPI” about a Human Subject means
private information from which the identity of the subject is or may readily be ascertained. Regulations defining and governing this information include 45 C.F.R. Part 46 and 21 C.F.R. Part 50. 

“Institutional Review Board” or “IRB” means, in accordance with 45 C.F.R. Part 46,

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 4 of 33	  	

 
21 C.F.R. Part 56, and other applicable regulations, an independent body comprising medical, scientific, and nonscientific members, whose responsibility is to ensure the protection of the rights,
safety, and well-being of the Human Subjects involved in a study. 
 “Invention” means any invention or discovery that is
or may be patentable or otherwise protected under Title 35 of the United States Code, or any novel variety of plant which is or may be protectable under the Plant Variety Protection Act, 7 U.S.C. §§ 2321 et seq.  

“Investigator’s Brochure” means, in accordance with the definition in 21 C.F.R. § 312.23(a)(5), a document
containing information about the Test Article, including animal screening, preclinical toxicology, and detailed pharmaceutical data, including a description of possible risks and side effects to be anticipated on the basis of prior experience with
the drug or related drugs, and precautions, such as additional monitoring, to be taken as part of the investigational use of the drug. 

“NIH CRADA Extramural Investigator/Officer(s)” means the NIDDK or other NIH employee who is responsible for the conduct
and/or management of the CRADA on behalf of the NIH IC. 
 “Patent Application” means an application for patent protection
for a CRADA Subject Invention with the United States Patent and Trademark Office (“U.S.P.T.O.”) or the corresponding patent-issuing authority of another nation. 

“Patent” means any issued United States patent, any international counterpart(s) and any corresponding grant(s) by a non-U.S.
government in place of a patent. 
 “Placebo” means an inactive substance identical in appearance to the material being
tested that is used to distinguish between drug action and suggestive effect of the material under study. 
 “Protocol”
means the formal, detailed description of a study to be performed as provided for in the Research Plan. It describes the objective(s), design, methodology, statistical considerations, and organization of a trial. For the purposes of this CRADA,
the term, Protocol, for clinical research involving Human Subjects, includes any and all associated documents, including informed consent forms, to be provided to Human Subjects and potential participants in the study. 

“Study Oversight Committee” means the study committee for this Clinical Trial that is responsible for the implementation,
management, and oversight of this Clinical Trial. The Protocol Committee is composed of [...***...]. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 5 of 33	  	

 “Raw Data” means all data collected from or generated under the Clinical Trial,
including data from the case report forms (CRFs) from the Clinical Trial and all datasets derived from such data, in each case with IPI removed. 

“Research Plan” means the statement in Appendix A of the respective research and development contributions and commitments of
the Parties. The Research Plan should describe provisions for sponsoring the IND, clinical and safety monitoring and data management. 

“Source Data” means the primary quantitative and empirical data first collected by the Clinical Research Site from the
Clinical Trial, including, without limitation, any documentation on the Human Subject’s medical history that supports the Raw Data on the CRF. Source Data will include IPI. 

“Sponsor” means, in accordance with the definition in 21 C.F.R. § 312.3, an organization or individual who assumes legal
responsibility for supervising or overseeing clinical trials with Test Articles, and is sometimes referred to as the IND holder. 

“Steering Committee” means the research and development team whose composition and responsibilities with regard to the
research performed under this CRADA are described in this CRADA. 
 “Summary Data” means any extract or summary of the Raw
Data, generated either by or, on behalf of, IC (including by Grantees) or by, or on behalf of, Collaborator. 
 “Test Article”
means, in accordance with 21 C.F.R. § 50.3(j), any drug (including a biological product), medical device, food additive, color additive, electronic product, or any other article subject to regulation under the Federal Food, Drug, and
Cosmetic Act that is intended for administration to humans or animals, including a drug or biologic as identified in the Research Plan and Appendix B, that is used within the scope of the Research Plan. The Test Article may also be referred to as
Investigational Agent, Study Material, Study Drug or Study Product. The Test Article under this CRADA is defined as Collaborator’s proprietary compound, LUM001, and placebo. 

“Unauthorized Use” means any unauthorized modifications to the Test Article or the conduct of any unauthorized research using
the Test Article or specimens or data collected as part of the Research Plan. 
  

	Article 3.	Cooperative Research and Development 

  

	3.1	 Performance of Research and Development. The research and development activities to be carried out under this CRADA will be performed by the
Parties identified on the Cover Page, as well as IC’s Grantees as described in the Research Plan. However, IC’s Grantees are not Parties to the CRADA, and this CRADA does not grant to Collaborator any rights to Inventions made by IC’s
Grantees. IC will ensure that prior to a Clinical 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 6 of 33	  	

	 	
Research Site or any other Grantee (other than the DCC) commencing activities in connection with this CRADA, such Clinical Research Site or other Grantee has executed the Collaborator Agreement
with Collaborator. IC will also ensure that prior to the DCC commencing activities in connection with this CRADA, the DCC has executed an agreement with the Collaborator mutually agreeable to IC, the DCC and the Collaborator (“DCC
Agreement”). The NIH CRADA Extramural Investigator/Officer(s), CRADA Collaborator PI(s), and the Data Coordination Center will be responsible for coordinating the scientific and technical conduct of this project on behalf of their employers. IC
will ensure that Clinical Research Sites are required to provide all Raw Data and Summary Data to the CRADA Collaborator upon Collaborator’s request to comply with regulatory reporting requirements (or as otherwise agreed in a Collaborator
Agreement), and in any event at the completion of the Clinical Trial. 

  

	3.2	Research Plan. The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are
good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6. 

 

	3.3	Use and Disposition of Collaborator Materials. IC agrees to use Collaborator Materials only in accordance with the Research Plan and Protocol(s), not to transfer these materials to third parties except in
accordance with the Research Plan and Protocol(s) or as approved by Collaborator, and, upon expiration or termination of the CRADA, to dispose of these materials as directed by Collaborator. 

 

	3.4	Third-Party Rights in Collaborator’s CRADA Subject Inventions. If Collaborator has received (or will receive) support of any kind from a third party in exchange for rights in any of Collaborator’s CRADA
Subject Inventions, Collaborator agrees to ensure that its obligations to the third party are both consistent with Articles 6 through 8 and subordinate to Article 7 of this CRADA. 

 

	3.5	Disclosures to IC. Prior to execution of this CRADA, Collaborator agrees to disclose to IC all instances in which outstanding royalties are due under a PHS license agreement and in which Collaborator had a PHS
license terminated in accordance with 37 C.F.R. § 404.10. These disclosures will be treated as Confidential Information upon request by Collaborator in accordance with the definition in Article 2 and Paragraphs 8.3 and 8.4. 

 

	3.6	 Clinical Investigator Responsibilities. The Clinical Investigator will be required to submit, or to arrange for submission of, each Protocol
associated with this CRADA to all appropriate IRBs, and for ensuring that the IRBs are notified of the role of Collaborator in the research. In addition to the Protocol all associated documents, including informational documents and advertisements,
must be reviewed and approved by the appropriate IRB(s) before starting the research at each Clinical Research Site. The research will be done in strict accordance with the Protocol(s) and no substantive changes in a finalized Protocol will be made
unless mutually agreed upon, in writing, by the 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 7 of 33	  	

	 	
Parties. Research will not commence (or will continue unchanged, if already in progress) until each substantive change to a Protocol, including those required by either the FDA or the IRB, has
been integrated in a way acceptable to the Parties, submitted to the FDA and approved by the appropriate IRBs. 

  

	3.7	Investigational Applications. 

  

	 	3.7.1	The Collaborator, as indicated in the Research Plan, will submit an IND and all required documents to the FDA. The Collaborator will comply with all FDA requirements, including obtaining and maintaining all Clinical
Investigator registration documents (1572 forms). 

  

	 	3.7.2	Collaborator agrees to provide IC with copies of all ND submissions related to the Clinical Trial at the time of their submission to the FDA. Collaborator further agrees to notify IC of any FDA correspondence related to
the Clinical Trial, and agrees to include IC representatives in any meeting with the FDA related to this Clinical Trial. 

  

	 	3.7.3	Any Confidential Information supplied to the IC by Collaborator in support of an IND filed by Collaborator will be protected by IC in accordance with the corresponding confidentiality provisions of Article 8.

  

	3.8	Test Article Information and Supply. Collaborator, through its designee, agrees to provide to IC’s Clinical Research Sites, without charge and on a schedule agreed by both Parties, a sufficient quantity of
formulated and acceptably labeled Test Article (and Placebo) to complete the Clinical Trial agreed to and approved under this CRADA. Collaborator, through its designee, will provide a Certificate of Analysis to the Clinical Research Sites for each
lot of the Test Article provided. 

  

	3.9	Test Article Delivery and Usage. Collaborator, through its designee, will ship the Test Article and Placebo to Clinical Research Sites in containers marked in accordance with 21 C.F.R. § 312.6. IC agrees
that the Clinical Investigators will keep appropriate records and take reasonable steps to ensure that the Test Article is used in accordance with the Protocol(s) and applicable FDA regulations. In addition, IC agrees, and will ensure that the
Clinical Research Sites and Clinical Investigators agree, that the Test Article (and all Confidential Information supplied by Collaborator relating to the Test Article) will be used solely for the conduct of the CRADA research and development
activities. Furthermore, IC agrees, and will ensure that the Clinical Research Sites and Clinical Investigators agree, not to engage in any Unauthorized Use of the Test Article and that no analysis or modification of the Test Article will be
performed without Collaborator’s prior written consent. At the completion of the Research Plan, any unused quantity of Test Article will be returned to Collaborator or disposed as directed by Collaborator. Pharmacy contacts at the Clinical
Research Sites will be determined by IC and communicated to Collaborator. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 8 of 33	  	

	3.10	Monitoring and Auditing. 

  

	 	3.10.1	The Collaborator will be primarily responsible for monitoring clinical sites and for assuring the quality of all clinical data, unless otherwise stated in the Research Plan. Monitoring will comply with FDA Good Clinical
Practice (International Conference on Harmonisation (ICH) E6: “Good Clinical Practice: Consolidated Guidance; 62 Federal Register 25, 691 (1997)). Collaborator will communicate significant Protocol violations and submit documentation of
monitoring outcomes on Protocol insufficiencies to the IC in a timely manner. 

  

	 	3.10.2	Subject to the restrictions in Article 8 concerning IPI, and with reasonable advance notice and at reasonable times, and at a frequency acceptable to Collaborator and the applicable Clinical Research Site (or as agreed
in the Collaborator Agreement), IC will permit Collaborator or its designee(s) access to Clinical Research Site(s) to monitor the conduct of the research and audit Source Data and Raw Data at Collaborator’s expense, to the extent necessary to
verify compliance with FDA Good Clinical Practice and the Protocol(s). 

  

	3.11	FDA Meetings/Communications. All meetings with the FDA concerning any clinical trial within the scope of the Research Plan will be discussed by Collaborator and IC in advance. Each Party reserves the right to
take part in setting the agenda for, to attend, and to participate in these meetings. The Sponsor will provide the other Party with copies of FDA meeting minutes, all transmittal letters for IND submissions, IND safety reports, formal questions and
responses that have been submitted to the FDA, Annual Reports, and official FDA correspondence, pertaining either to the INDs under this CRADA or to the Clinical Investigators on Protocols performed in accordance with the Research Plan, except to
the extent that those documents contain the proprietary information of a third party or dissemination is prohibited by law. 

  

	3.12	Steering Committee. The Steering Committee is comprised of representatives from each of the participating ChilDREN clinical research sites, the ChilDREN DCC, the NIDDK Division of Digestive Diseases and Nutrition
(DDN). Members of the Steering Committee will continue to remain employed by their respective employers under their respective terms of employment. The Steering Committee is responsible for reviewing all clinical studies conducted by the
ChilDREN’s network. 

 The Study Oversight Committee will be responsible for overseeing the conduct of the Clinical Trial
described in the Research Plan, and will meet on a regular basis in person or via teleconference with at least four in-person meetings per calendar year until completion or earlier termination of the Clinical Trial. The Parties agree to include the
Collaborator’s representatives on the ChilDREN Steering Committee during times that the agenda is discussing the protocol. 
  

	Article 4.	Reports 

  

	4.1	 Interim Research and Development Reports. The NIH CRADA Extramural 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 9 of 33	  	

	 	
Investigator/Officer(s) (on behalf of IC and the Grantees) and CRADA Collaborator PI(s) will exchange information regularly, in writing. This exchange may be accomplished through meeting minutes,
detailed correspondence, circulation of draft manuscripts, Steering Committee reports, copies of Annual Reports and any other reports updating the progress of the CRADA research. However, the Parties must exchange updated Investigator’s
Brochure, formulation and preclinical data, and toxicology findings, as they become available. In addition, any analysis of Raw Data will be made available to the Collaborator within 24 hours of availability from the Data Coordination Center.

  

	4.2	Final Research and Development Reports. The Parties will exchange final clinical study reports promptly (but no later than [.***.]) following data lock for the clinical study under this CRADA. These reports will
set forth the technical progress made; any publications proposed to be made on results arising from the research; and the existence of invention disclosures of potential CRADA Subject Inventions and/or any corresponding Patent Applications.

  

	4.3	Fiscal Reports. Upon the request of Collaborator, IC will submit to Collaborator a statement of all costs incurred by IC and its Grantees for the CRADA. If the CRADA has been terminated, IC will specify any costs
incurred before the date of termination for which IC has not received funds from Collaborator, as well as for all reasonable termination costs including the cost of returning Collaborator property or removal of abandoned Collaborator property, for
which Collaborator will be responsible. 

  

	4.4	Safety Reports. In accordance with FDA requirements, the Sponsor will establish and maintain records and submit safety reports to the FDA, as required by 21 C.F.R. § 312.32 and 21 C.F.R. 812.150(b)(1), or
other applicable regulations. In the conduct of research under this CRADA, the Parties will comply with specific IC guidelines and policies for reporting AEs and SAEs, as well as procedures specified in the Protocol(s). The Collaborator will provide
the IC with copies of all Safety Reports concurrently with their submission to the FDA, and with any other information affecting the safety of Human Subjects in research conducted under this CRADA. 

 

	4.5	Annual Reports. The Collaborator will provide the IC with a copy of the Annual Report concurrently with the submission of the Annual Report to the FDA. Annual Reports will be kept confidential in accordance with
Article 8. 

  

	Article 5.	Staffing, Financial, and Materials Obligations 

  

	5.1	IC and Collaborator Contributions. The contributions of any staff, funds, materials, and equipment by the Parties are set forth in Appendix B. The Federal Technology Transfer Act of 1986, 15 U.S.C. § 3710a(d)(1)
prohibits IC from providing funds to Collaborator for any research and development activities under this CRADA. 

  

	5.2	 IC Staffing. No IC employees will devote 100% of their effort or time to the research and development activities under this CRADA. IC will not
use funds provided by 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 10 of 33	  	

	 	
Collaborator under this CRADA for IC personnel to pay the salary of any permanent IC employee. Although personnel hired by IC using CRADA funds will focus principally on CRADA research and
development activities, Collaborator acknowledges that these personnel may nonetheless make contributions to other research and development activities, and the activities will be outside the scope of this CRADA. 

 

	5.3	Collaborator Funding. Collaborator acknowledges that Government funds received by Collaborator from an agency of the Department of Health and Human Services may not be used to fund IC under this CRADA. If
Collaborator has agreed to provide funds to IC then the payment schedule appears in Appendix B and Collaborator will make payments according to that schedule. If Collaborator fails to make any scheduled payment, IC will not be obligated to perform
any of the research and development activities specified herein or to take any other action required by this CRADA until the funds are received. IC will use these funds exclusively for the purposes of this CRADA. Each Party will maintain separate
and distinct current accounts, records, and other evidence supporting its financial obligations under this CRADA and, upon written request, will provide the other Party a fiscal report according to Paragraph 4.3, which delineates all payments made
and all obligated expenses, along with the final research report described in Paragraph 4.2. 

  

	Article 6.	Intellectual Property 

  

	6.1	Ownership of CRADA Subject Inventions, CRADA Data, and CRADA Materials. Subject to the Government license described in Paragraph 7.5, the sharing requirements of Paragraph 8.1 and the regulatory filing
requirements of Paragraph 8.2, the producing Party will retain sole ownership of and title to all CRADA Subject Inventions, all copies of CRADA Data, and all CRADA Materials produced solely by its employee(s). The Parties will own jointly all CRADA
Subject Inventions invented jointly and all CRADA Materials developed jointly. A Grantee’s rights in data it generates will not be affected by this CRADA and will be governed by the Collaborator Agreement or in the case of the DCC, by the DCC
Agreement. 

  

	6.2	Reporting. The Parties will promptly report to each other in writing each CRADA Subject Invention reported by their respective personnel, and any Patent Applications filed thereon, resulting from the research and
development activities conducted under this CRADA. Each Party will report all CRADA Subject Inventions to the other Party in sufficient detail to determine inventorship, which will be determined in accordance with U.S. patent law. These reports will
be treated as Confidential Information in accordance with Article 8. Formal reports will be made by and to the Patenting and Licensing Offices identified on the Contacts Information Page herein. 

 

	6.3	 Filing of Patent Applications. Each Party will make timely decisions regarding the filing of Patent Applications on the CRADA Subject
Inventions made solely by its employee(s), and will notify the other Party in advance of filing. Collaborator will have the first opportunity to file a Patent Application on joint CRADA Subject Inventions and

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 11 of 33	  	

	 	
will notify PHS of its decision within [...***...] of an Invention being reported or at least [...***...] before any patent filing deadline, whichever occurs sooner. If Collaborator fails to
notify PHS of its decision within that time period or notifies PHS of its decision not to file a Patent Application, then PHS has the right to file a Patent Application on the joint CRADA Subject Invention. Neither Party will be obligated to file a
Patent Application. The Parties may consult with each other regarding the prosecution of Patent Applications directed to CRADA Subject Inventions made solely by IC employees and will consult with each other regarding the prosecution of Patent
Applications directed to CRADA Subject Inventions made jointly by IC employees and employees or contractors of Collaborator. IC agrees to provide Collaborator with copies of any Patent Applications filed related to IC sole CRADA Subject Invention
using Collaborator’s Test Article. Collaborator will place the following statement in any Patent Application it files on a CRADA Subject Invention: “This invention was created in the performance of a Cooperative Research and Development
Agreement with the NIDDK of the NIH, an Agency of the Department of Health and Human Services. The Government of the United States has certain rights in this invention.” If either Party files a Patent Application on a joint CRADA Subject
Invention, then the filing Party will include a statement within the Patent Application that clearly identifies the Parties and states that the joint CRADA Subject Invention was made under this CRADA. 

 

	6.4	Patent Expenses. Unless agreed otherwise, the Party filing a Patent Application will pay all preparation and filing expenses, prosecution fees, issuance fees, post issuance fees, patent maintenance fees,
annuities, interference expenses, and attorneys’ fees for that Patent Application and any resulting Patent(s). If a license to any CRADA Subject Invention is granted to Collaborator, then Collaborator will be responsible for all expenses and
fees, past and future, in connection with the preparation, filing, prosecution, and maintenance of any Patent Applications and Patents claiming exclusively licensed CRADA Subject Inventions and will be responsible for a pro-rated share, divided
equally among all licensees, of those expenses and fees for non-exclusively licensed CRADA Subject Inventions. Collaborator may waive its exclusive option rights at any time, and incur no subsequent financial obligation for those Patent
Application(s) or Patent(s). 

  

	6.5	Prosecution of Patent Applications. The Party filing a Patent Application will provide the non-filing Party with a copy of any official communication relating to prosecution of the Patent Application within
[...***...] of transmission of the communication. Each Party will also provide the other Party with the power to inspect and make copies of all documents retained in the applicable Patent Application or Patent file. The Parties agree to consult with
each other regarding the prosecution of Patent Applications directed to joint CRADA Subject Inventions. If Collaborator elects to file and prosecute Patent Applications on joint CRADA Subject Inventions, then Collaborator agrees to use the
U.S.P.T.O. Customer Number Practice and/or grant PHS a power(s) of attorney (or equivalent) necessary to assure PHS access to its intellectual property rights in these Patent Applications. PHS and Collaborator will cooperate with each other to
obtain necessary signatures on Patent Applications, assignments, or other documents. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 12 of 33	  	

	Article 7.	Licensing 

  

	7.1	Background Inventions. Other than as specifically stated in this Article 7, nothing in this CRADA will be construed to grant any rights in one Party’s Background Invention(s) to the other Party, except to
the extent necessary for the Parties to conduct the research and development activities described in the Research Plan. 

  

	7.2	Collaborator’s License Option to CRADA Subject Inventions. 

  

	 	(a)	With respect to Government rights to any CRADA Subject Invention made solely by an IC employee(s) or made jointly by an IC employee(s) and a Collaborator employee(s) or Collaborator contractor for which a Patent
Application was filed, PHS hereby grants to Collaborator (i) for CRADA Subject Inventions that claim the method of use of the Test Article, an option to elect a royalty-free, paid-up (except for patent prosecution and maintenance fees for
Patent Applications and Patents claiming such CRADA Subject Inventions), worldwide, exclusive license for research, development and commercialization purposes with the right to sublicense to affiliates, or to contractors or collaborators working for
the benefit of Collaborator; and (ii) for CRADA Subject Inventions other than those covered by subparagraph (i) above, (A) an option to elect a paid-up, non-exclusive, non-transferable, royalty-free, worldwide license for research and
development purposes; and (B) an exclusive option to elect an exclusive or nonexclusive commercialization license. The licenses elected under 7.2(a) will be substantially in the form of the appropriate model PHS license agreement and will
fairly reflect the nature of the CRADA Subject Invention, the relative contributions of the Parties to the CRADA Subject Invention and the CRADA, a plan for the development and marketing of the CRADA Subject Invention, the risks incurred by
Collaborator, and the costs of subsequent research and development needed to bring the CRADA Subject Invention to the marketplace. The field of use of any license elected under 7.2(a) will not exceed the scope of the Research Plan.

  

	 	(b)	Under the licenses granted pursuant to Section 7.2(a), Collaborator will have the right (a) to disclose CRADA Subject Inventions to a regulatory authority when seeking marketing authorization of the
Investigational Agent, and (b) disclose CRADA Subject Inventions on a product insert or other promotional material regarding the Test Article after having obtained marketing authorization from a regulatory authority. 

 

	 	(c)	 In addition, for Inventions made by IC employees(s) which are or may be patentable or otherwise protectable, and arise from Unauthorized Use: PHS
agrees to grant to Collaborator an option to a royalty-free, paid-up (except for all out of pocket Patent prosecution and maintenance costs for Patent Applications and Patents claiming such inventions, which will be pro-rated and divided equally
among all licensees if a non-exclusive license is elected) exclusive or non-exclusive commercial license, with the right to sublicense, to Collaborator’s Affiliates, contractors working on Collaborator’s

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 13 of 33	  	

	 	
behalf and collaborators working with Collaborator, to Unauthorized Inventions. NIH will retain a non-exclusive, sublicensable royalty free license to practice such Inventions for Government
purposes. 

  

	7.3	Exercise of Collaborator’s License Option. To exercise the option(s) of Paragraph 7.2 Collaborator must submit a written notice to the PHS Patenting and Licensing Contact identified on the Contacts
Information Page (and provide a copy to the IC Contact for CRADA Notices) within [...***...] after either (i) Collaborator receives written notice from PHS that the Patent Application has been filed or (ii) the date on which Collaborator
files the Patent Application. The written notice exercising this option will include a completed “Application for License to Public Health Service Inventions” and will initiate a negotiation period that expires [...***...] after the
exercise of the option. If PHS has not responded in writing to the last proposal by Collaborator within this [...***...] period, the negotiation period will be extended to expire [...***...] after PHS so responds, during which month Collaborator may
accept in writing the final license proposal of PHS. If PHS and Collaborator fail to reach agreement within [...***...] (or the additional [...***...] period as described above) on the terms for an exclusive license for a particular Paragraph 7.2
CRADA Subject Invention, then for a period of[...***...] thereafter PHS agrees not to offer to license such CRADA Subject Invention to any third party on materially better terms than those last offered to Collaborator without first offering such
terms to Collaborator, in which case Collaborator will have a period of [...***...] in which to accept or reject the offer. In the absence of Collaborator’s exercise of the option, or upon election of a nonexclusive license, PHS will be free to
license the CRADA Subject Invention to others. These time periods may be extended at the sole discretion of PHS upon good cause shown in writing by Collaborator. 

 

	7.4	Government License in IC Sole CRADA Subject Inventions and Joint CRADA Subject Inventions. Pursuant to 15 U.S.C. § 3710a(b)(1)(A), for CRADA Subject Inventions owned solely by IC or jointly by IC and
Collaborator, and licensed pursuant to the option of Paragraph 7.2, Collaborator grants to the Government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the CRADA Subject Invention or have the CRADA Subject Invention
practiced throughout the world by or on behalf of the Government. In the exercise of this license, the Government will not publicly disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning
of 5 U.S.C. § 552(b)(4) or which would be considered privileged or confidential if it had been obtained from a non-federal party. 

  

	7.5	Government License in Collaborator Sole CRADA Subject Inventions. Pursuant to 15 U.S.C. § 3710a(b)(2), for CRADA Subject Inventions made solely by an employee of Collaborator, Collaborator grants to the
Government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the CRADA Subject Invention or have the CRADA Subject Invention practiced throughout the world by or on behalf of the Government for research or other Government
purposes. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 14 of 33	  	

	7.6	Third Party License. Pursuant to 15 U.S.C. § 3710a(b)(1)(B), if PHS grants Collaborator an exclusive license to a CRADA Subject Invention made solely by an IC employee or jointly with a Collaborator
employee, the Government will retain the right to require Collaborator to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the CRADA Subject Invention in Collaborator’s licensed field of use
on terms that are reasonable under the circumstances; or, if Collaborator fails to grant a license, to grant a license itself. The exercise of these rights by the Government will only be in exceptional circumstances and only if the Government
determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator, (ii) the action is necessary to meet requirements for public use specified by federal regulations, and such
requirements are not reasonably satisfied by Collaborator; or (iii) Collaborator has failed to comply with an agreement containing provisions described in 15 U.S.C. § 3710a(c)(4)(B). The determination made by the Government under this
Paragraph is subject to administrative appeal and judicial review under 35 U.S.C. § 203(b). 

  

	7.7	Third-Party Rights In IC Sole CRADA Subject Inventions. For a CRADA Subject Invention conceived prior to the Effective Date solely by an IC employee that is first actually reduced to practice after the Effective
Date in the performance of the Research Plan, the option offered to Collaborator in Paragraph 7.2 may be restricted if, prior to the Effective Date, PHS had filed a Patent Application and has either offered or granted a license in the CRADA Subject
Invention to a third party. Collaborator nonetheless retains the right to apply for a license to any such CRADA Subject Invention in accordance with the terms and procedures of 35 U.S.C. § 209 and 37 C.F.R. Part 404. 

 

	Article 8.	Rights of Access and Publication 

  

	8.1	Right of Access to CRADA Data and CRADA Materials. IC and Collaborator agree to regularly exchange all CRADA Data and to share all CRADA Materials. If the CRADA is terminated, both Parties agree to provide CRADA
Materials in quantities needed to complete the Research Plan. Such provision will occur before the termination date of the CRADA or sooner, if required by the Research Plan. IC will also, upon request from Collaborator, provide Collaborator with all
CRADA Data. If Collaborator possesses any human biological specimens from clinical trials under the CRADA, the specimens must be handled as described in the Protocol or as otherwise directed by IC before the termination date of the CRADA.

  

	8.2	 Use of CRADA Data and CRADA Materials. The Parties will be free to utilize CRADA Data, Raw Data and CRADA Materials internally for their own
purposes, consistent with their obligations under this CRADA. IC may share CRADA Data or CRADA Materials with Grantees it has engaged to conduct the CRADA research and development activities, provided the obligations of this Article 8.2 are
simultaneously conveyed. Collaborator may share CRADA Data, Raw Data or CRADA Materials with any contractors, Affiliates, and existing or potential investors, development partners, 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 15 of 33	  	

	 	
licensees, sublicensees, advisors and agents, provided the obligations of this Article 8.2 are simultaneously conveyed. 

 

	 	8.2.1	CRADA Data. 

 Collaborator and IC will use reasonable efforts to keep CRADA Data
confidential until published or until corresponding Patent Applications are filed. To the extent permitted by law, each Party will have the right to use any and all CRADA Data in and for any regulatory filing by or on behalf of the Party 

 

	 	8.2.2	CRADA Materials. 

 Collaborator and IC will use reasonable efforts to keep descriptions
of CRADA Materials confidential until published or until corresponding Patent Applications are filed. Collaborator acknowledges that the basic research mission of PHS includes sharing with third parties for further research those research resources
made in whole or in part with NIH funding. Consistent with this mission and the tenets articulated in “Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Research Grants and Contracts,” December 1999,
available at http.//ott.od.nih.gov/NewPages/RTguide_final.html, following publication either Party may make available to third parties for further research those CRADA Materials made jointly by both PHS and Collaborator. Notwithstanding the above,
if those joint CRADA Materials are the subject of a pending Patent Application or a Patent, or were created using a patent-pending or patented material or technology, the Parties may agree to restrict distribution or freely distribute them. Either
Party may distribute those CRADA Materials made solely by the other Party only upon written consent from that other Party or that other Party’s designee. 
  

	8.3	Confidential Information. Each Party agrees to limit its disclosure of Confidential Information of the other Party to the amount necessary to carry out the Research Plan or exercise its rights granted pursuant to
this CRADA, and will place a confidentiality notice on all this information. A Party orally disclosing Confidential Information to the other Party will summarize the disclosure in writing and provide it to the other Party within [...***...] of the
disclosure. Each Party receiving Confidential Information agrees to use it only for the purposes described in the Research Plan or the exercise of its rights granted pursuant to this CRADA. Either Party may object to the designation of information
as Confidential Information by the other Party. 

  

	8.4	 Protection of Confidential Information. Confidential Information will not be disclosed, copied, reproduced or otherwise made available to any
other person or entity without the consent of the owning or providing Party except (a) as required by a court or administrative body of competent jurisdiction, or federal law or regulation, (b) as permitted under Section 8.3 above and
(c) a Party may disclose Confidential Information of the other Party as necessary for the purposes of the Research Plan or the exercise of its licenses and rights granted hereunder, to its affiliates, directors, advisors, contractors and
existing and potential collaborators, licensees and sublicensees or to other third parties in 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 16 of 33	  	

	 	
connection with due diligence activities, provided in each case that such recipients are bound by obligations of confidentiality with respect to such information comparable to those in this
CRADA. Each Party agrees to use reasonable efforts to maintain the confidentiality of Confidential Information, which will in no instance be less effort than the Party uses to protect its own Confidential Information. Each Party agrees that a Party
receiving Confidential Information will not be liable for the disclosure of that portion of the Confidential Information which, after notice to and consultation with the disclosing Party, the receiving Party determines may not be lawfully withheld,
provided the disclosing Party has been given a reasonable opportunity to seek a court order to enjoin disclosure. 

  

	8.5	Human Subject Protection. The research to be conducted under this CRADA involves Human Subjects or human tissues within the meaning of 45 C.F.R. Part 46, and all research to be performed under this CRADA will
conform to applicable federal laws and regulations. Additional information is available from the HHS Office for Human Research Protections (http://www.hhs.gov/ohrp/). 

 

	8.6	Duration of Confidentiality Obligation. The obligation to maintain the confidentiality of Confidential Information will expire at the earlier of the date when the information is no longer Confidential Information
as defined in Article 2 or [...***...] after the expiration or termination date of this CRADA, except for IPI, for which the obligation to maintain confidentiality will extend indefinitely. Collaborator may request an extension to this term when
necessary to protect Confidential Information relating to products not yet commercialized. 

  

	8.7	Publication. The Parties are encouraged to make publicly available the results of their research and development activities. Before either Party submits a paper or abstract for publication or otherwise intends to
publicly disclose information about a CRADA Subject Invention, CRADA Data, or CRADA Materials, the other Party will have [...***...] to review proposed manuscripts and [...***...] to review proposed abstracts to assure that Confidential Information
is protected. Either Party may request in writing that the proposed publication or other disclosure be delayed for up to [...***...] as necessary to file a Patent Application. 

 

	8.8	Clinical Investigators’ Research and Development Activities. Although this CRADA does not grant to Collaborator any rights to Inventions made or Raw Data generated by, IC’s Grantees, as they are not
parties to this CRADA, IC agrees that: 

  

	 	8.8.1	Subject to the other provisions of Article 8 of this CRADA, IC will maintain, to the extent permitted by law, all CRADA Data, and Raw Data in its possession, as Confidential Information, and will make CRADA Data
available to Collaborator upon Collaborator’s request, for its own use and for exclusive use in obtaining regulatory approval for the commercial marketing of Test Article and related CRADA Subject Inventions. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 17 of 33	  	

	 	8.8.2	With regard to Collaborator’s Confidential Information, IC will require the Clinical Investigators and other Grantees to agree to confidentiality provisions at least as restrictive as those provided in this CRADA
and to Collaborator’s use of data in accordance with Paragraph 8.8.1 for obtaining regulatory approval for marketing Test Article. 

  

	 	8.8.3	The Data Coordination Center will transfer all Raw Data or any other data in the possession of the Clinical Investigators or other Grantees working with Test Article to Collaborator upon Collaborator’s request for
regulatory purposes (or as otherwise agreed by the Data Coordination Center and Collaborator), and in any event at the completion or earlier termination of the Clinical Trial. Collaborator will bear any costs associated with Raw Data provided in
formats customized for Collaborator. 

  

	 	8.8.4	If Collaborator abandons development or commercialization of Investigational Agent other than for safety concerns without the transfer of its development efforts to another party within [...***...] of discontinuation,
IC has the right to make CRADA Data available to a third party. 

  

	Article 9.	Representations and Warranties 

  

	9.1	Representations of IC. IC hereby represents to Collaborator that: 

  

	 	9.1.1	IC has the requisite power and authority to enter into this CRADA and to perform according to its terms, and that IC’s official signing this CRADA has authority to do so. 

 

	 	9.1.2	To the best of its knowledge and belief, neither IC nor any of its personnel involved in this CRADA or any Grantee is presently subject to debarment or suspension by any agency of the Government which would directly
affect its performance of the CRADA. Should IC or any of its personnel involved in this CRADA or any Grantee be debarred or suspended during the term of this CRADA, IC will notify Collaborator within [...***...] of receipt of awareness.

  

	9.2	Representations and Warranties of Collaborator. Collaborator hereby represents and warrants to IC that: 

  

	 	9.2.1	Collaborator has the requisite power and authority to enter into this CRADA and to perform according to its terms, and that Collaborator’s official signing this CRADA has authority to do so. 

 

	 	9.2.2	 Neither Collaborator nor any of its personnel involved in this CRADA, including Affiliates, agents, and contractors are presently subject to debarment
or suspension by any agency of the Government. Should Collaborator or any of its 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 18 of 33	  	

	 	
personnel involved in this CRADA be debarred or suspended during the term of this CRADA, Collaborator will notify IC within [...***...] of receipt of awareness. 

 

	 	9.2.3	Subject to Paragraph 12.3, and if and to the extent Collaborator has agreed to provide funding under Appendix B, Collaborator will be financially able to satisfy these obligations in a timely manner. 

 

	 	9.2.4	The Test Article provided has been produced in accordance with the FDA’s current Good Manufacturing Practice set out in 21 C.F.R. §§ 210-211, and ICH QA7, and meets the specifications cited in the
Certificate of Analysis and Investigator’s Brochure provided. 

  

	Article 10.	Expiration and Termination 

  

	10.1	Expiration. This CRADA will expire on the last date of the term set forth on the Summary Page. In no case will the term of this CRADA extend beyond the term indicated on the Summary Page unless it is extended in
writing in accordance with Paragraph 13.6. 

  

	10.2	Termination by Mutual Consent. IC and Collaborator may terminate this CRADA at any time by mutual written consent. 

  

	10.3	Unilateral Termination. Either IC or Collaborator may unilaterally terminate this CRADA at any time by providing written notice at least sixty (60) days before the desired termination date. IC may, at its
option, retain funds transferred to IC before unilateral termination by Collaborator for use in completing the Research Plan. If Collaborator terminates this Agreement before the completion of all approved or active Protocol(s), then Collaborator
will supply enough Test Article (and Placebo, if applicable) to complete these Protocol(s) unless termination is for safety concerns. 

  

	10.4	Funding for IC Personnel. If Collaborator has agreed to provide funding for IC personnel and this CRADA is mutually or unilaterally terminated by Collaborator before its expiration, then Collaborator agrees that
funds for that purpose will be available to IC for a period of [...***...] after the termination date or until the expiration date of the CRADA, whichever occurs sooner. If there are insufficient funds to cover this expense, Collaborator agrees to
pay the difference. 

  

	10.5	New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding
commitments and contracts by the termination date. Collaborator acknowledges that IC will have the authority to retain and expend any funds for up to [...***...] subsequent to the expiration or termination date to cover any unpaid costs obligated
during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 19 of 33	  	

	10.6	Collaborator Failure to Continue Development. If Collaborator suspends all development of the Test Article other than for reasons relating to safety, without the transfer of its active development efforts,
assets, and obligations to a third party within one hundred and eighty (180) days of discontinuation, Collaborator agrees that IC may continue developing the Test Article. In that event, the following will apply: Collaborator agrees to transfer
to IC all information necessary to enable IC to contract for the manufacture of the Test Article or arrange for an independent contractor to manufacture and provide Test Article to IC for the earlier of two years or until completion of ongoing
mutually agreed to Protocols, and, unless abandoned for reasons relating to safety as determined by the data safety monitoring board, to provide the Test Article (and Placebo, if any) in Collaborator’s inventory to IC. 

 

	Article 11.	Disputes 

  

	11.1	Settlement. Any dispute arising under this CRADA which is not disposed of by agreement of the NIH CRADA Extramural Investigator/Officer(s) and CRADA Collaborator PI(s) will be submitted jointly to the signatories
of this CRADA. If the signatories, or their designees, are unable to jointly resolve the dispute within [...***...] after notification thereof, the Assistant Secretary for Health (or his/her designee or successor) will propose a resolution. Nothing
in this Paragraph will prevent any Party from pursuing any additional administrative remedies that may be available and, after exhaustion of such administrative remedies, pursuing all available judicial remedies. 

 

	11.2	Continuation of Work. Pending the resolution of any dispute or claim pursuant to this Article 11, the Parties agree that performance of all obligations will be pursued diligently. 

 

	Article 12.	Liability 

  

	12.1	NO WARRANTIES. EXCEPT AS SPECIFICALLY STATED IN ARTICLE 9, THE PARTIES MAKE NO EXPRESS OR IMPLIED WARRANTY AS TO ANY MATTER WHATSOEVER, INCLUDING THE CONDITIONS OF THE RESEARCH OR ANY INVENTION OR MATERIAL,
WHETHER TANGIBLE OR INTANGIBLE, MADE OR DEVELOPED UNDER OR OUTSIDE THE SCOPE OF THIS CRADA, OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE RESEARCH OR ANY INVENTION OR MATERIAL, OR THAT A TECHNOLOGY UTILIZED BY A PARTY
IN THE PERFORMANCE OF THE RESEARCH PLAN DOES NOT INFRINGE ANY THIRD-PARTY PATENT RIGHTS. 

  

	12.2	 Indemnification and Liability. Collaborator agrees to hold the Government harmless and to indemnify the Government for all liabilities,
demands, damages, expenses and losses arising out of the use by Collaborator for any purpose of the CRADA Data, CRADA Materials or CRADA Subject Inventions produced in whole or part by IC employees under this CRADA, unless due to the negligence or
willful misconduct of IC, its employees, or agents. The Government has no statutory authority to indemnify 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 20 of 33	  	

	 	
Collaborator. Each Party otherwise will be liable for any claims or damages it incurs in connection with this CRADA, except that IC, as an agency of the Government, assumes liability only to the
extent provided under the Federal Tort Claims Act , 28 U.S.C. Chapter 171. 

  

	12.3	Force Majeure. Neither Party will be liable for any unforeseeable event beyond its reasonable control and not caused by its own fault or negligence, which causes the Party to be unable to perform its
obligations under this CRADA, and which it has been unable to overcome by the exercise of due diligence. If a force majeure event occurs, the Party unable to perform will promptly notify the other Party. It will use its best efforts to resume
performance as quickly as possible and will suspend performance only for such period of time as is necessary as a result of the force majeure event. 

  

	Article 13.	Miscellaneous 

  

	13.1	Governing Law. The construction, validity, performance and effect of this CRADA will be governed by U.S. federal law, as applied by the federal courts in the District of Columbia. If any provision in this CRADA
conflicts with or is inconsistent with any U.S. federal law or regulation, then the U.S. federal law or regulation will preempt that provision. 

  

	13.2	Compliance with Law. IC and Collaborator agree that they will comply with, and advise any contractors, grantees, or agents they have engaged to conduct the CRADA research and development activities to comply
with, all applicable Executive Orders, statutes, and HHS regulations relating to research on human subjects (45 C.F.R. Part 46, 21 C.F.R. Parts 50 and 56) and relating to the appropriate care and use of laboratory animals (7 U.S.C. §§ 2131
et seq.; 9 C.F.R. Part 1, Subchapter A). IC and Collaborator will advise any contractors, grantees, or agents they have engaged to conduct clinical trials for this CRADA that they must comply with all applicable federal regulations for the
protection of Human Subjects, which may include the Standards for Privacy of Individually Identifiable Health Information set forth in 45 C.F.R. Part 164. Collaborator agrees to ensure that its employees, contractors, and agents who might have
access to a “select agent or toxin” (as that term is defined in 42 C.F.R. §§ 73.4-73.5) transferred from IC is properly licensed to receive the “select agent or toxin.” 

 

	13.3	Waivers. None of the provisions of this CRADA will be considered waived by any Party unless a waiver is given in writing to the other Party. The failure of a Party to insist upon strict performance of any of the
terms and conditions hereof, or failure or delay to exercise any rights provided herein or by law, will not be deemed a waiver of any rights of any Party. 

  

	13.4	Headings. Titles and headings of the articles and paragraphs of this CRADA are for convenient reference only, do not form a part of this CRADA, and will in no way affect its interpretation. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 21 of 33	  	

	13.5	Severability. The illegality or invalidity of any provisions of this CRADA will not impair, affect, or invalidate the other provisions of this CRADA. 

 

	13.6	Amendments. Minor modifications to the Research Plan may be made by the mutual written consent of the NIH CRADA Extramural Investigator/Officer(s) and CRADA Collaborator PI(s). Substantial changes to the CRADA,
extensions of the term, or any changes to Appendix C will become effective only upon a written amendment signed by the signatories to this CRADA or by their representatives duly authorized to execute an amendment. A change will be considered
substantial if it directly expands the range of the potential CRADA Subject Inventions, alters the scope or field of any license option governed by Article 7, or requires a significant increase in the contribution of resources by either Party.

  

	13.7	Assignment. Neither this CRADA nor any rights or obligations of any Party hereunder shall be assigned or otherwise transferred by either Party without the prior written consent of the other Party. The
Collaborator acknowledges the applicability of 41 U.S.C. § 15, the Anti Assignment Act, to this Agreement. The Parties agree that the identity of the Collaborator is material to the performance of this CRADA and that the duties under this CRADA
are nondelegable. 

  

	13.8	Notices. All notices pertaining to or required by this CRADA will be in writing, signed by an authorized representative of the notifying Party, and delivered by first class, registered, or certified mail, or by
an express/overnight commercial delivery service, prepaid and properly addressed to the other Party at the address designated on the Contacts Information Page, or to any other address designated in writing by the other Party. Notices will be
considered timely if received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Notices regarding the exercise of license
options will be made pursuant to Paragraph 7.3. Either Party may change its address by notice given to the other Party in the manner set forth above. 

  

	13.9	Independent Contractors. The relationship of the Parties to this CRADA is that of independent contractors and not agents of each other or joint venturers or partners. Each Party will maintain sole and exclusive
control over its personnel and operations. Collaborator may engage contractors or consultants to perform any portion of the Research Plan activities, provided that any such contract is consistent with the terms of this CRADA. 

 

	13.10	 Use of Name; Press Releases. By entering into this CRADA, the Government does not directly or indirectly endorse any product or service that is
or will be provided, whether directly or indirectly related to either this CRADA or to any patent or other intellectual-property license or agreement that implements this CRADA by Collaborator, its successors, assignees, or licensees. Collaborator
will not in any way state or imply that the Government or any of its organizational units or employees endorses any product or services. Each Party agrees to provide proposed press releases that reference or rely upon

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 22 of 33	  	

	 	
the work under this CRADA to the other Party for review and comment at least five (5) business days before publication. Either Party may disclose the Title and Abstract of the CRADA to the
public without the approval of the other Party. 

  

	13.11	Reasonable Consent. Whenever a Party’s consent or permission is required under this CRADA, its consent or permission will not be unreasonably withheld. 

 

	13.12	Export Controls. Collaborator agrees to comply with U.S. export law and regulations. If Collaborator has a need to transfer any CRADA Materials made in whole or in part by IC, or IC Materials, or IC’s
Confidential Information to a person located in a country other than the United States, to an Affiliate organized under the laws of a country other than the United States, or to an employee of Collaborator in the United States who is not a citizen
or permanent resident of the United States, Collaborator will acquire any and all necessary export licenses and other appropriate authorizations. 

  

	13.13	Entire Agreement. This CRADA constitutes the entire agreement between the Parties concerning the subject matter of this CRADA and supersedes any prior understanding or written or oral agreement. Specifically, the
mutual Confidential Disclosure Agreement executed by the Parties on January 12, 2012 (Ref. No. DK-12-008) is hereby superseded and succeeded by the terms of this CRADA. The confidential data exchanged between the Parties under that agreement
shall be governed by the terms of this CRADA as if they had been exchanged after execution of this CRADA, and not under the terms of the prior agreement. 

  

	13.14	Survivability. The provisions of Paragraphs 3.3, 3.4, 3.9, 4.2, 4.3, 4.5, 5.3, 5.4, 6.1-8.8, 10.3-10.6, 11.1, 11.2, 12.1-12.3, 13.1-13.5, 13.7, 13.10 and 13.14 will survive the expiration or early termination of
this CRADA. 

 SIGNATURES BEGIN ON THE NEXT PAGE 

SIGNATURE PAGE 
 ACCEPTED AND
AGREED 
 BY EXECUTING THIS AGREEMENT, EACH PARTY
REPRESENTS THAT ALL STATEMENTS MADE HEREIN ARE TRUE, COMPLETE, AND ACCURATE
TO THE BEST OF ITS KNOWLEDGE. COLLABORATOR ACKNOWLEDGES THAT IT MAY
BE SUBJECT TO CRIMINAL, CIVIL, OR ADMINISTRATIVE PENALTIES FOR KNOWINGLY MAKING
A FALSE, FICTITIOUS, OR FRAUDULENT STATEMENT OR CLAIM. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 23 of 33	  	

							
	FOR IC:	 		  		  	
				
	 /s/ Griffin Rodgers
	 		  	 01/13/2013
	  	
	Signature	 		  	Date	  	
				
	Type Name:	 		  		  	
	Title:	 		  		  	
				
	FOR COLLABORATOR:	 		  		  	
				
	 /s/ Mike Grey
	 		  	 January 3, 2013
	  	
	Signature	 		  	Date	  	
				
	Type Name: Mike Grey	 		  		  	
	Title: President & CEO	 		  		  	
	Lumena Pharmaceuticals	 		  		  	

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 24 of 33	  	Confidential              

 CONTACTS INFORMATION PAGE 

CRADA Notices 
  

			
	For IC:	  	For Collaborator:
		
	Director	  	Mike Grey
	Technology Transfer & Development	  	President and CEO
	NIDDK, NIH, HHS	  	Lumena Pharmaceuticals, Inc.
	12 South Drive, Room 3011	  	2520 Meridian Parkway, Suite 400
	Bethesda, MD 20892-5632	  	Durham, NC 27713
	T: (301) 451-3636	  	T: [...***...]
	MTA@niddk.nih.gov	  	mgrey@lumenapharma.com
	  
	  	  

	Patenting and Licensing
		
	For IC:	  	For Collaborator (if separate from above):
		
	Division Director, Division of Technology	  	
	NIH Office of Technology Transfer	  	
	6011 Executive Boulevard, Suite 325	  	
	Rockville, Maryland 20852-3804	  	
	Tel: 301-496-7057	  	
	Fax: 301-402-0220	  	

 Delivery of Materials Identified In Appendix B (if any) 

 

			
	For IC:	    	
	 ChiLDREN Network Clinical Research Sites
	    	  

	  
	    	  

	  
	    	  

	  
	    	  

	  
	    	  

 IC Project Officer for Clinical Investigators 

 

			
	Name:	  	Averell Sherker, MD FRCP(C)
	Branch:	  	NIDDK Division of Digestive and Liver Diseases
	Address:	  	6707 Democracy Blvd., Room 659
		  	Bethesda, MD 20892-5450
	Telephone:	  	[...***...]
		  	FAX: (301) 480-8300
		  	Email: averell.sherker@nih.gov

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 25 of 33	  	Confidential              

 SUMMARY PAGE 

EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION OR PERMISSION, 

RELEASE THIS SUMMARY PAGE TO THE PUBLIC. 

TITLE OF CRADA: The evaluation of the Intestinal Bile Acid Transport (ASBT) Inhibitor LUM001 in the management of Progressive Familial Intrahepatic
Cholestasis 1 (BYLER) Disease and Alagille Syndrome Associated Pruritus (“ITCH Study”) 
  

			
	PHS [IC] Component:	  	 NIDDK

		
	IC CRADA Extramural Investigator/Officer:	  	Averell H. Sherker, MD, FRCP(C)
		
	Collaborator:	  	 Lumena Pharmaceuticals, Inc.

		
	Collaborator CRADA Officer:	  	 Mike Grey

		
	Term of CRADA:	  	 (5) years from the Effective Date

 ABSTRACT OF THE RESEARCH PLAN: 

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) will be collaborating with
Lumena Pharmaceuticals, Inc. (“Lumena”) to conduct a pediatric clinical trial, evaluating Lumena’s proprietary intestinal bile acid transport (ASBT) inhibitor (“LUM001”) in the management of Progressive Familial Intrahepatic
Cholestasis 1 (BYLER) Disease and Alagille Syndrome Associated Pruritus, also referred to as the “ITCH Study.” 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 26 of 33	  	Confidential              

 APPENDIX A 

RESEARCH PLAN 
 TITLE OF CRADA:

 The evaluation of the Intestinal Bile Acid Transport (ASBT) Inhibitor LUM001 in the 

management of Progressive Familial Intrahepatic Cholestasis 1 (BYLER) Disease and 

Alagille Syndrome Associated Pruritus (“ITCH Study”) 

NIH EXTRAMURAL INVESTIGATOR/OFFICER: 

Averell H. Sherker, MD, FRCP(C) 

Scientific Advisor for Viral Hepatitis and Liver Diseases 

National Institute of Diabetes and Digestive and Kidney Diseases 

COLLABORATOR OFFICER: 

Mike Grey 
 President &
Chief Executive Officer 
 Lumena Pharmaceuticals, Inc. 

TERM OF CRADA: Five (5) years from date of last execution 
  

	1.	Goals of this CRADA 

 The principal goal of this CRADA is to facilitate collaborative research evaluating
Lumena’s (hereafter “Collaborator”) proprietary compound, LUM001, as an intestinal bile acid transport inhibitor (ASBTi) in the management of Progressive Familial Intrahepatic Cholestatis 1 (also known as “Byler’s
Disease”) and Alagille Syndrome. In these investigations ALGS will serve as a model disease of a more generalized type of cholestasis. 
  

	2.	Background 

 LUM001 is an inhibitor of the ileal bile acid transporter/apical bile acid transporter
(IBAT/ASBT/SLC10A2), initially developed as a lipid lowering agent (SD-5613). At this time, further development for this indication is not planned. By virtue of its ability to inhibit bile acid absorption, however, LUM001 is now being
developed by Lumena Pharmaceuticals as a 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 27 of 33	  	Confidential              

 
potential therapeutic agent for signs and symptoms of cholestatic liver disease. Information regarding LUM001 and its initial disease targets is summarized below. 

Excess and/or abnormal distribution of bile acids are known to be the root cause of many liver diseases. IBAT/ASBT expression is under negative feedback
regulation by bile acids, thus in the setting of cholestasis IBAT/ASBT is maladaptively upregulated (Neimark E C. F., 2004) (Hofman, 2003). As such inhibiting the reuptake of bile acids may represent an ideal treatment for cholestatic disease in
general and more specifically for ALGS and FIC1 disease (Neimark E S. B., 2003). 
 Progressive Familial Intrahepatic Cholestasis (PFIC) 

Progressive familial intrahepatic cholestasis (PFIC), formerly known as “Byler’s Disease,” is a genetic, autosomal recessive disorder of
childhood that disrupts bile formation and causes poor bile flow and buildup of substances in the liver (e.g. cholestasis), resulting in liver cirrhosis usually within the first decade of life. PFIC affects between an estimated 1/50,000 to 1/100,000
children at birth. While three types of PFIC have been identified (e.g. PFICI , PFIC2 and PFIC3) and are each related to mutations in hepatocellular transport system genes involved in bile formation, the collaborative research under the auspices of
this CRADA will evaluate Collaborator’s proprietary compound for the treatment of PFIC 1. PFIC1 usually appears in the first months of life with symptoms that include pruritus (itching), jaundice, short stature, sensorineural deafness,
pancreatitis, watery diarrhea, and elevated sweat electrolyte concentration and liver steatosis. Patients with PFIC usually develop fibrosis and end-stage liver disease before adulthood. Diagnosis is based on clinical manifestations, liver
ultrasonography, cholangiography and liver histology, as well as on specific tests for excluding other causes of childhood cholestasis. 
 Current therapies
for PFIC include biliary diversion to relieve pruritus and slow disease progression or liver transplantation. Because both treatment options require surgical interventions that carry greater risk, a potential pharmacological treatment that can serve
as an alternative to slow disease progression such as LUM001 offers many benefits. 
 Alagille Syndrome 

Alagille syndrome (AGS) is variably characterized by chronic cholestasis, peripheral pulmonary artery stenosis, vertebrae segmentation anomalies,
characteristic facies, posterior embryotoxon/anterior segment abnormalities, pigmentary retinopathy, and dysplastic kidneys. The prevalence is approximately 1/70,000 in the US and EU. Alagille Syndrome diagnosis is based on the clinical picture and
liver biopsy revealing chronic cholestasis and paucity of interlobular bile ducts. Imaging (abdominal ultrasonography, cholangiography) helps to identify biliary anatomy. Differential diagnoses include biliary atresia, congenital hepatic fibrosis,
cystic fibrosis, neonatal jaundice, polycystic kidney disease, progressive familial intrahepatic cholestasis, and tyrosinemia. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 28 of 33	  	Confidential              

 Treatment is non-specific and includes high-carbohydrates and high-medium chain triglyceride diets and vitamin
supplementation. Pruritus may be reduced by cholestyramine or rifampin. Liver transplantation may be necessary for patients with refractory disease. Cardiac or vascular procedures may be required for significant symptomatic lesions. The prognosis is
usually favorable, but complications such as cirrhosis, variceal hemorrhage, refractory ascites, and spontaneous bacterial peritonitis may occur. Though the disease usually stabilizes between ages 4 and 10 years, LUM001 may potentially offer an
alternative to the side effects experienced from the currently available treatments in the relief of the debilitating pruritus that can accompany Alagille Syndrome. When hepatic failure and/or cardiac lesions are present, mortality risk is
increased. 
  

	3.	Description of the Research Plan 

 This CRADA covers a pediatric clinical trial evaluating
Collaborator’s proprietary compound, LUM001 for treatment in children with PFIC 1 and Alagille Syndrome, entitled, “The evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Serum Bile Acids and
the Management of Pruritus in Alagille Syndrome and Familial Intrahepatic Cholestasis 1 (FIC1/BYLER): ITCH Study. The Collaborator will submit an IND to the FDA covering the Protocol described above. This Research Plan is based on the Protocol;
the CRADA will incorporate the latest version of the Protocol and the CRADA research will follow the current version of the IRB approved Protocol, including any subsequent amendments. 

Study Objectives 
 The primary objective of the study is
to assess the safety and tolerability of LUM001 in pediatric patients who suffer from PFIC1 disease or Alagille Syndrome. 
 The secondary objective of the
study is to assess the effect of LUM001 as measured by changes in pruritus scores, and serum bile acids. 
 Study Design 

This Phase 1 clinical trial will be a double-blind, placebo controlled study. Subjects will be randomized at Day 0 to receive either LUM001 or placebo. The
dose for each subject will be increased incrementally weekly over a 4-week period to acclimate the subject to drug. 
 Subjects will thereafter remain on
dose 4 for the remainder of the stable dosing period. Dosing with LUM001 will be stopped after Week 13 and subjects will be followed for up to an additional 4 weeks. 

Subject safety will be evaluated through physical examinations, clinical laboratory tests, and evaluation of AEs. Efficacy will be determined by liver
biochemical tests, serum and urine bile acid levels, serum 7α-hydroxy-4-cholesten-3-one (7αC4) levels, subject/caregiver pruritus severity scores and quality of life/fatigue assessments. 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 29 of 33	  	Confidential              

 Subjects may be withdrawn from the study if they experience a serious or intolerable AE, develop a clinically
significant laboratory abnormality, require a medication or treatment that is prohibited by the protocol, do not follow guidelines specified in the protocol; are lost to follow-up or do not continue to meet entry criteria. 

 

	4.	Respective Contributions of the Parties 

 The NIDDK/ChilDREN will: 

 

	 	•	 	[...***...] 

 Collaborator will: 
  

	 	•	 	[...***...] 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 30 of 33	  	Confidential              

	5.	Description of Other Agreements and Intellectual Property of the Parties 

CRADAs: None. 

MTAs: None. 
 CDAs:
The mutual CDA (DK-12-008) executed between NIDDK and Collaborator on January 12, 2012 (the “Prior CDA”) is superseded by this CRADA. 

Patents: 

[...***...] 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 31 of 33	  	Confidential              

 APPENDIX B 

STAFFING, FUNDING AND MATERIALS/EQUIPMENT CONTRIBUTIONS 

OF THE PARTIES 
 Staffing
Contributions: 
 IC will provide scientific staff and other support necessary to conduct the research and other activities described in the Research
Plan. IC’s scientific staff will include IC’s CRADA Extramural Investigator/Officer and technical staff. 
 IC estimates that
        .10         person-years of effort per year will be required to complete the CRADA research. (RECOMMENDED) 

Collaborator will provide scientific staff and other support necessary to conduct the research and other activities described in the Research Plan.
Collaborator’s scientific staff will include Collaborator’s Principal Investigator and technical staff. 
 Collaborator estimates that
        .10         person-years of effort per year will be required to complete the CRADA research. (RECOMMENDED) 

Funding Contributions: 
 Collaborator
agrees to provide funds in the amount of $ 1,542,823.74 to conduct the Research Plan under the scope of this CRADA, in accordance with the schedule below. The funds will be used by the IC to acquire technical, statistical, and administrative support
for the research activities, as well as to pay for supplies and travel expenses. Collaborator will provide funds in installments according to the following payment schedule: 

	 	•	 	1.     [...***...] 

	 	•	 	2.     [...***...] 

	 	•	 	3.     [...***...] 

	 	•	 	4.     [...***...] 

	 	•	 	5.     [...***...] 

	 	•	 	6.     [...***...] 

 Collaborator agrees that IC can allocate the funding between the
various categories in support of the CRADA research as IC sees fit. 
 CRADA PAYMENTS: 

Collaborator will make checks payable to the NIDDK, will reference the CRADA number and title on each check, and will send them via trackable mail or courier
to: 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 32 of 33	  	Confidential              

 [...***...] 
 CRADA
Travel Payments: 
 Travel arrangements for all Government staff will be made in accordance with the Federal Travel Rules and Regulations, whether arranged
by IC and funded using either appropriated funds or CRADA funds, or arranged and funded directly by Collaborator. 
 Materials/Equipment
Contributions: 
 IC will provide the following IC Materials for use under this CRADA: None 

will Collaborator will provide the Test Article for performance of the Research Plan under this CRADA. 

Collaborator will provide the following Collaborator Materials and/or capital equipment for use under this CRADA: 

Collaborator Materials: Kits 
 Capital Equipment: None 

  

			
	PHS ECT-CRADA	  	Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012
	Page 33 of 33	  	ConfidentialEX-10.1

 Exhibit 10.1 

 
  

TERM LOAN CREDIT AGREEMENT 
 dated
as of 
 March 31, 2014 

among 
 NEWMONT MINING
CORPORATION, 
 The Lenders Party Hereto 

and 
 JPMORGAN CHASE BANK, N.A.,

 as Administrative Agent 
 BMO
CAPITAL MARKETS, THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., CITIGROUP GLOBAL MARKETS INC., CREDIT SUISSE SECURITIES (USA) LLC, HSBC SECURITIES (USA) INC., MIZUHO BANK, LTD., THE ROYAL BANK OF SCOTLAND PLC, CANADA BRANCH AND SUMITOMO MITSUI BANKING
CORPORATION, 
 as Co-Syndication Agents 
  

 
 J. P. MORGAN
SECURITIES LLC, BMO CAPITAL MARKETS, THE BANK OF TOKYO-MITSUBISHI UFJ, LTD., CITIGROUP GLOBAL MARKETS INC., CREDIT SUISSE SECURITIES (USA) LLC, HSBC SECURITIES (USA) INC., MIZUHO BANK, LTD., RBS SECURITIES INC. AND SUMITOMO MITSUI BANKING
CORPORATION, 
 as Joint Lead Arrangers and Joint Bookrunners 
  

 
  

 TABLE OF CONTENTS 
  

 

							
	 	  	 	  	Page	 
	
	ARTICLE I	 
	
	Definitions	  
			
	 SECTION 1.01.
	  	 Defined Terms
	  	 	1	  
	 SECTION 1.02.
	  	 Classification of Loans and Borrowings
	  	 	19	  
	 SECTION 1.03.
	  	 Terms Generally
	  	 	19	  
	 SECTION 1.04.
	  	 Accounting Terms; GAAP
	  	 	20	  
	
	ARTICLE II	  
	
	The Credits	  
			
	 SECTION 2.01.
	  	 Commitments
	  	 	20	  
	 SECTION 2.02.
	  	 Loans and Borrowings
	  	 	20	  
	 SECTION 2.03.
	  	 Requests for Borrowings
	  	 	21	  
	 SECTION 2.04.
	  	 [Reserved]
	  	 	22	  
	 SECTION 2.05.
	  	 [Reserved]
	  	 	22	  
	 SECTION 2.06.
	  	 [Reserved]
	  	 	22	  
	 SECTION 2.07.
	  	 Funding of Borrowings
	  	 	22	  
	 SECTION 2.08.
	  	 Interest Elections
	  	 	22	  
	 SECTION 2.09.
	  	 Termination and Reduction of Commitments
	  	 	23	  
	 SECTION 2.10.
	  	 Repayment of Loans; Evidence of Debt
	  	 	24	  
	 SECTION 2.11.
	  	 Amortization of Loans
	  	 	25	  
	 SECTION 2.12.
	  	 Prepayment of Loans
	  	 	26	  
	 SECTION 2.13.
	  	 Fees
	  	 	27	  
	 SECTION 2.14.
	  	 Interest
	  	 	27	  
	 SECTION 2.15.
	  	 Alternate Rate of Interest
	  	 	28	  
	 SECTION 2.16.
	  	 Increased Costs
	  	 	28	  
	 SECTION 2.17.
	  	 Break Funding Payments
	  	 	29	  
	 SECTION 2.18.
	  	 Taxes
	  	 	30	  
	 SECTION 2.19.
	  	 Payments Generally; Pro Rata Treatment; Sharing of Set-offs
	  	 	33	  
	 SECTION 2.20.
	  	 Mitigation Obligations; Replacement of Lenders
	  	 	35	  
	 SECTION 2.21.
	  	 Defaulting Lenders
	  	 	36	  
	 SECTION 2.22.
	  	 Incremental Facilities
	  	 	36	  
	 SECTION 2.23.
	  	 Extension of Maturity Date
	  	 	38	  
	
	ARTICLE III	  
	
	Representations and Warranties	  
			
	 SECTION 3.01.
	  	 Organization; Powers
	  	 	40	  
	 SECTION 3.02.
	  	 Authorization; Enforceability
	  	 	40	  

  
 i 

					
	SECTION 3.03.	  	 Governmental Approvals; No Conflicts
	  	40
	SECTION 3.04.	  	 Financial Condition; No Material Adverse Change
	  	41
	SECTION 3.05.	  	 Properties
	  	41
	SECTION 3.06.	  	 Litigation and Environmental Matters
	  	41
	SECTION 3.07.	  	 Compliance with Laws and Agreements
	  	42
	SECTION 3.08.	  	 Investment Company Status
	  	42
	SECTION 3.09.	  	 Taxes
	  	42
	SECTION 3.10.	  	 ERISA
	  	42
	SECTION 3.11.	  	 Disclosure
	  	42
	SECTION 3.12.	  	 Federal Regulations
	  	43
	SECTION 3.13.	  	 Subsidiaries
	  	43
	SECTION 3.14.	  	 Anti-Corruption Laws and Sanctions
	  	43
	
	ARTICLE IV
	
	Conditions
			
	SECTION 4.01.	  	 Effective Date
	  	43
	SECTION 4.02.	  	 Each Credit Event
	  	45
	
	ARTICLE V
	
	Affirmative Covenants
			
	SECTION 5.01.	  	 Financial Statements and Other Information
	  	45
	SECTION 5.02.	  	 Notices of Material Events
	  	47
	SECTION 5.03.	  	 Existence; Conduct of Business
	  	47
	SECTION 5.04.	  	 Payment of Obligations
	  	47
	SECTION 5.05.	  	 Maintenance of Properties; Insurance
	  	48
	SECTION 5.06.	  	 Books and Records; Inspection Rights
	  	48
	SECTION 5.07.	  	 Compliance with Laws
	  	48
	SECTION 5.08.	  	 Use of Proceeds
	  	48
	SECTION 5.09.	  	 Further Assurances
	  	49
	
	ARTICLE VI
	
	Negative Covenants
			
	SECTION 6.01.	  	 Consolidated Indebtedness
	  	49
	SECTION 6.02.	  	 Liens
	  	49
	SECTION 6.03.	  	 Fundamental Changes
	  	50
	
	ARTICLE VII
	
	Events of Default

  
 ii 

					
	
	ARTICLE VIII
	
	The Administrative Agent
	
	ARTICLE IX
	
	Miscellaneous
			
	SECTION 9.01.	  	Notices	  	57
	SECTION 9.02.	  	 Waivers; Amendments
	  	58
	SECTION 9.03.	  	 Expenses; Indemnity; Damage Waiver
	  	59
	SECTION 9.04.	  	 Successors and Assigns
	  	61
	SECTION 9.05.	  	 Survival
	  	64
	SECTION 9.06.	  	 Counterparts; Integration; Effectiveness
	  	64
	SECTION 9.07.	  	 Severability
	  	64
	SECTION 9.08.	  	 Right of Setoff
	  	65
	SECTION 9.09.	  	 Governing Law; Jurisdiction; Consent to Service of Process
	  	65
	SECTION 9.10.	  	 WAIVER OF JURY TRIAL
	  	66
	SECTION 9.11.	  	 Headings
	  	66
	SECTION 9.12.	  	 Confidentiality
	  	66
	SECTION 9.13.	  	 USA Patriot Act
	  	67
	SECTION 9.14.	  	 Release of Newmont USA as a Guarantor
	  	67
	SECTION 9.15.	  	 No Fiduciary Relationship
	  	67

  
 iii 

	
	SCHEDULES:
	
	Schedule 2.01 — Commitments
	Schedule 3.06 — Disclosed Matters
	Schedule 3.13 — Subsidiaries
	Schedule 6.02 — Existing Liens
	  
 EXHIBITS:

 

	Exhibit A — Form of Assignment and Acceptance
	Exhibit B — Form of Assumption Agreement
	Exhibit C — Form of U.S. Tax Certificate
	Exhibit D — Form of Guarantee Agreement
	Exhibit E — Form of Maturity Date Extension Request

  
 iv 

 TERM LOAN CREDIT AGREEMENT dated as of March 31, 2014 (this
“Agreement”), among NEWMONT MINING CORPORATION, a Delaware corporation (the “Borrower”), the Lenders party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent. 

The Borrower has requested the Lenders (such term and each other capitalized term used and not otherwise defined herein having the meaning
assigned to it in Article I) extend credit in the form of Commitments under which the Borrower may obtain Loans on the Funding Date in an aggregate principal amount not in excess of $575,000,000. 

The Lenders are willing to establish the credit facility referred to in the preceding paragraph and extend credit upon the terms and subject
to the conditions set forth herein. Accordingly, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

ARTICLE I  

Definitions 
 SECTION
1.01. Defined Terms. As used in this Agreement, the following terms have the meanings specified below: 
 “ABR”,
when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are bearing interest at a rate determined by reference to the Alternate Base Rate. 

“Adjusted LIBO Rate” means, with respect to any Eurocurrency Borrowing for any Interest Period, an interest rate per annum
(rounded upwards, if necessary, to the next 1/100 of 1.00%) equal to (a) the LIBO Rate for such Interest Period multiplied by (b) the Statutory Reserve Rate. 

“Administrative Agent” means JPMorgan Chase Bank, N.A., in its capacity as administrative agent for the Lenders hereunder, or
any successor thereto appointed in accordance with Article VIII. 
 “Administrative Questionnaire” means an
Administrative Questionnaire in a form supplied by the Administrative Agent. 
 “Affiliate” means, with respect to a
specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. 

“Agreement” has the meaning ascribed to such term in the preamble hereto. 

 “Alternate Base Rate” means, for any day, a rate per annum equal to the greatest
of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus  1⁄2 of 1.00% and (c) the Adjusted
LIBO Rate on such day (or if such day is not a Business Day, the immediately preceding Business Day) for a deposit in dollars with a maturity of one month plus 1.00%. For purposes of clause (c) above, the Adjusted LIBO Rate on any day shall be
based on the rate per annum appearing on the Reuters “LIBOR01” screen displaying Intercontinental Exchange Benchmark Administration Ltd. Rates (or on any successor or substitute screen provided by Reuters, or any successor to or substitute
for such service, providing rate quotations comparable to those currently provided on such screen, as determined by the Administrative Agent from time to time for purposes of providing quotations of interest rates applicable to dollar deposits in
the London interbank market) at approximately 11:00 a.m., London time, two Business Days prior to such day for deposits in dollars with a maturity of one month. Any change in the Alternate Base Rate due to a change in the Prime Rate, the Federal
Funds Effective Rate or the Adjusted LIBO Rate shall be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted LIBO Rate, respectively. 

“Anti-Corruption Laws” means the United States Foreign Corrupt Practices Act of 1977, as amended, and the United Kingdom
Bribery Act of 2010, as amended. 
 “Arrangers” means J.P. Morgan Securities LLC, BMO Capital Markets, The Bank of
Tokyo-Mitsubishi UFJ, Ltd., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC, HSBC Securities (USA) Inc., Mizuho Bank, Ltd., RBS Securities Inc. and Sumitomo Mitsui Banking Corporation, each in its capacity as joint lead arranger
and joint bookrunner for the credit facility provided for herein. 
 “Applicable Percentage” means, with respect to any
Lender, (i) prior to the Funding Date, the percentage of the total Commitments represented by such Lender’s Commitment or (ii) on or after the Funding Date, the percentage of the aggregate principal amount of outstanding Loans
represented by the outstanding Loans held by such Lender; provided that if any Defaulting Lender exists at such time, the Applicable Percentages shall be calculated disregarding such Defaulting Lender’s Commitment or outstanding Loans,
as applicable. If the Commitments have terminated or expired, the Applicable Percentages shall be determined based upon the Commitments most recently in effect, giving effect to any assignments and to any Lender’s status as a Defaulting Lender
at the time of determination. 

  
 2 

 “Applicable Rate” means, for any day, (a) with respect to any Incremental
Term Loan of any Series, the rate per annum specified in the Incremental Facility Agreement establishing the Incremental Term Commitments of such Series and (b) with respect to any Eurodollar Loan or any ABR Loan that is an Initial Term Loan,
the applicable rate per annum set forth under “LIBOR Margin” or “ABR Margin”, as the case may be, based upon the ratings by Moody’s and S&P applicable on such date to the Index Debt: 

 

					
	 Rating

(Moody’s, S&P)
	 	 LIBOR Margin

(% per annum)
	 	 ABR Margin

(% per annum)

	Category 1
 A/A2 or higher
	 	0.875%	 	0.000%
			
	Category 2
 A-/A3
	 	1.000%	 	0.000%
			
	Category 3
 BBB+/Baa1
	 	1.15%	 	0.15%
			
	Category 4
 BBB/Baa2
	 	1.40%	 	0.40%
			
	Category 5
 BBB-/Baa3 or lower

(or unrated)
	 	1.65%	 	0.65%

 For purposes of the foregoing, (i) if either Moody’s or S&P shall not have in effect a rating
for the Index Debt (other than by reason of the circumstances referred to in the last sentence of this definition), then such rating agency shall be deemed to have established a rating in Category 5; (ii) if the ratings established or deemed to
have been established by Moody’s and S&P for the Index Debt shall fall within different Categories, (a) until and including June 30, 2015, the Applicable Rate shall be based on the lower of the two ratings unless one of the two
ratings is more than one Category lower than the other, in which case the Applicable Rate shall be determined by reference to the Category next above that of the lower of the two ratings and (b) after June 30, 2015, the Applicable Rate
shall be based on the higher of the two ratings unless one of the two ratings is more than one Category lower than the other, in which case the Applicable Rate shall be determined by reference to the Category next below that of the higher of the two
ratings and (iii) if the ratings established or deemed to have been established by Moody’s and S&P for the Index Debt shall be changed (other than as a result of a change in the rating system of Moody’s or S&P), such change
shall be effective as of the date on which it is first announced by the applicable rating agency. Each change in the Applicable Rate shall apply during the period commencing on the effective date of such change and ending on the date immediately
preceding the effective date of the next such change. If the rating system of Moody’s or S&P shall change, or if either such rating agency shall cease to be in the business of rating corporate debt obligations, the Borrower and the
Administrative Agent shall negotiate in good faith to amend this definition to reflect such changed rating system or the unavailability of ratings from such rating agency and, pending the effectiveness of any such amendment, the Applicable Rate
shall be determined by reference to the rating most recently in effect prior to such change or cessation. 

  
 3 

 “Assignment and Acceptance” means an assignment and acceptance entered into by a
Lender and an assignee (with the consent of any party whose consent is required by Section 9.04), and accepted by the Administrative Agent, in the form of Exhibit A or any other form approved by the Administrative Agent. 

“Assumption Agreement” means an assumption agreement in the form of Exhibit B or any other form approved by the
Administrative Agent entered into by any Person that has merged or consolidated with the Borrower where such Person is the surviving corporation. 

“Bankruptcy Event” means, with respect to any Person, that such Person has become the subject of a bankruptcy or insolvency
proceeding, or has had a receiver, conservator, trustee, administrator, custodian, assignee for the benefit of creditors or similar Person charged with the reorganization or liquidation of its business appointed for it, or, in the good faith
determination of the Administrative Agent, has taken any action in furtherance of, or indicating its consent to, approval of or acquiescence in, any such proceeding or appointment; provided that a Bankruptcy Event shall not result solely by
virtue of any ownership interest, or the acquisition of any ownership interest, in such Person by a Governmental Authority; provided, however, that such ownership interest does not result in or provide such Person with immunity from
the jurisdiction of courts within the United States of America or from the enforcement of judgments or writs of attachment on its assets or permit such Person (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any agreements
made by such Person. 
 “Board” means the Board of Governors of the Federal Reserve System of the United States of America.

 “Borrower” has the meaning ascribed such term in the preamble to this Agreement. 

“Borrowing” means Loans of the same Type made, converted or continued on the same date and, in the case of Eurodollar Loans,
as to which a single Interest Period is in effect. 
 “Borrowing Request” means a request by the Borrower for a Borrowing
in accordance with Section 2.03. 
 “Business Day” means any day that is not a Saturday, Sunday or other day on which
commercial banks in New York City are authorized or required by law to remain closed; provided that when used in connection with a Eurodollar Loan, the term “Business Day” shall also exclude any day on which banks are
not open for dealings in dollar deposits in the London interbank market. 
 “Capital Lease Obligations” of any Person means
the obligations of such Person to pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations are required to be classified and accounted for
as capital leases on a balance sheet of such 

  
 4 

 
Person under GAAP, and the amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP. 

“Change in Control” means (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any
Person or group (within the meaning of the Exchange Act), of shares representing more than 50% of the aggregate ordinary voting power represented by the issued and outstanding capital stock of the Borrower, (b) the occupation of a majority of
the seats (other than vacant seats) on the board of directors of the Borrower by Persons who were neither (i) nominated by the board of directors of the Borrower nor (ii) appointed by directors so nominated or (c) for so long as
Newmont USA is a Guarantor of the Obligations, the Borrower shall cease to own, directly or through subsidiaries, capital stock and other equity interests of Newmont USA, representing, after giving effect to ownership attributable to all minority
interests in subsidiaries through which such capital stock or equity interests are indirectly owned, at least 51% of the economic interest in Newmont USA represented by all of its outstanding capital stock and other equity securities. 

“Change in Law” means the occurrence, after the Effective Date, of any of the following: (a) the adoption of any rule,
regulation, treaty or other law, (b) any change in any rule, regulation, treaty or other law or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c) the making or issuance of any
request, rule, guideline or directive (whether or not having the force of law) of any Governmental Authority; provided that, notwithstanding anything herein to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection
Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking
Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall, in each case, be deemed to be a “Change in Law”, regardless of the date enacted,
adopted, promulgated or issued. 
 “Class”, when used in reference to (a) any Loan or Borrowing, refers to whether
such Loan, or the Loans comprising such Borrowing, are Initial Term Loans or Incremental Term Loans of any Series, (b) any Commitment, refers to whether such Commitment is a Commitment in respect of the Initial Term Loans or an Incremental Term
Commitment and (c) any Lender, refers to whether such Lender has a Loan or Commitment of a particular Class. 
 “Code”
means the Internal Revenue Code of 1986, as amended. 
 “Commission” means the Securities and Exchange Commission. 

“Commitments” means (x) Initial Term Commitments or (y) Incremental Term Commitments. 

“Commodity Hedging Agreement” means any commodity price protection agreement or other commodity price hedging agreement to
which the Borrower or any 

  
 5 

 
Significant Subsidiary is a party, but, in any event, shall not include any agreement for the sale in the ordinary course of business and on standard trade terms of any commodity produced
(a) from properties or (b) by other interests owned by the Borrower or its Subsidiaries. 
 “Connection Income
Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes. 

“Consenting Lender” has the meaning assigned to such term in Section 2.23. 

“Contingent Obligation” means as to any Person, any obligation of such Person guaranteeing or in effect guaranteeing any
Indebtedness, leases, dividends or other obligations (“primary obligations”) of any other Person (the “primary obligor”) in any manner, whether directly or indirectly, including, without limitation, any obligation
of such Person, whether or not contingent (a) to purchase any such primary obligation or any property constituting direct or indirect security therefor, (b) to advance or supply funds (i) for the purchase or payment of any such
primary obligation or (ii) to maintain working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor, (c) to purchase property, securities or services primarily for the
purpose of assuring the owner of any such primary obligation of the ability of the primary obligor to make payment of such primary obligation or (d) otherwise to assure or hold harmless the owner of any such primary obligation against loss in
respect thereof; provided, however, that the term Contingent Obligation shall not include endorsements of instruments for deposit or collection in the ordinary course of business. Unless otherwise limited by the terms of such
Contingent Obligation, the amount of any Contingent Obligation shall be deemed to be an amount equal to the stated or determinable amount of the primary obligation in respect of which such Contingent Obligation is made or, if not stated or
determinable, the maximum reasonably anticipated liability in respect thereof as determined by the Borrower in good faith. 

“Control” means the possession, directly or indirectly, of the power to direct or cause the direction of the management or
policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto. 

“Credit Party” means the Administrative Agent and each Lender. 

“Declining Lender” has the meaning assigned to such term in Section 2.23. 

“Default” means any event or condition which constitutes an Event of Default or which upon notice, lapse of time or both
would, unless cured or waived, become an Event of Default. 
 “Defaulting Lender” means any Lender that (a) has
failed, within two Business Days of the date required to be funded or paid, (i) to fund any portion of its 

  
 6 

 
Loans or (ii) to pay to any Credit Party any other amount required to be paid by it hereunder, unless, in the case of clause (i) above, such Lender notifies the Administrative Agent in
writing that such failure is the result of such Lender’s good faith determination that a condition precedent to funding (specifically identified in such writing, including, if applicable, by reference to a specific Default) has not been
satisfied, (b) has notified the Borrower or any Credit Party in writing, or has made a public statement, to the effect that it does not intend or expect to comply with any of its funding obligations under this Agreement (unless such writing or
public statement indicates that such position is based on such Lender’s good-faith determination that a condition precedent (specifically identified in such writing, including, if applicable, by reference to a specific Default) to funding a
Loan cannot be satisfied) or generally under other agreements in which it commits to extend credit, (c) has failed, within three Business Days after request by a Credit Party made in good faith to provide a certification in writing from an
authorized officer of such Lender that it will comply with its obligations to fund prospective Loans, provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon such Credit Party’s receipt of
such certification in form and substance satisfactory to it and the Administrative Agent, or (d) has become the subject of a Bankruptcy Event. 

“Disclosed Matters” means the actions, suits and proceedings and the environmental matters disclosed in Schedule 3.06 or
in the Form 10-K of the Borrower, in respect of its fiscal year ended December 31, 2013. 
 “dollars” or
“$” refers to lawful money of the United States of America. 
 “Effective Date” means the date on
which the conditions specified in Section 4.01 are satisfied (or waived in accordance with Section 9.02). 

“Environmental Laws” means all laws, rules, regulations, codes, ordinances, orders, decrees, judgments, injunctions, notices
or binding agreements issued, promulgated or entered into by any Governmental Authority, relating in any way to the environment, preservation or reclamation of natural resources, the management, release or threatened release of any Hazardous
Material or to health and safety matters relating to the foregoing. 
 “Environmental Liability” means any liability,
contingent or otherwise (including any liability for damages, costs of investigation, reclamation or remediation, fines, penalties or indemnities), of the Borrower or any Subsidiary directly or indirectly resulting from or based upon
(a) compliance or non-compliance with any Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the presence,
release or threatened release of any Hazardous Materials or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing. 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended from time to time. 

  
 7 

 “ERISA Affiliate” means any trade or business (whether or not incorporated)
that, together with the Borrower, is treated as a single employer under Section 414(b) or (c) of the Code. 
 “ERISA
Event” means (a) any “reportable event”, as defined in Section 4043 of ERISA or the regulations issued thereunder, with respect to a US Plan (other than an event for which the
30-day notice period is waived) (or, with respect to a Plan that is not a US Plan, any similar event under any similar non-US law, regulation or rule); (b) failure by any US Plan to meet the minimum
funding standards (as defined in Section 412 of the Code or Section 302 of ERISA) applicable to such US Plan in each instance, whether or not waived (or, with respect to a Plan that is not a US Plan, any similar funding deficiency under
any similar non-US law, regulation or rule); (c) the filing pursuant to Section 412(c) of the Code or Section 302(c) of ERISA of an application for a waiver of the minimum funding standard with respect to any Plan (or, with respect to
a Plan that is not a US Plan, any similar filing under any similar non-US law, regulation or rule); (d) the incurrence by the Borrower or any of its ERISA Affiliates of any liability under Title IV of ERISA with respect to the termination
of any Plan (or, with respect to a Plan that is not a US Plan, the incurrence of any similar liability under any similar non-US law, regulation or rule); (e) the receipt by the Borrower or any ERISA Affiliate from the PBGC, any non-US
Governmental Authority (with respect to a Plan that is not a US Plan) or a plan administrator of any notice relating to an intention to terminate any Plan or Plans or to appoint a trustee to administer any Plan; (f) the incurrence by the
Borrower or any of its ERISA Affiliates of any liability with respect to the withdrawal or partial withdrawal from any Plan or Multiemployer Plan; or (g) the receipt by the Borrower or any ERISA Affiliate of any notice concerning the imposition
of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent or in reorganization, within the meaning of Title IV of ERISA (or, with respect to a Plan that is not a US Plan, any similar notice under
provisions of similar non-US law, regulation or rule). 
 “Eurodollar”, when used in reference to any Loan or Borrowing,
refers to whether such Loan, or the Loans comprising such Borrowing, are bearing interest at a rate determined by reference to the Adjusted LIBO Rate. 

“Event of Default” has the meaning assigned to such term in Article VII. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
promulgated thereunder. 
 “Excluded Taxes” means, with respect to any payment made by any Loan Party under any Loan
Document, any of the following Taxes imposed on or with respect to a Recipient: 
 (a) income (including, in the case of a
Recipient that is a U.S. Person, any backup withholding tax), or franchise Taxes imposed on (or measured by) net income by (i) the United States of America (or any political subdivision or taxing authority thereof or therein), or by the
jurisdiction under the laws of which such 

  
 8 

 
Recipient is organized or registered or in which its principal office is located or, in the case of any Lender, in which its applicable lending office is located, or any subdivision thereof or
therein, or (ii) any other jurisdiction with which such Recipient has a present or former connection (other than any such connection arising from such Recipient having executed, delivered, enforced or become a party to, or performed its
obligations or received payment under, received or perfected a security interest under, or engaged in any other transaction pursuant to, or enforced any Loan Document, or sold or assigned an interest in any Loan Document), 

(b) any branch profits Taxes imposed by the United States of America or any similar Taxes imposed by any other jurisdiction in
which the Borrower is located, 
 (c) in the case of a Non-U.S. Lender (other than an assignee pursuant to a request by the
Borrower under Section 2.20(b)), any U.S. Federal withholding Taxes resulting from any law in effect on the date such Non-U.S. Lender becomes a party to this Agreement (or designates a new lending office) or attributable to such Non-U.S.
Lender’s failure to comply with Section 2.18(f)), except, to the extent that such Non-U.S. Lender (or its assignor, if any) was entitled, at the time of designation of a new lending office (or assignment), to receive additional amounts
from the Borrower with respect to such withholding Taxes pursuant to Section 2.18(a), and 
 (d) any withholding Taxes
imposed under FATCA. 
 “FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any
amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any intergovernmental agreements entered into thereunder and any
agreements entered into pursuant to Section 1471(b) of the Code. 
 “Federal Funds Effective Rate” means, for any day,
the weighted average (rounded upwards, if necessary, to the next 1/100 of 1.00%) of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers, as published on the next succeeding
Business Day by the Federal Reserve Bank of New York, or, if such rate is not so published for any day that is a Business Day, the average (rounded upwards, if necessary, to the next 1/100 of 1.00%) of the quotations for such day for such
transactions received by the Administrative Agent from three Federal funds brokers of recognized standing selected by it. 

“Financial Officer” means the chief financial officer, principal accounting officer, treasurer, assistant treasurer or
controller of the Borrower. 
 “Funding Date” means the date on which the Initial Term Loans are funded by the Lenders for
the account of the Borrower pursuant to Section 2.01(a). 

  
 9 

 “GAAP” means generally accepted accounting principles in the United States of
America. 
 “Governmental Authority” means the government of the United States of America, any other nation or any
political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or
functions of or pertaining to government (including any supra-national body exercising such powers or functions, such as the European Union). 

“Guarantee Agreement” means the Guarantee Agreement made by Newmont USA in favor of the Administrative Agent for the benefit
of the Lenders substantially in the form of Exhibit D. 
 “Guarantee Requirement” means, at any time that Newmont
USA guarantees any Material Indebtedness of the Borrower, that (a) the Guarantee Agreement shall have been executed by Newmont USA and (b) if Newmont USA shall become a party to the Guarantee Agreement after the Effective Date, the
Administrative Agent shall have received documents comparable to those delivered under paragraphs (c) and (d) of Section 4.01 with respect to Newmont USA on the Effective Date. 

“Guarantor” means, at any time that it is a party to the Guarantee Agreement, Newmont USA. 

“Hazardous Materials” means all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes
or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to
any Environmental Law. 
 “Incremental Facility Agreement” means an Incremental Facility Agreement, in form and substance
reasonably satisfactory to the Administrative Agent and the Borrower, among the Borrower, the Administrative Agent and one or more Incremental Lenders, establishing Incremental Term Commitments of any Series and effecting such other amendments
hereto and to the other Loan Documents as are contemplated by Section 2.22. 
 “Incremental Lender” means a Lender
with an Incremental Term Commitment or an outstanding Incremental Term Loan. 
 “Incremental Term Commitment” means, with
respect to any Lender, the commitment, if any, of such Lender, established pursuant an Incremental Facility Agreement and Section 2.22, to make Incremental Term Loans of any Series hereunder, expressed as an amount representing the maximum
principal amount of the Incremental Term Loans of such Series to be made by such Lender. 

  
 10 

 “Incremental Term Loan” means a term loan made by an Incremental Lender to the
Borrower pursuant to an Incremental Facility Agreement in accordance with Section 2.22. 
 “Incremental Term Maturity
Date” means, with respect to Incremental Term Loans of any Series, the scheduled date on which such Incremental Term Loans shall become due and payable in full hereunder, as specified in the applicable Incremental Facility Agreement, as
such date may be extended pursuant to Section 2.23. 
 “Indebtedness” of any Person means, at a particular date, the
sum (without duplication) at such date of (a) all indebtedness of such Person for borrowed money or for the deferred purchase price of property or services (other than accounts payable arising in the ordinary course of such Person’s
business payable on terms customary in the trade), (b) the capitalized portion of all obligations of such Person under Capital Lease Obligations, (c) obligations as recorded in such Person’s financial statements in respect of
borrowings of gold, (d) deferred revenues from sales of future production and all obligations in respect of prepaid production arrangements, prepaid forward sale arrangements or derivative contracts in respect of which such Person receives
upfront payments in consideration of an obligation to deliver product or commodities (or make cash payments based on the value of product or commodities) at a future time, but, in any event, excluding any agreement for the sale in the ordinary
course of business and on standard trade terms (including standard trade payment terms) of any commodity produced (i) from properties or (ii) by other interests owned by such Person and (e) without duplication, all Contingent
Obligations of such Person in respect of obligations of another Person of the type described in the preceding clauses (a) through (d). The amount of Indebtedness in respect of the upfront payments referred to in clause (d) of this
definition shall be the amount in respect of the obligations referred to in such clause that would be required to appear as a liability on a consolidated balance sheet of such Person and its subsidiaries prepared in accordance with GAAP. 

“Indemnified Taxes” means (a) Taxes other than Excluded Taxes, imposed on or with respect to any payment made by any
Loan Party under any Loan Document and (b) Other Taxes. 
 “Index Debt” means senior, unsecured, long-term
indebtedness for borrowed money of the Borrower that is not guaranteed by any other Person (other than unsecured guarantees by the Guarantor) or subject to any other credit enhancement. 

“Initial Term Commitment” means, with respect to each Lender, the commitment of such Lender to make Initial Term Loans
pursuant to Section 2.01(a). The initial amount of each Lender’s Initial Term Commitment is set forth on Schedule 2.01. The aggregate amount of the Initial Term Commitments on the date hereof is $575,000,000. 

“Initial Term Loans” means the term loans made by the Lenders on the Funding Date to the Borrower pursuant to
Section 2.01(a). 

  
 11 

 “Initial Term Loan Maturity Date” means the five year anniversary of the Funding
Date, as such term may be extended pursuant to Section 2.23. 
 “Interest Election Request” means a request by the
Borrower to convert or continue a Borrowing in accordance with Section 2.08. 
 “Interest Payment Date” means
(a) with respect to any ABR Loan, the last day of each March, June, September and December and (b) with respect to any Eurodollar Loan, the last day of the Interest Period applicable to the Borrowing of which such Loan is a part and, in
the case of a Eurodollar Borrowing with an Interest Period of more than three months’ duration, each day prior to the last day of such Interest Period that occurs at intervals of three months’ duration after the first day of such Interest
Period. 
 “Interest Period” means with respect to any Eurodollar Borrowing, the period commencing on the date of such
Borrowing and ending on the numerically corresponding day in the calendar month that is one, two, three or six months (or twelve months if made available by all participating Lenders) thereafter, as the Borrower may elect; provided, that
(i) if any Interest Period would end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless, in the case of a Eurodollar Borrowing only, such next succeeding Business Day would fall
in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day and (ii) any Interest Period pertaining to a Eurodollar Borrowing that commences on the last Business Day of a calendar month (or on a
day for which there is no numerically corresponding day in the last calendar month of such Interest Period) shall end on the last Business Day of the last calendar month of such Interest Period. For purposes hereof, the date of a Borrowing initially
shall be the date on which such Borrowing is made and thereafter shall be the effective date of the most recent conversion or continuation of such Borrowing. 

“IRS” means, the United States Internal Revenue Service. 

“JPMorgan” means JPMorgan Chase Bank, N.A. and its successors. 

“Lease Accounting GAAP Change” has the meaning assigned to such term in Section 1.04. 

“Lender Parent” means, with respect to any Lender, any Person in respect of which such Lender is a subsidiary. 

“Lenders” means the Persons listed on Schedule 2.01 and any other Person that shall have become a party hereto pursuant
to an Assignment and Acceptance or an Incremental Facility Agreement pursuant to Section 2.22, other than any such Person that ceases to be a party hereto pursuant to an Assignment and Acceptance. 

“LIBO Rate” means, with respect to any Eurodollar Borrowing for any Interest Period, the rate appearing on Reuters Screen
LIBOR01 Page displaying Intercontinental Exchange Benchmark Administration Ltd. Rates (or on any successor or 

  
 12 

 
substitute page on such screen) at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period, as the rate for dollar deposits in the London
interbank market with a maturity comparable to such Interest Period. In the event that such rate does not appear on such page (or on any successor or substitute page on such screen or otherwise on such screen), the “LIBO Rate” shall be
determined by reference to such other comparable publicly available service for displaying interest rates applicable to dollar deposits in the London interbank market as may be selected by the Administrative Agent or, in the absence of such
availability, by reference to the rate at which dollar deposits of $5,000,000 and for a maturity comparable to such Interest Period are offered by the principal London office of the Administrative Agent in immediately available funds in the London
interbank market at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period. 

“Lien” means, with respect to any asset, (a) any mortgage, deed of trust, lien, pledge, hypothecation, encumbrance,
charge or security interest in, on or of such asset and (b) the interest of a vendor or a lessor under any conditional sale agreement, capital lease or title retention agreement (or any financing lease having substantially the same economic
effect as any of the foregoing) relating to such asset. 
 “Loan Documents” means this Agreement, each Incremental Facility
Agreement, if any, the Guarantee Agreement and each promissory note delivered pursuant to this Agreement. 
 “Loan Parties”
means the Borrower and the Guarantor. 
 “Loans” means the Initial Term Loans and the Incremental Term Loans, if any. 

“Margin Stock” means “margin stock” as defined in Regulation U of the Board. 

“Material Adverse Effect” means a material adverse effect on the business, assets, operations or financial condition of the
Borrower and its Subsidiaries taken as a whole. 
 “Material Commodity Hedging Indebtedness” means obligations under any
Commodity Hedging Agreement with respect to which the Borrower or any Significant Subsidiary is obligated to pay more than $100,000,000 (after giving effect to any netting provisions of such agreement and subtracting the value of any cash (or cash
equivalent) collateral provided by the Borrower or any Significant Subsidiary under such agreement) as a result of an event of default by, or termination event applicable solely to, the Borrower or any Significant Subsidiary. 

“Material Indebtedness” means Indebtedness (other than the Loans) of any one or more of the Borrower, Newmont USA and the
Significant Subsidiaries in an aggregate principal amount exceeding $100,000,000. 

  
 13 

 “Maturity Date” means (a) the Initial Term Loan Maturity Date or
(b) the Incremental Term Maturity Date with respect to Incremental Term Loans of any Series, as the context requires. 

“Maturity Date Extension Request” means a request by the Borrower, in the form of Exhibit E hereto or such other form as
shall be approved by the Administrative Agent, for the extension of the Maturity Date pursuant to Section 2.23. 

“Moody’s” means Moody’s Investors Service, Inc. 

“Multiemployer Plan” means a US Multiemployer Plan or a non-US defined benefit retirement plan (i) to which the Borrower
or an ERISA Affiliate contributes or is obligated to contribute any amounts and (ii) to which any entity other than the Borrower and its ERISA Affiliates contributes or is obligated to contribute any amounts. 

“Newmont USA” means Newmont USA Limited, a Delaware corporation. 

“Non-Defaulting Lender” means, at any time, any Lender that is not a Defaulting Lender at such time. 

“Non-Recourse Indebtedness” means any Indebtedness incurred in connection with the development, construction or operation of
a project that is limited in recourse to the project assets and/or the ownership interest held by the Borrower or any Subsidiary (a) in such project assets or (b) in any limited purpose entity owning such project assets, so long as
substantially all of the assets of such limited purpose entity are comprised of such project assets. 
 “Non-U.S. Lender”
means a Lender that is not a U.S. Person. 
 “Obligations” means (a) the principal of and premium, if any, and
interest (including interest accruing during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding) on the Loans, when and as due, whether at maturity, by
acceleration, upon one or more dates set for prepayment or otherwise and (b) all other monetary obligations, including fees, costs, expenses and indemnities, whether primary, secondary, direct, contingent, fixed or otherwise (including monetary
obligations incurred during the pendency of any bankruptcy, insolvency, receivership or other similar proceeding, regardless of whether allowed or allowable in such proceeding), of the Borrower under this Agreement or any other Loan Document. 

“OFAC” means the Office of Foreign Assets Control of the United States Department of the Treasury. 

“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection
between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received

  
 14 

 
payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan
Document). 
 “Other Taxes” means any and all present or future recording, stamp, court, documentary, excise, filing,
transfer, or similar Taxes arising from any payment made, from the execution, delivery, performance, enforcement or registration of, or from the registration, receipt or perfection of a security interest under, or otherwise with respect to, any Loan
Document, except any such Taxes imposed with respect to an assignment (other than an assignment under Section 2.20(b)). 

“Participant” has the meaning assigned to such term in Section 9.04(e). 

“Participant Register” has the meaning assigned to such term in Section 9.04(e). 

“PBGC” means the Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing
similar functions. 
 “Permitted Encumbrances” means: 

(a) Liens imposed by law for Taxes that are not yet due or are being contested in compliance with Section 5.04; 

(b) carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s and other like Liens imposed by
law, arising in the ordinary course of business and securing obligations that are not overdue by more than 30 days or are being contested in compliance with Section 5.04; 

(c) pledges and deposits made in the ordinary course of business in compliance with workers’ compensation, unemployment
insurance and other social security laws or regulations; 
 (d) deposits to secure the performance of bids, trade contracts,
leases, statutory obligations, surety, customs and appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business; 

(e) landlord’s liens arising in the ordinary course of business; 

(f) easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the
ordinary course of business that do not secure any monetary obligations and do not materially detract from the value of the affected property or interfere with the ordinary conduct of business of the Borrower or any Subsidiary; 

(g) any lien created in favor of a partner or co-joint venturer in connection with any agreement with such party relating to an
unincorporated joint venture over interests in and the assets of that unincorporated joint venture, the product 

  
 15 

 
derived from it, the sales proceeds payable and revenues received in respect of it and tariffs payable in respect of the assets of that unincorporated joint venture; 

(h) any lien created in favor of a partner or co-joint venturer in connection with any agreement with such party relating to an
incorporated joint venture over the shares in such joint venture company and/or its distributions from that company; 
 (i)
Liens securing judgments not constituting an Event of Default under clause (j) of Article VII; 
 (j) leases, licenses,
subleases or sublicenses granted to others in the ordinary course of business which do not (i) interfere in any material respect with the business of the Borrower or any Subsidiary or (ii) secure any Indebtedness; 

(k) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in
connection with the importation of goods in the ordinary course of business; 
 (l) Liens (i) of a collection bank
arising under Section 4-210 of the Uniform Commercial Code on items in the course of collection, (ii) in favor of a banking institution arising as a matter of law encumbering deposits (including the right of set-off) and which are within
the general parameters customary in the banking industry and (iii) that are contractual rights of set-off (A) relating to the establishment of depository relations with banks in the ordinary course of business and not given in connection
with the issuance of any Indebtedness and (B) provided for in Section 9.08 and in similar provisions of other credit facilities permitted by this Agreement; 

(m) any interest or title of a lessor under leases entered into by the Borrower or any Subsidiary in the ordinary course of
business; and 
 (n) Liens arising out of conditional sale, title retention, consignment or similar arrangements for sale of
goods entered into by the Borrower or any Subsidiary in the ordinary course of business. 
 provided that the term “Permitted Encumbrances”
shall not include any Lien securing Indebtedness. 
 “Person” means any natural person, corporation, limited liability
company, trust, joint venture, association, company, partnership, Governmental Authority or other entity. 
 “Plan” means
any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA sponsored, maintained or contributed by the Borrower or any ERISA
Affiliate. 

  
 16 

 “Prime Rate” means the rate of interest per annum publicly announced from time
to time by JPMorgan as its prime rate in effect at its principal office in New York City; each change in the Prime Rate shall be effective from and including the date such change is publicly announced as being effective. 

“Recipient” means, as applicable, (a) the Administrative Agent and (b) any Lender. 

“Register” has the meaning set forth in Section 9.04(c). 

“Related Parties” means, with respect to any Person, such Person’s Affiliates and the directors, officers, employees,
agents and advisors of such Person and such Person’s Affiliates. 
 “Required Lenders” means, at any time, Lenders
having Commitments and Loans representing at least a majority of the total Commitments and Loans at such time. 
 “Sanctioned
Country” means, at any time, a country or territory which is the subject or target of any Sanctions. 
 “Sanctioned
Person” means, at any time, (a) any Person that is named as a “specially designated national and blocked person” on the most current list published by OFAC at its official website or any replacement website or other
replacement official publication of such list or (b) any Person operating, organized or resident in a Sanctioned Country. 

“Sanctions” means comprehensive economic or financial sanctions or trade embargoes imposed, administered or enforced from
time to time by (a) the U.S. government, including those administered by OFAC or the U.S. Department of State, or (b) the United Nations Security Council, the European Union or Her Majesty’s Treasury of the United Kingdom. 

“Series” has the meaning set forth in Section 2.22(b). 

“S&P” means Standard & Poor’s. 

“Significant Subsidiary” means (a) any Subsidiary now or at any time hereafter meeting any one of the following
conditions: (i) the assets of such Subsidiary exceed 10.0% of the aggregate assets appearing on the consolidated balance sheet of the Borrower and its consolidated Subsidiaries for the most recently ended fiscal year, or (ii) the gross
revenues of such Subsidiary for the fiscal year of the Borrower most recently ended exceed 10.0% of the gross revenues of the Borrower and its consolidated Subsidiaries for such fiscal year, or (iii) such Subsidiary has one or more Subsidiaries
and together therewith would, if considered in the aggregate, constitute a Significant Subsidiary within the terms of clauses (i) or (ii) of this definition, and (b) Newmont USA. 

  
 17 

 “Statutory Reserve Rate” means a fraction (expressed as a decimal), the
numerator of which is the number one and the denominator of which is the number one minus the aggregate of the maximum reserve percentages (including any marginal, special, emergency or supplemental reserves), expressed as a decimal, established by
the Board to which the Administrative Agent is subject for eurocurrency funding (currently referred to as “Eurocurrency Liabilities” in Regulation D of the Board). Such reserve percentages shall include those imposed pursuant to such
Regulation D. Eurodollar Loans shall be deemed to constitute eurocurrency funding and to be subject to such reserve requirements without benefit of or credit for proration, exemptions or offsets that may be available from time to time to any
Lender under such Regulation D or any comparable regulation. The Statutory Reserve Rate shall be adjusted automatically on and as of the effective date of any change in any reserve percentage. 

“subsidiary” means, with respect to any Person (the “parent”) at any date, any corporation, limited liability
company, partnership, association or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of
such date, as well as any other corporation, limited liability company, partnership, association or other entity of which securities or other ownership interests representing more than 50% of the equity or more than 50% of the ordinary voting power
or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, controlled or held. 

“Subsidiary” means any subsidiary of the Borrower. 

“Taxes” means any present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other
charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. 
 “Total
Capitalization” means, on any date, the sum of (a) all Indebtedness that would appear as a liability on a consolidated balance sheet of the Borrower and its Subsidiaries prepared as of such date in accordance with GAAP, less the
aggregate amount of all cash and cash equivalents of the Borrower and its Subsidiaries that would appear on such balance sheet plus (b) total stockholders’ equity of the Borrower and its Subsidiaries determined as of such date on a
consolidated basis in accordance with GAAP, less goodwill and intangible assets of the Borrower and its Subsidiaries, determined on a consolidated basis in accordance with GAAP. 

“Total Indebtedness” means, as of any date, without duplication, the aggregate amount of Indebtedness of the Borrower and its
Subsidiaries on such date, less the aggregate amount of all cash and cash equivalents of the Borrower and its Subsidiaries on such date, in each case as would appear as a liability or as cash or cash equivalents, on a consolidated balance sheet of
the Borrower and its Subsidiaries prepared as of such date in accordance with GAAP. 

  
 18 

 “Transactions” means, collectively, the execution, delivery and performance by
each of the Borrower and the Guarantor of this Agreement and the other Loan Documents to which it is a party, the borrowing of Loans hereunder and the use of the proceeds thereof. 

“Type”, when used in reference to any Loan or Borrowing, refers to whether the rate of interest on such Loan, or on the Loans
comprising such Borrowing, is determined by reference to the Adjusted LIBO Rate, the Alternate Base Rate. 
 “USA PATRIOT
Act” means the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001. 

“US Multiemployer Plan” means a multiemployer plan as defined in Section 4001(a)(3) of ERISA. 

“U.S. Person” means a “United States person” within the meaning of Section 7701(a)(30) of the Code. 

“US Plan” means a Plan that is subject to ERISA. 

“U.S. Tax Certificate” has the meaning assigned to such term in Section 2.18(f)(ii)(D)(2). 

“Withdrawal Liability” means liability to a US Multiemployer Plan as a result of a complete or partial withdrawal from such
US Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA. 
 “Withholding
Agent” means any Loan Party and the Administrative Agent. 
 SECTION 1.02. Classification of Loans and Borrowings. For
purposes of this Agreement, Loans may be classified and referred to by Class (e.g., an “Initial Term Loan”) or by Type (e.g., a “Eurodollar Loan”) or by Class and Type (e.g., a “Eurodollar Initial Term
Loan”) and Borrowings may be classified and referred to by Class (e.g., an “Initial Term Borrowing”) or by Type (e.g., a “Eurodollar Borrowing”) or by Class and Type (e.g., a “Eurodollar Term
Borrowing”). 
 SECTION 1.03. Terms Generally. The definitions of terms herein shall apply equally to the singular and plural
forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and “including” shall be deemed to be
followed by the phrase “without limitation”. The word “will” shall be construed to have the same meaning and effect as the word “shall”. Unless the context requires otherwise (a) any definition of or reference to
any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments,
supplements or modifications set forth herein), (b) any reference herein to any Person shall be construed to include such Person’s 

  
 19 

 
successors and assigns, (c) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its
entirety and not to any particular provision hereof, (d) all references herein to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, this Agreement and (e) the
words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights. 

SECTION 1.04. Accounting Terms; GAAP. Except as otherwise expressly provided herein, all terms of an accounting or financial nature
shall be construed in accordance with GAAP, as in effect from time to time; provided that, notwithstanding the foregoing, for purposes of this Agreement (other than Section 5.01) GAAP shall be determined without giving effect to any
change thereto occurring after the date hereof as a result of the adoption of any proposals set forth in the Proposed Accounting Standards Update, Leases (Topic 840), issued by the Financial Accounting Standards Board on August 17, 2010,
or any other proposals issued by the Financial Accounting Standards Board in connection therewith, in each case if such change would require treating any lease or similar agreement as a Capital Lease where such lease or similar agreement was not
required to be so treated under GAAP as in effect on the date hereof (any such change being referred to herein as a “Lease Accounting GAAP Change”); provided further that, if the Borrower notifies the Administrative
Agent that the Borrower requests an amendment to any provision hereof to eliminate the effect of any change occurring after the date hereof in GAAP or in the application thereof on the operation of such provision (or if the Administrative Agent
notifies the Borrower that the Required Lenders request an amendment to any provision hereof for such purpose), regardless of whether any such notice is given before or after such change in GAAP or in the application thereof, then such provision
shall be interpreted on the basis of GAAP as in effect and applied immediately before such change shall have become effective until such notice shall have been withdrawn or such provision amended in accordance herewith. 

ARTICLE II 
 The Credits

 SECTION 2.01. Commitments. (a) Subject to the terms and conditions set forth herein, each Lender agrees to make Initial Term
Loans to the Borrower on the Funding Date in a principal amount not exceeding its Commitment. 
 (b) Amounts repaid or prepaid in respect of
Loans may not be reborrowed. 
 SECTION 2.02. Loans and Borrowings. (a) Each Loan shall be made as part of a Borrowing
consisting of Loans made by the Lenders ratably in accordance with their Commitments. The failure of any Lender to make any Loan required to be made by it shall not relieve any other Lender of its obligations hereunder; provided that the

  
 20 

 
Commitments of the Lenders are several and no Lender shall be responsible for any other Lender’s failure to make Loans as required. 

(b) Subject to Section 2.14, (i) each Borrowing shall be comprised entirely of Eurodollar Loans or ABR Loans, as the Borrower may
request in accordance herewith. 
 (c) At the commencement of each Interest Period for any Eurodollar Borrowing, such Borrowing shall be in
an aggregate amount that is not less than $5,000,000. At the time that each ABR Borrowing is made, such Borrowing shall be in an aggregate amount that is not less than $5,000,000 (or, if less, the then outstanding principal amount of the Loans).
Borrowings of more than one Type and Class may be outstanding at the same time; provided that there shall not at any time be outstanding more than a total of 7 Eurodollar Borrowings (or such greater number as the Administrative Agent
shall agree). 
 (d) Notwithstanding any other provision of this Agreement, the Borrower shall not be entitled to request, or to elect to
convert or continue, any Borrowing if the Interest Period requested with respect thereto would end after the Maturity Date applicable to such Class of Loans. 

SECTION 2.03. Requests for Borrowings. To request a Borrowing, the Borrower shall notify the Administrative Agent of such request by
telephone or by telecopy (a) in the case of a Eurodollar Borrowing, not later than 12:00 noon, New York City time, three Business Days before the date of the proposed Borrowing and (b) in the case of an ABR Borrowing, not later than 11:00
a.m., New York City time, on the Business Day of the proposed Borrowing. Each such Borrowing Request shall be irrevocable and, if telephonic, shall be confirmed promptly by hand delivery or telecopy to the Administrative Agent of a written Borrowing
Request in a form agreed to by the Administrative Agent and the Borrower and signed by the Borrower. Each such telephonic and written Borrowing Request shall specify the following information in compliance with Section 2.02: 

(i) the aggregate amount of the requested Borrowing; 

(ii) the date of such Borrowing, which shall be a Business Day; 

(iii) the Type and Class of the requested Borrowing; 

(iv) in the case of a Eurodollar Borrowing, the initial Interest Period to be applicable thereto, which shall be a period
contemplated by the definition of the term “Interest Period” and shall end no later than the Maturity Date in respect of such Class of Loans; and 

(v) the location and number of the Borrower’s account to which funds are to be disbursed, which shall comply with the
requirements of Section 2.07. 

  
 21 

 If no election as to the Type of Borrowing is specified, then the requested Borrowing shall be an ABR Borrowing.
If no Interest Period is specified with respect to any requested Eurodollar Borrowing, then the Borrower shall be deemed to have selected an Interest Period of one month’s duration. Promptly following receipt of a Borrowing Request in
accordance with this Section, the Administrative Agent shall advise each Lender of the details thereof and of the amount of such Lender’s Loan to be made as part of the requested Borrowing. 

SECTION 2.04. [Reserved].  

SECTION 2.05. [Reserved].  

SECTION 2.06. [Reserved].  

SECTION 2.07. Funding of Borrowings. Each Lender shall make each Loan to be made by it hereunder on the proposed date thereof by wire
transfer of immediately available funds by 12:00 noon, New York City time, to the account of the Administrative Agent most recently designated by it for such purpose by notice to the applicable Lenders. The Administrative Agent will make such Loans
available to the Borrower by promptly crediting the amounts so received to an account of the Borrower maintained with the Administrative Agent in New York City and designated by the Borrower in the applicable Borrowing Request. 

SECTION 2.08. Interest Elections. (a) Each Borrowing initially shall be of the Type specified in the applicable Borrowing Request
and, in the case of a Eurodollar Borrowing, shall have an initial Interest Period as specified in such Borrowing Request. Thereafter, the Borrower may elect to convert such Borrowing to a different Type or to continue such Borrowing and, in the case
of a Eurodollar Borrowing, may elect Interest Periods therefor, all as provided in this Section. The Borrower may elect different options with respect to different portions of the affected Borrowing, in which case each such portion shall be
allocated ratably among the Lenders holding the Loans comprising such Borrowing, and any Loans resulting from an election made with respect to any such portion shall be considered a separate Borrowing. Notwithstanding any other provision of this
Section, no Borrowing may be converted into or continued as a Borrowing with an Interest Period ending after the Maturity Date applicable to such Class of Loans. 

(b) To make an election pursuant to this Section, the Borrower shall notify the Administrative Agent of such election by telephone or by
telecopy by the time and date that a Borrowing Request would be required under Section 2.03 if the Borrower were requesting a Borrowing of the Type resulting from such election to be made on the effective date of such election. Each such
Interest Election Request shall be irrevocable and, if telephonic, shall be confirmed promptly by hand delivery or telecopy to the Administrative Agent of a written Interest Election Request in a form approved by the Administrative Agent and signed
by the Borrower. Notwithstanding any other provision of this Section, the Borrower shall not be permitted to elect an Interest Period for Eurodollar Loans that does not comply with Section 2.02(d). 

  
 22 

 (c) Each telephonic and written Interest Election Request shall specify the following information
in compliance with Section 2.02: 
 (i) the Borrowing to which such Interest Election Request applies and, if different
options are being elected with respect to different portions thereof, the portions thereof to be allocated to each resulting Borrowing (in which case the information to be specified pursuant to clauses (iii) and (iv) below shall be
specified for each resulting Borrowing); 
 (ii) the effective date of the election made pursuant to such Interest Election
Request, which shall be a Business Day; 
 (iii) whether the resulting Borrowing is to be an ABR Borrowing or a Eurodollar
Borrowing; and 
 (iv) if the resulting Borrowing is a Eurodollar Borrowing, the Interest Period to be applicable thereto
after giving effect to such election, which shall be a period contemplated by the definition of the term “Interest Period” and shall end no later than the Maturity Date applicable to such Class of Loans. 

If any such Interest Election Request requests a Eurodollar Borrowing, but does not specify an Interest Period, then the Borrower shall be deemed to have
selected an Interest Period of one month’s duration. 
 (d) Promptly following receipt of an Interest Election Request, the
Administrative Agent shall advise each Lender of the details thereof and of such Lender’s portion of each resulting Borrowing. 
 (e)
If the Borrower fails to deliver a timely Interest Election Request with respect to a Eurodollar Borrowing prior to the end of the Interest Period applicable thereto, then, unless such Borrowing is repaid as provided herein, at the end of such
Interest Period, such Eurodollar Borrowing will be converted to an ABR Borrowing. Notwithstanding any contrary provision hereof, if an Event of Default has occurred and is continuing and the Administrative Agent, at the written request of the
Required Lenders, so notifies the Borrower (such notification to be promptly confirmed in writing), then, so long as an Event of Default is continuing each outstanding Eurodollar Borrowing may only be continued as a Eurodollar Borrowing with an
Interest Period of one month. 
 SECTION 2.09. Termination and Reduction of Commitments.  

(a) Unless previously terminated, the Initial Term Commitments shall automatically terminate at 5:00 pm, New York City time, on the earlier of
(i) the Funding Date and (ii) July 15, 2014 (in each case, after giving effect to any incurrence of Loans on either such date). 

(b) The Borrower may at any time prior to the Funding Date terminate, or from time to time permanently reduce, the Initial Term Commitments;
provided that each 

  
 23 

 
reduction of the Initial Term Commitments shall be in an amount that is an integral multiple of $1,000,000 and not less than $5,000,000. 

(c) The Borrower shall notify the Administrative Agent of any election to terminate or reduce the Initial Term Commitments under
paragraph (b) of this Section at least one Business Day (or such shorter period as may be acceptable to the Administrative Agent) prior to the effective date of such termination or reduction, specifying such election and the effective date
thereof. Promptly following receipt of any notice, the Administrative Agent shall advise the applicable Lenders of the contents thereof. Each notice delivered by the Borrower pursuant to this Section shall be irrevocable; provided that a notice of
termination of the Initial Term Commitments delivered by the Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities, in which case such notice may be revoked by the Borrower (by notice to the
Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. Any termination or reduction of the Initial Term Commitments shall be permanent. Each reduction of the Initial Term Commitments shall be made
ratably among the Lenders in accordance with their respective Initial Term Commitments. 
 SECTION 2.10. Repayment of Loans;
Evidence of Debt. (a) The Borrower hereby unconditionally promises to pay (i) to the Administrative Agent for the account of each Lender the unpaid principal amount of each Initial Term Loan made to the Borrower on the Initial Term
Loan Maturity Date and (ii) to the Administrative Agent for the account of each Incremental Lender of a Series the unpaid principal amount of each Incremental Term Loan of such Series made to the Borrower on the applicable Incremental Term
Maturity Date for such Series. 
 (b) Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing the
Indebtedness of the Borrower to such Lender resulting from each Loan made by such Lender, including the amounts of principal and interest payable and paid to such Lender from time to time hereunder. 

(c) The Administrative Agent shall maintain accounts in which it shall record (i) the amount of each Loan made hereunder, the Class and
Type thereof and the Interest Period, if any, applicable thereto, (ii) the amount of any principal or interest due and payable or to become due and payable from the Borrower to each Lender hereunder and (iii) the amount of any sum received
by the Administrative Agent hereunder for the account of the Lenders and each Lender’s share thereof. 
 (d) The entries made in the
accounts maintained pursuant to paragraph (b) or (c) of this Section shall, absent manifest error, be prima facie evidence of the existence and amounts of the obligations recorded therein; provided that the failure of any
Lender or the Administrative Agent to maintain such accounts or any error therein shall not in any manner affect the obligation of the Borrower to repay the Loans in accordance with the terms of this Agreement. 

  
 24 

 (e) Any Lender may request that Loans made by it be evidenced by a promissory note. In such
event, the Borrower shall prepare, execute and deliver to such Lender a promissory note payable to such Lender (or, if requested by such Lender, to such Lender and its registered assigns) and in a form approved by the Borrower and the Administrative
Agent. Thereafter, the Loans evidenced by such promissory note and interest thereon shall at all times (including after assignment pursuant to Section 9.04) be represented by one or more promissory notes in such form payable to the payee named
therein (and its registered assigns). 
 SECTION 2.11. Amortization of Loans. (a) The Borrower shall repay outstanding Initial
Term Loans on each date set forth below in an aggregate principal amount equal to the percentage set forth opposite such date of the original aggregate principal amount of the Initial Term Loans made on the Funding Date (as such amounts may be
adjusted pursuant to paragraph (c) of this Section): 
  

					
	Date	  	Amount	 
	 September 30, 2015
	  	 	1.25	% 
	 December 31, 2015
	  	 	1.25	% 
	 March 31, 2016
	  	 	1.25	% 
	 June 30, 2016
	  	 	1.25	% 
	 September 30, 2016
	  	 	2.50	% 
	 December 31, 2016
	  	 	2.50	% 
	 March 31, 2017
	  	 	2.50	% 
	 June 30, 2017
	  	 	2.50	% 
	 September 30, 2017
	  	 	3.75	% 
	 December 31, 2017
	  	 	3.75	% 
	 March 31, 2018
	  	 	3.75	% 
	 June 30, 2018
	  	 	3.75	% 

 The Borrower shall repay Incremental Term Loans as set forth in the applicable Incremental Facility Agreement. 

(b) To the extent not previously paid, (i) all Initial Term Loans shall be due and payable on the Initial Term Loan Maturity Date and
(ii) all Incremental Term Loans of any Series shall be due and payable on the Incremental Term Maturity Date applicable thereto. 
 (c)
Any prepayment of an Initial Term Borrowing shall be applied to reduce the subsequent scheduled repayments (including the payment due at maturity) of the Initial Term Borrowing to be made pursuant to this Section in the case of voluntary prepayments
pursuant to Section 2.12(a), as directed by the Borrower (or, in the absence of any direction, in direct order of maturity). Any prepayment of an Incremental Term Borrowing of any Series shall be applied to reduce the subsequent scheduled
repayments of Incremental Term Borrowings of such Series to be made pursuant to this Section as shall be specified therefor in the Incremental Facility Agreement applicable to such Series. 

  
 25 

 (d) Prior to (or, in the case of any ABR Loan, at the time of) any repayment of any Borrowing of
any Class under this Section, the Borrower shall select the Borrowing or Borrowings of the applicable Class to be repaid and shall notify the Administrative Agent by telephone (confirmed by hand delivery or facsimile) of such selection not later
than (i) 12:00 noon, New York City time, three Business Days before the scheduled date of such repayment in the case of a Eurodollar Borrowing or (ii) 10:00 a.m., New York City time on the Business Day of such repayment, in the case of an
ABR Borrowing. Each repayment of a Borrowing shall be applied ratably to the Loans included in the repaid Borrowing. Repayments of Borrowings shall be accompanied by accrued interest on the amounts repaid. If no such Borrowing or Borrowings shall be
selected, such Borrowings shall be selected by the Administrative Agent in a manner to minimize (based on the reasonable judgment of the Administrative Agent) the payment of any breakage costs pursuant to Section 2.17. 

SECTION 2.12. Prepayment of Loans. (a) The Borrower shall have the right at any time and from time to time to prepay any Borrowing
in whole or in part, subject to prior notice in accordance with paragraph (d) of this Section and payment, when required thereby, of any amounts required under Section 2.17. 

(b) [Reserved] 
 (c) Prior to
any prepayment of Borrowings, the Borrower shall select the Borrowing or Borrowings to be prepaid and shall specify such selection in the notice of such prepayment pursuant to paragraph (d) below. In the event of any prepayment of Borrowings
made at a time when Borrowings of more than one Class remain outstanding, the Borrower shall select such Class to be prepaid (unless otherwise agreed by the Incremental Lenders); provided that the amounts so allocable to Incremental Term
Loans of any Series may be applied to other Borrowings as provided in the applicable Incremental Facility Agreement. 
 (d) The Borrower
shall notify the Administrative Agent by telephone (confirmed by telecopy) or by telecopy of any prepayment hereunder (i) in the case of prepayment of a Eurodollar Borrowing, not later than 12:00 noon, New York City time, three Business Days
before the date of prepayment or (ii) in the case of prepayment of an ABR Borrowing, not later than 10:00 a.m., New York City time, on the Business Day of prepayment. Each such notice shall be irrevocable and shall specify the prepayment
date and the principal amount of each Borrowing or portion thereof, to be prepaid; provided that, a notice of prepayment of Borrowings pursuant to paragraph (a) of this Section may state that such notice is conditioned upon the
occurrence of one or more events specified therein, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified date of prepayment) if such condition is not satisfied. Promptly
following receipt of any such notice, the Administrative Agent shall advise the Lenders of the contents thereof. Each partial prepayment of any Borrowing shall be in an amount that would be permitted in the case of an advance of a Borrowing of the
same Type as provided in Section 2.02. Each prepayment of a Borrowing shall be applied ratably to the Loans included in the prepaid Borrowing. 

  
 26 

 
Prepayments shall be accompanied by accrued interest to the extent required by Section 2.14. 

SECTION 2.13. Fees. (a) The Borrower agrees to pay to the Administrative Agent, for the account of each Lender (other than a
Defaulting Lender) a ticking fee, which shall accrue at an annual rate of 0.20% per annum on the daily undrawn amount of the Initial Term Commitments of such Lender during the period from and including the Effective Date to but excluding the
earlier of (i) the date on which such Initial Term Commitments terminate and (ii) the Funding Date. Accrued ticking fees shall be payable in arrears on the earlier of (i) the date on which all the Initial Term Commitments terminate
and (ii) the Funding Date. All ticking fees shall be computed on the basis of a year of 365 (or 366, as the case may be) days and shall be payable for the actual number of days elapsed (including the first day but excluding the last day). 

(b) The Borrower agrees to pay to the Administrative Agent, for its own account, fees payable in the amounts and at the times separately
agreed upon between the Borrower and the Administrative Agent. 
 (c) All fees payable hereunder shall be paid on the dates due, in
immediately available funds, to the Administrative Agent for its own account or, in the case of ticking fees, for distribution to the Lenders. Fees paid shall not be refundable under any circumstances. 

SECTION 2.14. Interest. (a) The Loans comprising each ABR Borrowing shall bear interest at the Alternate Base Rate
plus the Applicable Rate. 
 (b) The Loans comprising each Eurodollar Borrowing shall bear interest at the Adjusted LIBO Rate for the
Interest Period in effect for such Borrowing plus the Applicable Rate. 
 (c) Notwithstanding the foregoing, if any principal of or
interest on any Loan or any fee or other amount payable by the Borrower hereunder is not paid when due, whether at stated maturity, upon acceleration or otherwise, such overdue amount shall bear interest, after as well as before judgment, at a rate
per annum equal to (i) in the case of overdue principal of any Loan, 2.00% plus the rate otherwise applicable to such Loan as provided in the preceding paragraphs of this Section or (ii) in the case of any other amount, 2.00%
plus the rate applicable to ABR Loans as provided in paragraph (a) of this Section. 
 (d) Accrued interest on each Loan shall
be payable in arrears on each Interest Payment Date for such Loan; provided that (i) interest accrued pursuant to paragraph (c) of this Section shall be payable on demand, (ii) in the event of any repayment or prepayment of any
Loan, accrued interest on the principal amount repaid or prepaid shall be payable on the date of such repayment or prepayment and (iii) in the event of any conversion of any Eurodollar Loan prior to the end of the current Interest Period
therefor, accrued interest on such Loan shall be payable on the effective date of such conversion. 

  
 27 

 (e) All interest hereunder shall be computed on the basis of a year of 360 days, except that
interest computed by reference to the Alternate Base Rate at times when the Alternate Base Rate is based on the Prime Rate shall be computed on the basis of a year of 365 days (or 366 days in a leap year), and in each case shall be payable
for the actual number of days elapsed (including the first day but excluding the last day). The applicable Alternate Base Rate or Adjusted LIBO Rate shall be determined by the Administrative Agent, and such determination shall be conclusive absent
manifest error. 
 SECTION 2.15. Alternate Rate of Interest. If prior to the commencement of any Interest Period for a Eurodollar
Borrowing: 
 (a) the Administrative Agent determines (which determination shall be conclusive absent manifest error) that
adequate and reasonable means do not exist for ascertaining the Adjusted LIBO Rate for such Interest Period; or 
 (b) the
Administrative Agent is advised by the Required Lenders that the Adjusted LIBO Rate for such Interest Period will not adequately and fairly reflect the cost to such Lenders (or Lender) of making or maintaining their Loans (or its Loan) included in
such Borrowing for such Interest Period; 
 then the Administrative Agent shall give notice thereof to the Borrower and the Lenders by telephone or telecopy
as promptly as practicable thereafter and, until the Administrative Agent notifies the Borrower and the Lenders that the circumstances giving rise to such notice no longer exist, (i) any Interest Election Request that requests the conversion of
any Borrowing to, or continuation of any Borrowing as, a Eurodollar Borrowing shall be ineffective and (ii) if any Borrowing Request requests a Eurodollar Borrowing, such Borrowing shall be made as an ABR Borrowing ; provided that if the
circumstances giving rise to such notice affect only one Type of Borrowings, then the other Type of Borrowings shall be permitted. 

SECTION 2.16. Increased Costs. (a) If any Change in Law shall: 

(i) impose, modify or deem applicable any reserve, special deposit, insurance charge or similar requirement against assets of,
deposits with or for the account of, or credit extended by, any Lender (except for any such requirement reflected in the Adjusted LIBO Rate); 

(ii) impose on any Lender or the London interbank markets any other condition affecting this Agreement or Eurodollar Loans made
by such Lender; or 
 (iii) subject any Recipient to any Taxes on its Loans, loan principal, Commitments, or other
obligations, or its deposits, reserves, other liabilities or capital attributable thereto (other than (A) Indemnified Taxes, (B) Taxes described in clauses (b) through (d) of the definition of “Excluded Taxes” and
(C) Connection Income Taxes); 

  
 28 

 and the result of any of the foregoing shall be to increase the cost to such Lender or such other Recipient of
making or maintaining any Eurodollar Loan or to reduce the amount of any sum received or receivable by such Lender or such other Recipient hereunder (whether of principal, interest or otherwise), then the Borrower will pay to such Lender or such
other Recipient, as the case may be, such additional amount or amounts as will compensate such Lender or such other Recipient, as the case may be, for such additional costs incurred or reduction suffered. 

(b) If any Lender determines that any Change in Law regarding capital or liquidity requirements has or would have the effect of reducing the
rate of return on such Lender’s capital or on the capital of such Lender’s holding company, if any, as a consequence of this Agreement or the Loans made, to a level below that which such Lender or such Lender’s holding company could
have achieved but for such Change in Law (taking into consideration such Lender’s policies and the policies of such Lender’s holding company with respect to capital adequacy), then from time to time the Borrower will pay to such Lender
such additional amount or amounts as will compensate such Lender or such Lender’s holding company for any such reduction suffered, but only to the extent that such Lender has generally requested such compensation from similarly situated
borrowers. 
 (c) A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or its holding company,
as the case may be, as specified in paragraph (a) or (b) of this Section, shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate
within 10 Business Days after receipt thereof. 
 (d) Failure or delay on the part of any Lender to demand compensation pursuant to
this Section shall not constitute a waiver of such Lender’s right to demand such compensation; provided that, the Borrower shall not be required to compensate a Lender pursuant to paragraph (a) or (b) of this Section for any
increased costs or reductions incurred more than 180 days prior to the date that such Lender notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender’s intention to claim compensation
therefor; provided further that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the 180-day period referred to above shall be extended to include the period of retroactive effect thereof.

 SECTION 2.17. Break Funding Payments. In the event of (a) the payment of any principal of any Eurodollar Loan other than on
the last day of an Interest Period applicable thereto (including as a result of an Event of Default), (b) the conversion of any Eurodollar Loan other than on the last day of the Interest Period applicable thereto, (c) the failure to
borrow, convert, continue or prepay any Eurodollar Loan on the date specified in any notice delivered pursuant hereto (regardless of whether such notice may be revoked under Section 2.12(d) and is revoked in accordance therewith), or
(d) the assignment of any Eurodollar Loan other than on the last day of the Interest Period, as the case may be, applicable thereto as a result of a request by the Borrower pursuant to 

  
 29 

 
Section 2.20, then, in any such event, the Borrower shall compensate each Lender for the loss, cost and expense (excluding loss of anticipated profit) attributable to such event. In the case
of a Eurodollar Loan, such loss, cost or expense to any Lender shall be deemed to include an amount determined by such Lender to be the excess, if any, of (i) the amount of interest which would have accrued on the principal amount of such Loan
had such event not occurred, at the Adjusted LIBO Rate that would have been applicable to such Loan, for the period from the date of such event to the last day of the then current Interest Period therefor (or, in the case of a failure to borrow,
convert or continue, for the period that would have been the Interest Period for such Loan), over (ii) the amount of interest which would accrue on such principal amount for such period at the interest rate which such Lender would bid were it
to bid, at the commencement of such period, for dollar deposits of a comparable amount and period from other banks in the London interbank market. A certificate of any Lender setting forth any amount or amounts that such Lender is entitled to
receive pursuant to this Section shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within 10 Business Days after receipt thereof.
Notwithstanding the foregoing, the Borrower shall not be required to compensate a Lender pursuant to this Section 2.17 for any loss, cost or expense incurred more than 180 days prior to the date that such Lender notifies the Borrower of the
event giving rise to such loss, cost or expense and of such Lender’s intention to claim compensation therefor. 
 SECTION 2.18.
Taxes. (a) Each payment by any Loan Party under any Loan Document shall be made without withholding for any Taxes, unless such withholding is required by any law. If any Withholding Agent determines, in its sole discretion exercised in
good faith, that it is so required to withhold any Taxes, then such Withholding Agent may so withhold and shall timely pay the full amount of withheld Taxes to the relevant Governmental Authority in accordance with applicable law. If such Taxes are
Indemnified Taxes, then the amount payable by such Loan Party shall be increased as necessary so that, net of such withholding (including such withholding applicable to additional amounts payable under this Section), the applicable Recipient
receives the amount it would have received had no such withholding been made. 
 (b) The Borrower shall timely pay any Other Taxes to the
relevant Governmental Authority in accordance with applicable law. 
 (c) As soon as practicable after any payment of Taxes by any Loan
Party pursuant to Section 2.18(a) to a Governmental Authority, such Loan Party shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the
return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent. 
 (d) The Loan Parties
shall jointly and severally indemnify each Recipient for any Indemnified Taxes that are paid or payable by such Recipient in connection with any Loan Document (including amounts paid or payable under this Section 2.18(d)) and any reasonable
expenses arising therefrom or with respect thereto, whether or not such 

  
 30 

 
Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. The indemnity under this Section 2.18(d) shall be paid within 10 days after the
Recipient delivers to any Loan Party a certificate stating the amount of any Indemnified Taxes so paid or payable by such Recipient and describing the basis for the indemnification claim; provided that no Loan Party shall be required to
indemnify any Recipient pursuant to this paragraph for any such Indemnified Taxes (including expenses arising therefrom or with respect thereto) paid by the Recipient more than 180 days prior to the date that the Recipient notifies the applicable
Loan Party of such payment by the Recipient of such Indemnified Taxes and of the Recipient’s intention to claim indemnification therefor. Such certificate shall be conclusive of the amount so paid or payable absent manifest error. Such
Recipient shall deliver a copy of such certificate to the Administrative Agent. 
 (e) Each Lender shall severally indemnify the
Administrative Agent for any Taxes (but, in the case of any Indemnified Taxes, only to the extent that any Loan Party has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Loan
Parties to do so) attributable to such Lender that are paid or payable by the Administrative Agent in connection with any Loan Document and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly
or legally imposed or asserted by the relevant Governmental Authority. The indemnity under this Section 2.18(e) shall be paid within 10 days after the Administrative Agent delivers to the applicable Lender a certificate stating the amount of
Taxes so paid or payable by the Administrative Agent. Such certificate shall be conclusive of the amount so paid or payable absent manifest error. 

(f) (i) Any Lender that is entitled to an exemption from, or reduction of, any applicable withholding Tax with respect to any payments
under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the
Borrower or the Administrative Agent as will permit such payments to be made without, or at a reduced rate of, withholding. In addition, any Lender, if requested by either the Borrower or the Administrative Agent, shall deliver such other
documentation prescribed by law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to any withholding (including backup
withholding) or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in
Section 2.18(f)(ii)(A) through (E) below) shall not be required if in the Lender’s judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice
the legal or commercial position of such Lender. Upon the reasonable request of the Borrower or the Administrative Agent, any Lender shall update any form or certification previously delivered pursuant to this Section 2.18(f). If any form or
certification previously delivered pursuant to this Section expires or becomes obsolete or inaccurate in any respect with respect to a Lender, such Lender shall promptly (and in any event within 10 days after such expiration, obsolescence or
inaccuracy) notify the Borrower and the 

  
 31 

 
Administrative Agent in writing of such expiration, obsolescence or inaccuracy and update the form or certification if it is legally eligible to do so. 

(ii) Without limiting the generality of the foregoing, any Lender shall, if it is legally eligible to do so, deliver to the Borrower and the
Administrative Agent (in such number of copies reasonably requested by the Borrower and the Administrative Agent) on or prior to the date on which such Lender becomes a party hereto, duly completed and executed copies of whichever of the following
is applicable: 
 (A) in the case of a Lender that is a U.S. Person, IRS Form W-9 certifying that such Lender is exempt from
U.S. Federal backup withholding tax; 
 (B) in the case of a Non-U.S. Lender claiming the benefits of an income tax treaty to
which the United States is a party (1) with respect to payments of interest under any Loan Document, IRS Form W-8BEN establishing an exemption from, or reduction of, U.S. Federal withholding Tax pursuant to the “interest” article of
such tax treaty and (2) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN establishing an exemption from, or reduction of, U.S. Federal withholding Tax pursuant to the “business profits” or
“other income” article of such tax treaty; 
 (C) in the case of a Non-U.S. Lender for whom payments under this
Agreement constitute income that is effectively connected with such Lender’s conduct of a trade or business in the United States, IRS Form W-8ECI; 

(D) in the case of a Non-U.S. Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of
the Code both (1) IRS Form W-8BEN and (2) a certificate substantially in the form of Exhibit C (a “U.S. Tax Certificate”) to the effect that such Lender is not (a) a “bank” within the meaning of
Section 881(c)(3)(A) of the Code, (b) a “10 percent shareholder” of the Borrower within the meaning of Section 881(c)(3)(B) of the Code (c) a “controlled foreign corporation” described in
Section 881(c)(3)(C) of the Code and (d) conducting a trade or business in the United States with which the relevant interest payments are effectively connected; 

(E) in the case of a Non-U.S. Lender that is not the beneficial owner of payments made under this Agreement (including an
entity treated as a partnership for U.S. federal income tax purposes or a participating Lender) (1) an IRS Form W-8IMY on behalf of itself and (2) the relevant forms prescribed in clauses (A), (B), (C), (D) and (F) of this
paragraph (f)(ii) that would be required of each such beneficial owner or partner of such partnership if such beneficial owner or partner were a Lender; provided, however, that if the Lender is a partnership (and not a participating
Lender) and one or more of its partners are claiming the exemption for portfolio interest under Section 881(c) of the Code, such Lender may provide a U.S. Tax Certificate on behalf of such partners; or 

(F) any other form prescribed by law as a basis for claiming exemption 

  
 32 

 
from, or a reduction of, U.S. Federal withholding Tax together with such supplementary documentation necessary to enable the Borrower or the Administrative Agent to determine the amount of Tax
(if any) required by law to be withheld. 
 (iii) If a payment made to a Lender under any Loan Document would be subject to U.S. Federal
withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the
Withholding Agent, at the time or times prescribed by law and at such time or times reasonably requested by the Withholding Agent, such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code)
and such additional documentation reasonably requested by the Withholding Agent as may be necessary for the Withholding Agent to comply with its obligations under FATCA, to determine that such Lender has or has not complied with such Lender’s
obligations under FATCA and, as necessary, to determine the amount to deduct and withhold from such payment. Solely for purposes of this Section 2.18(f)(iii), “FATCA” shall include any amendments made to Sections 1471 through 1474 of
the Code, and any regulations or official interpretations thereof, after the date of this Agreement. 
 (g) If any party determines, in its
sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 2.18 (including additional amounts paid pursuant to this Section 2.18), it shall pay to the
indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including any Taxes) of such
indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the
amount paid to such indemnifying party pursuant to the previous sentence (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event such indemnified party is required to repay such refund to such
Governmental Authority. Notwithstanding anything to the contrary in this Section 2.18(g), in no event will any indemnified party be required to pay any amount to any indemnifying party pursuant to this Section 2.18(g) if such payment would
place such indemnified party in a less favorable position (on a net after-Tax basis) than such indemnified party would have been in if the indemnification payments or additional amounts giving rise to such refund had never been paid. This
Section 2.18(g) shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes which it deems confidential) to the indemnifying party or any other Person. 

SECTION 2.19. Payments Generally; Pro Rata Treatment; Sharing of Set-offs. (a) The Borrower shall make each payment required to be
made by it hereunder or under any other Loan Document (whether of principal, interest or fees, or of amounts payable under Section 2.16, 2.17 or 2.18, or otherwise) prior to 12:00 noon, New York City time, on the date when due, in
immediately available funds, without set-off or counterclaim. Any amounts received after such time on any date may, in the discretion 

  
 33 

 
of the Administrative Agent, be deemed to have been received on the next succeeding Business Day for purposes of calculating interest thereon. All such payments shall be made to the
Administrative Agent for the account of the applicable Lenders or, in any such case, to such other account as the Administrative Agent shall from time to time specify in a notice delivered to the Borrower, except that payments pursuant to
Sections 2.16 (other than paragraph (b) thereof), 2.17, 2.18 and 9.03 shall be made directly to the Persons entitled thereto. The Administrative Agent shall distribute any such payments received by it for the account of any other Person to
the appropriate recipient promptly following receipt thereof. If any payment under any Loan Document shall be due on a day that is not a Business Day, the date for payment shall be extended to the next succeeding Business Day, and, in the case of
any payment accruing interest, interest thereon shall be payable for the period of such extension. Any payment required to be made by the Administrative Agent shall be deemed to have been made by the time required if the Administrative Agent shall,
at or before such time, have taken the necessary steps to make such payment in accordance with the regulations or operating procedures of the clearing or settlement system used by the Administrative Agent to make such payment. 

(b) If at any time insufficient funds are received by and available to the Administrative Agent from the Borrower to pay fully all amounts of
principal, interest and fees then due from the Borrower hereunder, such funds shall be applied (i) first, towards payment of interest and fees then due from the Borrower hereunder, ratably among the parties entitled thereto in accordance
with the amounts of interest and fees then due to such parties, and (ii) second, towards payment of principal then due from the Borrower hereunder, ratably among the parties entitled thereto in accordance with the amounts of principal
then due to such parties. 
 (c) If any Lender shall, by exercising any right of set-off or
counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of its Loans resulting in such Lender receiving payment of a greater proportion of the aggregate amount of its Loans and accrued interest thereon than the
proportion received by any other Lender, then the Lender receiving such greater proportion shall purchase (for cash at face value) participations in the Loans of other Lenders to the extent necessary so that the benefit of all such payments shall be
shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans; provided that (i) if any such participations are purchased and all or any portion of the payment giving
rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest, and (ii) the provisions of this paragraph shall not be construed to apply to any payment made by
the Borrower pursuant to and in accordance with the express terms of this Agreement or any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans to any assignee or participant, other than
to the Borrower or any Subsidiary or Affiliate thereof (as to which the provisions of this paragraph shall apply). The Borrower consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender
acquiring a participation pursuant to the foregoing arrangements may exercise against the Borrower rights of set-off and 

  
 34 

 
counterclaim with respect to such participation as fully as if such Lender were a direct creditor of the Borrower in the amount of such participation. 

(d) Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the
Administrative Agent for the account of the Lenders hereunder that the Borrower will not make such payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon
such assumption, distribute to the Lenders the amount due. In such event, if the Borrower has not in fact made such payment, then each of the Lenders severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed
to such Lender with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Effective Rate and a rate
determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. 
 (e) If any Lender shall fail
to make any payment required to be made by it pursuant to Section 2.07(b) or paragraph (d) of this Section 2.19, then the Administrative Agent may, in its discretion (notwithstanding any contrary provision hereof), apply any amounts
thereafter received by the Administrative Agent for the account of such Lender to satisfy such Lender’s obligations under such Sections until all such unsatisfied obligations are fully paid. 

SECTION 2.20. Mitigation Obligations; Replacement of Lenders. (a) If any Lender requests compensation under Section 2.16, or
if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.18, then such Lender shall use reasonable efforts to designate a different lending
office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the reasonable judgment of such Lender, such designation or assignment (i) would
eliminate or reduce amounts payable pursuant to Section 2.16 or 2.18, as the case may be, in the future and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender.
The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment. 

(b) If (i) any Lender requests compensation under Section 2.16, (ii) the Borrower is required to pay any additional amount to
any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.18, (iii) any Lender has become a Defaulting Lender, (iv) any Lender has failed to consent to a proposed amendment, waiver, discharge or
termination that under Section 9.02 requires the consent of all the Lenders (or all the affected Lenders) and with respect to which the Required Lenders shall have granted their consent or (v) any Lender is a Declining Lender under
Section 2.23, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions
contained in Section 9.04), all its interests, rights and obligations under this Agreement to an assignee 

  
 35 

 
that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment); provided that (A) the Borrower shall have received the prior written
consent of the Administrative Agent, which consent shall not unreasonably be withheld, (B) such Lender shall have received payment of an amount equal to the outstanding principal of its Loans accrued interest thereon, accrued fees and all other
amounts payable to it hereunder, from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts), (C) in the case of any such assignment resulting from a claim for
compensation under Section 2.16 or payments required to be made pursuant to Section 2.18, such assignment will result in a reduction or elimination in such compensation, payments or additional interest and (D) in the case of any such
assignment and delegation resulting from the failure to provide a consent, the assignee shall have given such consent and, as a result of such assignment and delegation and any contemporaneous assignments and delegations and consents, the applicable
amendment, waiver, discharge or termination can be effected. A Lender shall not be required to make any such assignment and delegation if, prior thereto, as a result of a waiver or consent by such Lender or otherwise, the circumstances entitling the
Borrower to require such assignment and delegation have ceased to apply. Each party hereto agrees that an assignment and delegation required pursuant to this paragraph may be effected pursuant to an Assignment and Acceptance executed by the
Borrower, the Administrative Agent and the assignee and that the Lender required to make such assignment and delegation need not be a party thereto. 

SECTION 2.21. Defaulting Lenders. Notwithstanding any provision of this Agreement to the contrary, if any Lender becomes a Defaulting
Lender, then the following provisions shall apply for so long as such Lender is a Defaulting Lender: 
 (a) ticking fees
shall cease to accrue pursuant to Section 2.13(a) on the unused amount of the Commitment of such Defaulting Lender; and 

(b) the Commitment and outstanding Loans of such Defaulting Lender shall not be included in determining whether the Required
Lenders or any other requisite Lenders have taken or may take any action hereunder or under any other Loan Document (including any consent to any amendment, waiver or other modification pursuant to Section 9.02); provided that any
amendment, waiver or other modification requiring the consent of all Lenders or all Lenders affected thereby shall, except as otherwise provided in Section 9.02, require the consent of such Defaulting Lender in accordance with the terms hereof.

 SECTION 2.22. Incremental Facilities. (a) The Borrower may on one or more occasions after the Funding Date, by written notice
to the Administrative Agent, request the establishment of Incremental Term Commitments, provided that the aggregate amount of all the Incremental Term Commitments established hereunder shall not exceed $250,000,000 during the term of this
Agreement. Each such notice shall specify (A) the date on which the Borrower proposes that the Incremental Term Commitments shall be effective, which shall be a date not less than 10 Business Days (or such shorter period as may be agreed to by
the Administrative Agent) after the date on which such notice is delivered to the Administrative Agent, and (B) the amount of the Incremental Term 

  
 36 

 
Commitments being requested (it being agreed that (x) any Lender approached to provide any Incremental Term Commitment may elect or decline, in its sole discretion, to provide such
Incremental Term Commitment and (y) any Person that the Borrower proposes to become an Incremental Lender, if such Person is not then a Lender, must be approved by the Borrower and the Administrative Agent (such approvals not to be unreasonably
withheld)). 
 (b) The terms and conditions of any Incremental Term Commitments and the Incremental Term Loans to be made thereunder shall
be, except with respect to pricing, upfront, closing or similar fees or original issue discount, amortization and maturity, substantially identical to those of the Commitments in respect of the Initial Term Loans; provided that (i) the
Incremental Term Loans and the Initial Term Loans shall rank pari passu in right of payment, (ii) the weighted average life to maturity of any Incremental Term Loans shall be no shorter than the remaining weighted average life to maturity of
the Initial Term Loans and (iii) no Incremental Term Loan Maturity Date shall be earlier than the Initial Term Loan Maturity Date. Any Incremental Term Commitments established pursuant to an Incremental Facility Agreement that have identical
terms and conditions, and any Incremental Term Loans made thereunder, shall be designated as a separate series (each a “Series”) of Incremental Term Commitments and Incremental Term Loans for all purposes of this Agreement. 

(c) The Incremental Commitments shall be effected pursuant to one or more Incremental Facility Agreements executed and delivered by the
Borrower, each Incremental Lender providing such Incremental Commitments and the Administrative Agent; provided that, except as set forth in the penultimate sentence of this paragraph (c), no Incremental Commitments shall become effective
unless (i) on the date of effectiveness thereof, both immediately prior to and immediately after giving effect to such Incremental Commitments (and assuming that the full amount of such Incremental Commitments shall have been funded as Loans on
such date), the Borrower shall be in compliance with the condition set forth in Section 4.02(b) (and assuming, for such purposes, that a Borrowing is made on such date of effectiveness), (ii) on the date of effectiveness thereof, the
Borrower shall be in compliance with the condition set forth in Section 4.02(a) (and assuming, for such purposes, that a Borrowing is made on such date of effectiveness), (iii) after giving effect to such Incremental Commitments (and
assuming that the full amount of such Incremental Commitments shall have been funded as Loans on such date), and any related transaction, on a pro forma basis, the Borrower shall be in compliance with the covenant set forth in Section 6.01
calculated as of the last day of the fiscal quarter of the Borrower then most recently ended for which the financial statements have been delivered pursuant to Section 5.01(a) or 5.01(b) (or, prior to the delivery of any such financial
statements, the most recent period of four consecutive fiscal quarters included in the financial statements referred to in Section 3.04(a)), (iv) the Borrower shall have paid all fees and expenses required to be made to any arranger or
lender in connection with such Incremental Commitments and the related transactions under this Section and (v) the Borrower shall have delivered to the Administrative Agent such legal opinions, board resolutions, secretary’s certificates,
officer’s certificates and other documents as shall reasonably be requested by the Administrative Agent in connection with any such transaction. Each Incremental Facility Agreement may, 

  
 37 

 
without the consent of any Lender, effect such amendments to this Agreement and the other Loan Documents as may be necessary or appropriate, in the opinion of the Administrative Agent, to give
effect to the provisions of this Section. 
 (d) Upon the effectiveness of an Incremental Commitment of any Incremental Lender, such
Incremental Lender shall be deemed to be a “Lender” (and a Lender in respect of Commitments and Loans of the applicable Class) hereunder, and henceforth shall be entitled to all the rights of, and benefits accruing to, Lenders (or Lenders
in respect of Commitments and Loans of the applicable Class) hereunder and shall be bound by all agreements, acknowledgements and other obligations of Lenders (or Lenders in respect of Commitments and Loans of the applicable Class) hereunder and
under the other Loan Documents. 
 (e) Subject to the terms and conditions set forth herein and in the applicable Incremental Facility
Agreement, each Lender holding an Incremental Term Commitment of any Series shall make a loan to the Borrower in an amount equal to such Incremental Term Commitment on the date specified in such Incremental Facility Agreement. 

(f) The Administrative Agent shall notify the Lenders promptly upon receipt by the Administrative Agent of any notice from the Borrower
referred to in Section 2.22(a) and of the effectiveness of any Incremental Commitments, in each case advising the Lenders of the details thereof. 

SECTION 2.23. Extension of Maturity Date. (a) From and after the Funding Date, the Borrower may, by delivery of a Maturity Date
Extension Request to the Administrative Agent (which shall promptly deliver a copy thereof to each of the Lenders of the applicable Class of Loans) not less than 30 days prior to the then existing Maturity Date with respect to any Class of
Loans hereunder (the “Existing Maturity Date”), request that the Lenders of such Class of Loans extend the Existing Maturity Date in accordance with this Section 2.23. Each Maturity Date Extension Request shall (i) specify
the applicable Class of Loans and the date to which the applicable Maturity Date is sought to be extended, (ii) specify the changes, if any, to the Applicable Rate to be applied in determining the interest payable on Loans of, and fees payable
hereunder to, Consenting Lenders in respect of that portion of their Loans extended to such new Maturity Date and the time as of which such changes will become effective (which may be prior to the Existing Maturity Date), and (iii) specify any
other amendments or modifications to this Agreement to be effected in connection with such Maturity Date Extension Request (including in respect of amortization), provided that no such changes or modifications requiring approvals pursuant to
Section 9.02(b) shall become effective prior to the Existing Maturity Date unless such other approvals have been obtained. In the event a Maturity Date Extension Request shall have been delivered by the Borrower, each Lender shall have the
right to agree to the extension of the Existing Maturity Date and other matters contemplated thereby on the terms and subject to the conditions set forth therein (each Lender agreeing to the Maturity Date Extension Request being referred to herein
as a “Consenting Lender” and each Lender not agreeing thereto being referred to herein as a “Declining Lender”), which right may be exercised by written 

  
 38 

 
notice thereof, specifying the maximum amount of the Loans of such Lender with respect to which such Lender agrees to the extension of the Existing Maturity Date, delivered to the Borrower (with
a copy to the Administrative Agent) not later than a day to be agreed upon by the Borrower and the Administrative Agent following the date on which the Maturity Date Extension Request shall have been delivered by the Borrower (it being understood
that any Lender that shall have failed to exercise such right as set forth above shall be deemed to be a Declining Lender). If a Lender elects to extend only a portion of its then existing Loans, it will be deemed for purposes hereof to be a
Consenting Lender in respect of such extended portion and a Declining Lender in respect of the remaining portion of its Loans. If Consenting Lenders shall have agreed to such Maturity Date Extension Request in respect of Loans held by them, then,
subject to paragraph (d) of this Section, on the date specified in the Maturity Date Extension Request as the effective date thereof (the “Extension Effective Date”), (i) the Existing Maturity Date of the applicable Loans
shall, as to the Consenting Lenders, be extended to such date as shall be specified therein, (ii) the terms and conditions of the Loans of the Consenting Lenders (including interest and fees payable in respect thereof), shall be modified as set
forth in the Maturity Date Extension Request and (iii) such other modifications and amendments hereto specified in the Maturity Date Extension Request shall (subject to any required approvals (including those of the Required Lenders) having
been obtained) become effective. 
 (b) Notwithstanding the foregoing, the Borrower shall have the right, in accordance with the provisions
of Sections 2.20 and 9.04, at any time prior to the Existing Maturity Date, to replace a Declining Lender (for the avoidance of doubt, only in respect of that portion of such Lender’s Loans subject to a Maturity Date Extension Request that it
has not agreed to extend) with a Lender or other financial institution that will agree to such Maturity Date Extension Request, and any such replacement Lender shall for all purposes constitute a Consenting Lender in respect of the Loans assigned to
and assumed by it on and after the effective time of such replacement. 
 (c) If a Maturity Date Extension Request has become effective
hereunder, on the Existing Maturity Date, the Borrower shall repay all the Loans of each Declining Lender, to the extent such Loans shall not have been so purchased, assigned and transferred, in each case together with accrued and unpaid interest
and all fees and other amounts owing to such Declining Lender hereunder. For the avoidance of doubt, any amortization in respect of the Loans of a Declining Lender shall continue to be payable pursuant to the terms of this Agreement. 

(d) Notwithstanding the foregoing, no Maturity Date Extension Request shall become effective hereunder unless, on the Extension Effective
Date, the conditions set forth in Section 4.02 shall be satisfied (with all references in such Section to a Borrowing being deemed to be references to such Maturity Date Extension Request) and the Administrative Agent shall have received a
certificate to that effect dated such date and executed by a Financial Officer. 
 (e) Notwithstanding any provision of this Agreement to
the contrary, it is hereby agreed that no extension of an Existing Maturity Date in accordance with the 

  
 39 

 
express terms of this Section 2.23, or any amendment or modification of the terms and conditions of the Loans of the Consenting Lenders effected pursuant thereto, shall be deemed to
(i) violate the last sentence of Section 2.09(c) or Section 2.19(b) or 2.19(c) or any other provision of this Agreement requiring the ratable sharing of payments or (ii) require the consent of all Lenders or all affected Lenders
under Section 9.02(b). 
 (f) The Borrower, the Administrative Agent and the Consenting Lenders may enter into an amendment to this
Agreement to effect such modifications as may be necessary to reflect the terms of any Maturity Date Extension Request that has become effective in accordance with the provisions of this Section 2.23. 

ARTICLE III  

Representations and Warranties 

The Borrower represents and warrants (as to itself and its own Subsidiaries) to the Lenders that: 

SECTION 3.01. Organization; Powers. The Borrower and each Significant Subsidiary is duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization, has all requisite power and authority to carry on its business as now conducted and, except where the failure to do so, individually or in the aggregate, could not reasonably be
expected to result in a Material Adverse Effect, is qualified to do business in, and is in good standing in, every jurisdiction where such qualification is required. 

SECTION 3.02. Authorization; Enforceability. The Transactions are within the Borrower’s and the Guarantor’s corporate powers
and have been duly authorized by all necessary corporate and, if required, stockholder action. This Agreement has been duly executed and delivered by the Borrower and constitutes, and the Guarantee Agreement, when executed and delivered by the
Guarantor, will constitute, a legal, valid and binding obligation of the Borrower or the Guarantor, as the case may be, enforceable in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium or other laws
affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law. 

SECTION 3.03. Governmental Approvals; No Conflicts. The Transactions (a) do not require any consent or approval of, registration
or filing with, or any other action by, any Governmental Authority, except such as have been obtained or made and are in full force and effect, (b) will not violate any applicable law or regulation or the charter, by-laws or other
organizational documents of the Borrower or any of the Subsidiaries or any order of any Governmental Authority, (c) will not violate or result in a default under any material indenture, agreement or other instrument binding upon the Borrower or
any of the Subsidiaries or its assets, or give rise to a right thereunder to require any payment to be made by the Borrower or any of the Subsidiaries, and (d) will 

  
 40 

 
not result in the creation or imposition of any Lien on any asset of the Borrower or any of the Subsidiaries. 

SECTION 3.04. Financial Condition; No Material Adverse Change. (a) The Borrower has heretofore furnished to the Lenders the
consolidated balance sheet and statements of income, stockholders’ equity and cash flows of the Borrower and its consolidated Subsidiaries as of and for the fiscal year ended December 31, 2013, reported on by PricewaterhouseCoopers LLP,
independent registered public accounting firm. Such financial statements present fairly, in all material respects, the financial position, results of operations and cash flows of the Borrower and its consolidated Subsidiaries as of such dates and
for such periods in accordance with GAAP, subject to normal year-end audit adjustments. 
 (b) Since December 31, 2013, there has been
no material adverse change in the business, assets, operations or financial condition of the Borrower and its Subsidiaries, taken as a whole. 

SECTION 3.05. Properties. (a) The Borrower and each Significant Subsidiary has good title to, or valid leasehold interests in, all
its real and personal property material to the business of the Borrower and its Subsidiaries taken as a whole, except for minor defects in title that do not interfere with its ability to conduct its business as currently conducted or to utilize such
properties for their intended purposes. 
 (b) The Borrower and each Significant Subsidiary owns, or is licensed to use, all trademarks,
tradenames, copyrights, patents and other intellectual property material to the business of the Borrower and its Subsidiaries taken as a whole, and the use thereof by the Borrower or such Significant Subsidiary does not infringe upon the rights of
any other Person, except for any such ownership, licenses or infringements that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. 

SECTION 3.06. Litigation and Environmental Matters. (a) There are no actions, suits or proceedings by or before any arbitrator or
Governmental Authority pending against or, to the knowledge of the Borrower, threatened against or affecting the Borrower or any of the Subsidiaries (i) which could reasonably be expected, individually or in the aggregate, to result in a
Material Adverse Effect (other than the Disclosed Matters) or (ii) that involve this Agreement or the Transactions. 
 (b) Except for
the Disclosed Matters and except with respect to any other matters that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, neither the Borrower nor any of the Subsidiaries (i) has failed
to comply with any Environmental Law or to obtain, maintain or comply with any permit, license or other approval required under any Environmental Law, (ii) has become subject to any Environmental Liability, (iii) has received notice of any
claim with respect to any Environmental Liability or (iv) knows of any basis for any Environmental Liability. 

  
 41 

 SECTION 3.07. Compliance with Laws and Agreements. The Borrower and each Subsidiary is in
compliance with all laws, regulations and orders of any Governmental Authority applicable to it or its property and all indentures, agreements and other instruments binding upon it or its property, except where the failure to do so, individually or
in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. 
 SECTION 3.08. Investment Company
Status. Neither the Borrower nor the Guarantor is an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940. 

SECTION 3.09. Taxes. The Borrower and each Subsidiary has filed or caused to be filed on a timely basis (taking into account all
extensions granted by the applicable Governmental Authority) all United States federal and applicable foreign, state and local Tax returns and reports and all other Tax returns and reports which are required to be filed and have paid or caused to be
paid all Taxes required to have been paid by it, except (a) such Taxes, if any, as are being contested in good faith by appropriate proceedings as to which adequate reserves have been provided in accordance with GAAP or (b) to the extent
the failure to do so could not reasonably be expected to have a Material Adverse Effect. 
 SECTION 3.10. ERISA. No ERISA Event has
occurred or is reasonably expected to occur that, when taken together with all other such ERISA Events for which liability is reasonably expected to occur, could reasonably be expected to result in a Material Adverse Effect. The present value of all
accumulated benefit obligations under each Plan (based on the assumptions used for purposes of Accounting Standards Codification Topic 715) did not, as of the date of the most recent financial statements reflecting such amounts, exceed the fair
market value of the assets of such Plan by an amount which could reasonably be expected to result in a Material Adverse Effect, and the present value of all accumulated benefit obligations of all underfunded Plans (based on the assumptions used for
purposes of Accounting Standards Codification Topic 715) did not, as of the date of the most recent financial statements reflecting such amounts, exceed the fair market value of the assets of all such underfunded Plans by an amount which could
reasonably be expected to result in a Material Adverse Effect. 
 SECTION 3.11. Disclosure. As of the Effective Date, none of the
written reports, financial statements, certificates or other written information furnished by or on behalf of the Borrower to the Administrative Agent or any Lender in connection with the negotiation of this Agreement (as modified or supplemented by
other information so furnished on or prior to the Effective Date) contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading; provided that, with respect to projected financial information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time (it being recognized by
the Lenders that such projected financial information are not to be viewed as facts or a guarantee of performance and are subject to significant uncertainties and circumstances many of which are beyond the Borrower’s control, that

  
 42 

 
no assurance can be given that any particular financial projections will be realized, and that actual results during the periods covered by any such projected financial information may differ
from the projected results, and such differences may be material). 
 SECTION 3.12. Federal Regulations. The proceeds of the Loans
will be used only to repay certain existing Indebtedness as well as for working capital and general corporate purposes. No part of the proceeds of any Loan will be used to purchase or carry any Margin Stock in violation of Regulation U or X of
the Board. As of the date of this Agreement, if the full amount of the Lenders’ Commitments were used to purchase Margin Stock, no more than 25% of the value of the assets of the Borrower, or of the Borrower and its Subsidiaries taken as a
whole, which are subject to the restrictions contained in Article VI would constitute Margin Stock. If the proceeds of any Loan are to be used in a manner which would cause such Loans to be classified as “purpose loans” under
Regulation U, then at the time of the making of such Loan and at the time of the making of each Loan thereafter (after applying the proceeds of all Loans then being or theretofore made), no more than 25% of the value of the assets of the
Borrower, or of the Borrower and its Subsidiaries taken as a whole, which are subject to the restrictions contained in Article VI shall constitute Margin Stock. 

SECTION 3.13. Subsidiaries. Schedule 3.13 sets forth as of the Effective Date a list of all Subsidiaries and the percentage
ownership (directly or indirectly) of the Borrower therein. Except to the extent that could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, the shares of capital stock or other ownership
interests so indicated on Schedule 3.13 are fully paid and non-assessable and are owned by the Borrower, directly or indirectly, free and clear of all Liens other than Liens permitted under Section 6.02(a), (c), (f) or, to the extent
applicable to any of the foregoing paragraphs of Section 6.02, 6.02(i). 
 SECTION 3.14. Anti-Corruption Laws and Sanctions.
None of (a) the Borrower, any Subsidiary or to the knowledge of the Borrower or such Subsidiary any of their respective directors, officers or employees, or (b) to the knowledge of the Borrower, any agent of the Borrower or any Subsidiary
that will act in any capacity in connection with or benefit from the credit facility established hereby, is a Sanctioned Person. No Borrowing, use of proceeds or other transaction contemplated by the Credit Agreement will violate Anti-Corruption
Laws or applicable Sanctions. 
 ARTICLE IV 

Conditions 
 SECTION 4.01.
Effective Date. The obligations of the Lenders hereunder shall not become effective until the date on which each of the following conditions is satisfied (or waived in accordance with Section 9.02): 

(a) The Administrative Agent (or its counsel) shall have received from each party hereto either (i) a counterpart of this Agreement
signed on behalf of such party 

  
 43 

 
or (ii) written evidence satisfactory to the Administrative Agent (which may include telecopy transmission of a signed signature page of this Agreement) that such party has signed a counterpart
of this Agreement. 
 (b) The Guarantee Agreement shall have been duly executed and delivered to the Administrative Agent by Newmont USA.

 (c) The Administrative Agent shall have received reasonably satisfactory written opinions (addressed to the Administrative Agent and the
Lenders and dated the Effective Date) of Stephen P. Gottesfeld, Executive Vice President and General Counsel of the Borrower and the Guarantor and White & Case LLP, special counsel for the Borrower and the Guarantor. The Borrower and
the Guarantor hereby request such counsel to deliver such opinions. 
 (d) The Administrative Agent shall have received such documents and
certificates as the Administrative Agent or its counsel may reasonably request relating to the organization, existence and good standing of the Borrower and the Guarantor and the authorization of the Transactions by the Borrower and the Guarantor,
all in form and substance reasonably satisfactory to the Administrative Agent. 
 (e) The Administrative Agent shall have received a
certificate, dated the Effective Date and signed by the President, a Vice President or a Financial Officer of the Borrower, confirming compliance with the conditions set forth in paragraphs (a) and (b) of Section 4.02 (without giving
effect to the first parenthetical in Section 4.02(a)). 
 (f) The Administrative Agent shall have received all fees and other amounts
due and payable on or prior to the Effective Date, including, to the extent invoiced, payment or reimbursement of all fees and expenses (including reasonable fees, charges and disbursements of counsel) required to be paid or reimbursed by any Loan
Party to the Administrative Agent or the Arrangers in connection with the Transactions. 
 (g) The Lenders shall have received all
documentation and other information required by bank regulatory authorities under applicable “know your customer” and anti-money laundering rules and regulations, including the USA PATRIOT Act to the extent requested at least 10 days prior
to the Effective Date. 
 The Administrative Agent shall notify the Borrower and the Lenders of the Effective Date, and such notice shall be
conclusive and binding. Notwithstanding the foregoing, the obligations of the Lenders to make Loans hereunder shall not become effective unless each of the foregoing conditions is satisfied (or waived pursuant to Section 9.02) at or prior to
5:00 p.m., New York City time, on July 1, 2014 (and, in the event such conditions are not so satisfied or waived, the Commitments shall terminate at such time). 

SECTION 4.02. Each Credit Event. The obligation of each Lender to make a Loan on the occasion of any Borrowing is subject to the
satisfaction (or waiver in accordance with Section 9.02) of the following conditions: 

  
 44 

 (a) The representations and warranties of the Borrower set forth in this Agreement shall (other
than the representations and warranties set forth in Sections 3.04(b) and 3.06) be true and correct in all material respects on and as of the date of such Borrowing (except to the extent expressly made as of another date, in which case such
representations and warranties shall be true and correct in all material respects as of such other date). 
 (b) At the time of and
immediately after giving effect to such Borrowing, no Default shall have occurred and be continuing. 
 (c) The Company shall have delivered
a Borrowing Request in accordance with the requirements of Section 2.03. 
 (d) After giving effect to such Borrowing, and any related
transaction, on a pro forma basis, the Borrower shall be in compliance with the covenant set forth in Section 6.01 calculated as of the last day of the fiscal quarter of the Borrower then most recently ended for which financial statements have
been delivered pursuant to Section 5.01(a) or 5.01(b) (or, prior to the delivery of any such financial statements, the most recent quarter included in the financial statements referred to in Section 3.04(a)). 

(e) The Administrative Agent shall have received all fees required to be paid or reimbursed by any Loan Party to the Administrative Agent or
the Arrangers in connection with the Transactions on or prior to the date of such Borrowing. 
 Each Borrowing shall be deemed to constitute
a representation and warranty by the Borrower on the date thereof as to the matters specified in paragraphs (a) and (b) of this Section. 

ARTICLE V 
 Affirmative
Covenants 
 Until the Commitments have expired or been terminated and the principal of and interest on each Loan and all fees payable
hereunder have been paid in full, the Borrower covenants and agrees with the Lenders that: 
 SECTION 5.01. Financial Statements and
Other Information. The Borrower will furnish to the Administrative Agent for distribution to each Lender: 
 (a) within
100 days after the end of each fiscal year of the Borrower, its audited consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows as of the end of and for such year, setting forth in each case in
comparative form the figures for the previous fiscal year, all reported on by Pricewaterhouse Coopers LLP or other independent registered public accounting firm of recognized national standing (without a “going concern” or like
qualification or exception and without any qualification or exception as to the scope of such audit, other than any exception solely as a result 

  
 45 

 
of (x) an upcoming maturity date under any Indebtedness occurring within one year from the time such opinion is delivered or (y) any potential inability to satisfy any financial maintenance
covenant on a future date or in a future period) to the effect that such consolidated financial statements present fairly in all material respects the financial condition and results of operations of the Borrower and its consolidated Subsidiaries on
a consolidated basis in accordance with GAAP consistently applied (it being understood that the foregoing can be satisfied by delivery of the Borrower’s relevant Form 10-K); 

(b) within 55 days after the end of each of the first three fiscal quarters of each fiscal year of the Borrower, its
consolidated balance sheet and related statements of operations, stockholders’ equity and cash flows as of the end of and for such fiscal quarter and the then elapsed portion of the fiscal year, setting forth in each case in comparative form
the figures for the corresponding period or periods of (or, in the case of the balance sheet, as of the end of) the previous fiscal year, all certified by a Financial Officer as presenting fairly in all material respects the financial condition and
results of operations of the Borrower and its consolidated Subsidiaries on a consolidated basis in accordance with GAAP consistently applied, subject to normal year-end audit adjustments and the absence of footnotes (it being understood that the
foregoing can be satisfied by delivery of the Borrower’s relevant Form 10-Q); 
 (c) concurrently with any delivery
of financial statements under clause (a) or (b) above, a certificate of a Financial Officer (i) certifying as to whether a Default has occurred and, if a Default has occurred, specifying the details thereof and any action taken or
proposed to be taken with respect thereto, (ii) setting forth reasonably detailed calculations demonstrating compliance with Section 6.01, (iii) stating whether any change in GAAP or in the application thereof has occurred since the
date of the audited financial statements referred to in Section 3.04 and, if any such change has occurred, specifying the effect of such change on the financial statements accompanying such certificate and (iv) if any Lease Accounting GAAP
Change shall have become effective and shall have been applied by the Borrower, and such Lease Accounting GAAP Change affects the comparability of the consolidated financial statements (or any part thereof) for such fiscal year or such fiscal
quarter compared to the corresponding consolidated financial statements (or such part thereof) for the prior fiscal year or the corresponding fiscal quarter of such prior fiscal year in any material respect, specifying the effect of such Lease
Accounting GAAP Change on the consolidated financial statements for such fiscal year or such fiscal quarter; 
 (d)
concurrently with any delivery of financial statements under clause (a) above, (i) to the extent permitted by the internal policies of the independent registered accounting firm referred to in paragraph (a) above, a certificate of
such accounting firm in customary form stating whether they obtained knowledge during the course of their examination of such financial statements of any Default or Event of Default continuing under Section 6.01 on the date of such certificate,
except as specified in such certificate (which certificate may be limited to the 

  
 46 

 
extent required by accounting rules or guidelines) and (ii) a certificate of a Financial Officer setting forth any Non-Recourse Indebtedness outstanding as of the last day of such period;
and 
 (e) promptly following any request therefor, such other information regarding the operations, business affairs and
financial condition of the Borrower or any Subsidiary, or compliance with the terms of this Agreement, as the Administrative Agent or any Lender (through the Administrative Agent) may reasonably request. 

SECTION 5.02. Notices of Material Events. The Borrower will furnish to the Administrative Agent and each Lender prompt written notice
of the following: 
 (a) the occurrence of any Default; 

(b) the filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against
or affecting the Borrower or any Subsidiary thereof as to which there is a reasonable possibility of an adverse determination and which, if adversely determined, could reasonably be expected to result in a Material Adverse Effect; 

(c) the occurrence of any ERISA Event that, alone or together with any other ERISA Events that have occurred, could reasonably
be expected to result in a Material Adverse Effect; and 
 (d) any other development, including without limitation any
development relating to an Environmental Liability, that results in, or could reasonably be expected to result in, a Material Adverse Effect. 
 Each notice
delivered under this Section shall be accompanied by a statement of a Financial Officer or other executive officer of the Borrower setting forth the details of the event or development requiring such notice and any action taken or proposed to be
taken with respect thereto. 
 SECTION 5.03. Existence; Conduct of Business. (i) The Borrower will, and will cause each of its
Significant Subsidiaries to, do or cause to be done all things necessary to preserve, renew and keep in full force and effect its legal existence and (ii) the Borrower will, and will cause each of its Significant Subsidiaries to, do or cause to
be done all things necessary to preserve, renew and keep in full force and effect the rights, licenses, permits, privileges and franchises material to the conduct of the business of the Borrower and its Subsidiaries taken as a whole; provided
that the foregoing shall not (x) prohibit any merger, consolidation, liquidation, dissolution or sale permitted (or not restricted) under Section 6.03 or (y) require the maintenance of any right, license, permit, privilege or
franchise where the failure to maintain the same could not reasonably be expected to have a Material Adverse Effect. 
 SECTION 5.04.
Payment of Obligations. The Borrower will, and will cause each of its Subsidiaries to, pay its Tax liabilities that, if not paid, could reasonably 

  
 47 

 
be expected to result in a Material Adverse Effect before the same shall become delinquent or in default, except where (a) the validity or amount thereof is being contested in good faith by
appropriate proceedings and (b) the Borrower or such Subsidiary has set aside on its books adequate reserves with respect thereto in accordance with GAAP. 

SECTION 5.05. Maintenance of Properties; Insurance. The Borrower will, and will cause each of its Subsidiaries to, (a) keep and
maintain all property material to the conduct of the business of the Borrower and its Subsidiaries, taken as a whole, in good working order and condition, ordinary wear and tear and damage by casualty excepted, and (b) maintain, with financially
sound and reputable insurance companies, insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses operating in the same or similar locations, except, in each case, where
the failure to do so could not reasonably be expected to result in a Material Adverse Effect. 
 SECTION 5.06. Books and Records;
Inspection Rights. The Borrower will, and will cause each of its Subsidiaries to, keep proper books of record and account in which full, true and correct entries are made of all material dealings and transactions in relation to its business and
activities. The Borrower will, and will cause each of its Subsidiaries to, permit any representatives designated by the Administrative Agent, upon reasonable prior notice, to visit and inspect its properties, to examine and make extracts from its
books and records, and to discuss its affairs, finances and condition with its officers and independent accountants, all at such reasonable times and as often as reasonably requested. 

SECTION 5.07. Compliance with Laws. The Borrower will, and will cause each of its Subsidiaries to, comply with all laws, rules,
regulations and orders of any Governmental Authority, including without limitation all Environmental Laws, applicable to it or its property, except where the failure to do so, individually or in the aggregate, could not reasonably be expected to
result in a Material Adverse Effect. 
 SECTION 5.08. Use of Proceeds. The proceeds of the Initial Term Loans will be used to repay
certain existing Indebtedness as well as for working capital and general corporate purposes. The proceeds of the Incremental Term Loans will be used for the purpose or purposes set forth in the applicable Incremental Facility Agreement or for
working capital and general corporate purposes. No part of the proceeds of any Loan will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board, including Regulations U and X
(after giving effect to Article X). The Borrower will not request any Borrowing, and the Borrower shall not use, and shall take reasonable steps to ensure that none of its Subsidiaries and its or their respective directors, officers, employees
and agents shall use, the proceeds of any Borrowing (A) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws,
or (B) for the purpose of funding, financing or facilitating any activities, business or transaction of or with any Sanctioned Person, or in any Sanctioned Country. 

  
 48 

 SECTION 5.09. Further Assurances. The Borrower will, and will cause Newmont USA to,
execute any and all further documents, agreements and instruments, and take all further actions that may be required under any applicable law or regulation, or that the Administrative Agent may reasonably request, to cause the Guarantee Requirement
to be and remain satisfied at all times, subject to Section 9.14. 
 ARTICLE VI 

Negative Covenants 
 Until
the Commitments have expired or terminated and the principal of and interest on each Loan and all fees payable hereunder have been paid in full, the Borrower covenants and agrees with the Lenders that: 

SECTION 6.01. Consolidated Indebtedness. The Borrower will not, as of the last day of any fiscal quarter, permit Total Indebtedness as
of such date to exceed an amount equal to 62.5% of Total Capitalization as of such date. 
 SECTION 6.02. Liens. The Borrower will
not, and will not permit any Subsidiary to, create, incur, assume or permit to exist any Lien on any property or asset now owned or hereafter acquired by it, except: 

(a) Permitted Encumbrances; 

(b) any Lien on any property or asset of the Borrower or any Subsidiary existing on the Effective Date and (to the extent
securing Indebtedness in excess of $25,000,000) set forth in Schedule 6.02; provided that (i) such Lien shall not apply to any other property or asset of the Borrower or any Subsidiary and (ii) such Lien shall secure only those
obligations which it secured on the Effective Date; 
 (c) any Lien existing on any property or asset prior to the
acquisition thereof by the Borrower or any Subsidiary or existing on any property or asset of any Person that becomes a Subsidiary after the Effective Date prior to the time such Person becomes a Subsidiary; provided that (i) such Lien
is not created in contemplation of or in connection with such acquisition or such Person becoming a Subsidiary, as the case may be, (ii) such Lien shall not apply to any other property or assets of the Borrower or any Subsidiary and
(iii) such Lien shall secure only those obligations which it secures on the date of such acquisition or the date such Person becomes a Subsidiary, as the case may be; 

(d) Liens (including Liens arising in connection with any Capital Lease Obligation) on fixed or capital assets acquired,
constructed or improved by the Borrower or any Subsidiary; provided that (i) such security interests secure Indebtedness permitted by Section 6.01, (ii) such security interests and the Indebtedness secured thereby are incurred
prior to, at the time of, or within 180 days after such acquisition or the completion of such construction or 

  
 49 

 
improvement, (iii) the Indebtedness secured thereby does not exceed the cost of acquiring, constructing or improving such fixed or capital assets and (iv) such security interests shall
not apply to any other property or assets of the Borrower or any Subsidiary; 
 (e) Liens securing Indebtedness otherwise
permitted pursuant to this Agreement incurred in connection with any Capital Lease Obligation related solely to the Gold Ore Treatment facility located near Carlin, Nevada; 

(f) Liens securing Indebtedness otherwise permitted pursuant to this Agreement incurred in connection with the development,
construction or operation of a project developed or constructed after the Effective Date so long as such Liens encumber only the project itself and/or the ownership interest held by the Borrower or any Subsidiary therein; 

(g) a sale-leaseback transaction with respect to the Autoclave Equipment Plants; 

(h) Liens not otherwise permitted by this Section 6.02 which, in the aggregate, secure Indebtedness and other obligations
not exceeding (as to the Borrower and all of its Subsidiaries) $600,000,000 in aggregate principal amount at any time outstanding; 

(i) Liens in respect of the cash collateralization of (i) letters of credit issued under other bank credit facilities
permitted by this Agreement to the extent the aggregate stated face amounts of such letters of credit exceed the commitments under the applicable bank credit facility and (ii) any defaulting lender’s participation in letters of credit or
swingline loans under other bank credit facilities permitted by this Agreement; and 
 (j) extensions, renewals, refinancings
or replacements of any Lien referred to in paragraphs (b), (c), (d), (e), (f) and (g) of this Section 6.02, provided that the principal amount of the Indebtedness or obligation secured thereby is not increased (except by
the amount of any accrued and unpaid interest or premium in connection therewith and any reasonable fees associated with such extension, renewal, refinancing or replacement) and that any such extension, renewal or replacement is limited to the
property originally encumbered thereby. 
 SECTION 6.03. Fundamental Changes. The Borrower will not merge into or consolidate with
any other Person, nor permit any other Person to merge into or consolidate with it, or sell, transfer, lease or otherwise dispose of (in one transaction or in a series of transactions) all or substantially all of its assets (in each case, whether
now owned or hereafter acquired) or liquidate or dissolve, except that, if at the time thereof and immediately after giving effect thereto no Default shall have occurred and be continuing: 

(a) any Subsidiary may merge or consolidate with the Borrower; 

  
 50 

 (b) the Borrower may merge or consolidate with any other Person so long as: 

(i) the Borrower, is the surviving corporation or the surviving corporation (if the surviving corporation is not the Borrower)
shall assume all of the Loans and other obligations of the Borrower under this Agreement pursuant to an Assumption Agreement substantially in the form of Exhibit B; and 

(ii) the credit rating for Index Debt of the surviving corporation from either Moody’s or S&P immediately after such
transaction is at least equal to the credit rating for Index Debt of the Borrower immediately prior to the initial public announcement of such transaction, provided, that in any event the requirements of this clause (ii) shall be
deemed satisfied if the surviving corporation has a credit rating after such merger or consolidation of at least BBB, in the case of S&P, or Baa2, in the case of Moody’s. 

ARTICLE VII 
 Events of Default

 If any of the following events (“Events of Default”) shall occur: 

(a) the Borrower shall fail to pay any principal of any Loan when and as the same shall become due and payable, whether at the
due date thereof or at a date fixed for prepayment thereof or otherwise; 
 (b) the Borrower shall (i) fail to pay
(A) any interest on any Loan or (B) any regularly accruing fees hereunder, when and as the same shall become due and payable, and such failure shall continue unremedied for a period of three Business Days or (ii) fail to pay any other
amount (other than an amount referred to in clause (a) of this Article) payable under this Agreement, when and as the same shall become due and payable, and such failure shall continue for 15 days after the Borrower is notified thereof by the
Administrative Agent or any Lender; 
 (c) any representation or warranty made or deemed made by or on behalf of the Borrower
in or in connection with this Agreement or any amendment or modification hereof or waiver hereunder, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this Agreement or any amendment or
modification hereof or waiver hereunder, shall prove to have been incorrect in any material respect when made or deemed made; 

(d) the Borrower shall fail to observe or perform any covenant, condition or agreement contained in Section 5.02(a), 5.03
(with respect to the Borrower’s existence) or 5.08 or in Article VI; 

  
 51 

 (e) the Borrower shall fail to observe or perform any covenant, condition or
agreement contained in this Agreement (other than those specified in clause (a), (b) or (d) of this Article), and such failure shall continue unremedied for a period of 30 days after notice thereof from the Administrative Agent to the
Borrower (which notice will be given at the request of the Required Lenders); 
 (f) the Borrower or any Significant
Subsidiary shall fail to make any payment of principal or interest (and regardless of amount) in respect of any Material Indebtedness (other than Non-Recourse Indebtedness), when and as the same shall become due and payable (after giving effect
to the period of grace, if any, provided in the instrument or agreement relating to such Material Indebtedness); 
 (g) any
event or condition occurs (i) that results in any Material Indebtedness (other than Non-Recourse Indebtedness) becoming due prior to its scheduled maturity or (ii) that enables or permits (with or without the giving of notice, the lapse of
time or both) the holder or holders of any Material Indebtedness (other than Non-Recourse Indebtedness) or any trustee or agent on its or their behalf to cause any such Material Indebtedness (other than any Non-Recourse Indebtedness) to become due,
or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; 
 (h) an
involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i) liquidation, reorganization or other relief in respect of the Borrower or any Significant Subsidiary or its debts, or of a substantial part of its
assets, under any Federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect or (ii) the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for the Borrower
or any Significant Subsidiary or for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed for 60 days or an order or decree approving or ordering any of the foregoing shall be entered;

 (i) the Borrower or any Significant Subsidiary shall (i) voluntarily commence any proceeding or file any petition
seeking liquidation, reorganization or other relief under any Federal, state or foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect, (ii) consent to the institution of, or fail to contest in a timely and
appropriate manner, any proceeding or petition described in clause (h) of this Article, (iii) apply for or consent to the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for the Borrower or any
Significant Subsidiary or for a substantial part of its assets, (iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding, (v) make a general assignment for the benefit of creditors or
(vi) take any corporate action for the purpose of effecting any of the foregoing; 

  
 52 

 (j) one or more judgments for the payment of money in an aggregate amount in
excess of $100,000,000 (excluding any amount paid or covered by independent third-party insurance as to which the insurer has been notified of such judgment and has not denied coverage) shall be rendered against the Borrower, any Significant
Subsidiary or any combination thereof and the same shall remain undischarged for a period of 60 consecutive days during which execution shall not be effectively stayed (or, in the case of a judgment in a jurisdiction other than the
United States of America or any political subdivision thereof, such longer period as the Borrower and the Administrative Agent shall agree in good faith, provided that the Borrower or such Significant Subsidiary shall be contesting such
execution in accordance with appropriate proceedings; provided further that the Administrative Agent shall not agree to an additional period in excess of 120 consecutive days without the consent of the Required Lenders), or any action
shall be legally taken by a judgment creditor to attach or levy upon any assets of the Borrower or any Significant Subsidiary to enforce any such judgment; 

(k) an ERISA Event shall have occurred that, when taken together with all other ERISA Events that have occurred, could
reasonably be expected to result in a Material Adverse Effect; 
 (l) a Change in Control shall occur; 

(m) the Borrower or any Significant Subsidiary (i) shall fail to make any payment or delivery in respect of any Material
Commodity Hedging Indebtedness, and (ii) after giving effect to any applicable notice requirement or grace period, there occurs a liquidation of, an acceleration of obligations under, or an early termination of, the Commodity Hedging Agreement
under which such Material Commodity Hedging Indebtedness arises, and (iii) the Borrower or such Significant Subsidiary shall fail to make any payment due under such Commodity Hedging Agreement as a result of such liquidation, acceleration or
early termination within the period provided under such Commodity Hedging Agreement; or 
 (n) except as provided in
Section 9.14, the Guarantee Agreement shall cease to be enforceable with respect to the Guarantor or the Guarantor shall assert in writing that the Guarantee Agreement or any guarantee thereunder has ceased to be or is not enforceable; 

then, and in every such event (other than an event with respect to the Borrower described in clause (h) or (i) of this Article), and at any time
thereafter during the continuance of such event, the Administrative Agent may, and at the request of the Required Lenders shall, by notice to the Borrower, take any or all of the following actions, at the same or different
times: (i) terminate the Commitments, and thereupon the Commitments shall terminate immediately and (ii) declare the Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to be
due and payable may thereafter be declared to be due and payable), and thereupon the principal of the 

  
 53 

 
Loans so declared to be due and payable, together with accrued interest thereon and all fees and other obligations of the Borrower accrued hereunder, shall become due and payable immediately, in
each case without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower; and in case of any event with respect to the Borrower described in clause (h) or (i) of this Article, the
Commitments shall automatically terminate, the principal of the Loans and, together with accrued interest thereon and all fees and other obligations of the Borrower accrued hereunder, shall automatically become due and payable, in each case without
presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower. 
 ARTICLE VIII 

The Administrative Agent 

Each of the Lenders hereby irrevocably appoints the entity named as Administrative Agent in the heading of this Agreement and its successors
to serve as administrative agent under the Loan Documents, and authorizes the Administrative Agent to take such actions and to exercise such powers as are delegated to the Administrative Agent by the terms of the Loan Documents, together with such
actions and powers as are reasonably incidental thereto. 
 The Person serving as the Administrative Agent hereunder shall have the same
rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent, and such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or
in any other advisory capacity for and generally engage in any kind of business with the Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to
the Lenders. 
 The Administrative Agent shall not have any duties or obligations except those expressly set forth in the Loan Documents.
Without limiting the generality of the foregoing, (a) the Administrative Agent shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing, (b) the Administrative Agent
shall not have any duty to take any discretionary action or to exercise any discretionary power, except discretionary rights and powers expressly contemplated by the Loan Documents that the Administrative Agent is required to exercise as directed in
writing by the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith to be necessary, under the circumstances as provided in the Loan Documents),
provided that the Administrative Agent shall not be required to take any action that, in its opinion, could expose the Administrative Agent to liability or be contrary to any Loan Document or applicable law, and (c) except as expressly
set forth in the Loan Documents, the Administrative Agent shall not have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower, any Subsidiary or any other Affiliate of any of the
foregoing that is communicated to or 

  
 54 

 
obtained by the Person serving as Administrative Agent or any of its Affiliates in any capacity. The Administrative Agent shall not be liable for any action taken or not taken by it with the
consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith to be necessary, under the circumstances as provided in the Loan
Documents) or in the absence of its own gross negligence or wilful misconduct, as determined by a court of competent jurisdiction by a final and non-appealable judgment. The Administrative Agent shall be deemed not to have knowledge of any Default
unless and until written notice thereof is given to the Administrative Agent by the Borrower or a Lender, and the Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or
representation made in or in connection with any Loan Document, (ii) the contents of any certificate, report or other document delivered thereunder or in connection therewith, (iii) the performance or observance of any of the covenants,
agreements or other terms or conditions set forth in any Loan Document or the occurrence of any Default, (iv) the sufficiency, validity, enforceability, effectiveness or genuineness of any Loan Document or any other agreement, instrument or
document, or (v) the satisfaction of any condition set forth in Article IV or elsewhere in any Loan Document, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent or satisfaction of any
condition that expressly refers to the matters described therein being acceptable or satisfactory to the Administrative Agent. 
 The
Administrative Agent shall be entitled to rely, and shall not incur any liability for relying, upon any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet
website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person (whether or not such Person in fact meets the requirements set forth in the Loan Documents for being
the signatory, sender or authenticator thereof). The Administrative Agent also shall be entitled to rely, and shall not incur any liability for relying, upon any statement made to it orally or by telephone and believed by it to be made by the proper
Person (whether or not such Person in fact meets the requirements set forth in the Loan Documents for being the signatory, sender or authenticator thereof), and may act upon any such statement prior to receipt of written confirmation thereof. The
Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any
such counsel, accountants or experts. 
 The Administrative Agent may perform any of and all its duties and exercise its rights and powers
hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any of and all their duties and exercise their rights and powers
through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in
connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. 

  
 55 

 Subject to the terms of this paragraph, the Administrative Agent may resign at any time from its
capacity as such. In connection with such resignation, the Administrative Agent shall give notice of its intent to resign to the Lenders and the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right,
with the consent of the Borrower (not to be unreasonably withheld), to appoint a successor. If no successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring
Administrative Agent gives notice of its intent to resign, then the retiring Administrative Agent may, on behalf of the Lenders, appoint a successor Administrative Agent reasonably acceptable to the Borrower, which shall be a bank with an office in
New York, New York, or an Affiliate of any such bank. Upon the acceptance of its appointment as Administrative Agent hereunder by a successor, such successor shall succeed to and become vested with all the rights, powers, privileges and duties of
the retiring Administrative Agent, and the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents. The fees payable by the Borrower to a successor Administrative Agent shall be
the same as those payable to its predecessor unless otherwise agreed by the Borrower and such successor. Following the effectiveness of the Administrative Agent’s resignation from its capacity as such, the provisions of this Article and
Section 9.03, as well as any exculpatory, reimbursement and indemnification provisions set forth in any other Loan Document, shall continue in effect for the benefit of such retiring Administrative Agent, its
sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while it was acting as Administrative Agent. 

Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent, the Arrangers or any other Lender, or
any of the Related Parties of any of the foregoing, and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will,
independently and without reliance upon the Administrative Agent, the Arrangers or any other Lender, or any of the Related Parties of any of the foregoing, and based on such documents and information as it shall from time to time deem appropriate,
continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder. 

Each Lender, by delivering its signature page to this Agreement and funding its Loans on the Effective Date, or delivering its signature page
to an Assignment and Acceptance or an Incremental Facility Agreement pursuant to which it shall become a Lender hereunder, shall be deemed to have acknowledged receipt of, and consented to and approved, each Loan Document and each other document
required to be delivered to, or be approved by or satisfactory to, the Administrative Agent or the Lenders on the Effective Date. 

Notwithstanding anything herein to the contrary, neither the Arrangers nor any Person named on the cover page of this Agreement as a
Documentation Agent shall have any duties or obligations under this Agreement or any other Loan Document (except 

  
 56 

 
in its capacity, as applicable, as a Lender), but all such Persons shall have the benefit of the indemnities provided for hereunder. 

The provisions of this Article are solely for the benefit of the Administrative Agent and the Lenders (except as provided herein with respect to consent
rights over successor Administrative Agents), and neither the Borrower nor any other Loan Party shall have any rights as a third party beneficiary of any such provisions. 

ARTICLE IX 
 Miscellaneous

 SECTION 9.01. Notices. Except in the case of notices and other communications expressly permitted to be given by telephone, all
notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by telecopy, as follows: 

(a) if to the Borrower, to it at 6363 South Fiddlers Green Circle, Greenwood Village, Colorado 80111, Attention of Treasurer
(Telecopy No. (303) 837-5150), Attention: Treasurer; 
 (b) if to the Administrative Agent, to JPMorgan Chase Bank,
N.A. Loan and Agency Services Group, 500 Stanton Christiana Road, 3/Ops2, Newark, DE 19713, Attention of Rea Seth (Telecopy No. (302) 634-4712), with a copy to JPMorgan Chase Bank, N.A., 383 Madison Avenue, New York 10179, Attention of
Gitanjali Pundir (Telecopy No. (212) 270-5100); 
 (c) if to any Lender, to it at its address (or telecopy number) set
forth in its Administrative Questionnaire; and 
 (d) notices and other communications to the Lenders hereunder may be
delivered or furnished by electronic communications pursuant to procedures approved by the Administrative Agent; provided that the foregoing shall not apply to notices pursuant to Article II unless otherwise agreed by the Administrative Agent
and the applicable Lender. The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it; provided that
approval of such procedures may be limited to particular notices or communications. 
 Any party hereto may change its address or telecopy number for
notices and other communications hereunder by notice to the other parties hereto. All notices and other communications given to any party hereto in accordance with the provisions of this Agreement shall be deemed to have been given on the date of
receipt. 

  
 57 

 SECTION 9.02. Waivers; Amendments. (a) No failure or delay by the Administrative
Agent or any Lender in exercising any right or power hereunder or under any other Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to
enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Administrative Agent and the Lenders hereunder and under any other Loan Documents are
cumulative and are not exclusive of any rights or remedies that they would otherwise have. No waiver of any provision of any Loan Document or consent to any departure by any Loan Party therefrom shall in any event be effective unless the same shall
be permitted by paragraph (b) of this Section, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. Without limiting the generality of the foregoing, the making of a Loan shall
not be construed as a waiver of any Default, regardless of whether the Administrative Agent or any Lender may have had notice or knowledge of such Default at the time. 

(b) Except as provided in Section 2.23, neither this Agreement nor any other Loan Document nor any provision hereof or thereof may be
waived, amended or modified except pursuant to an agreement or agreements in writing entered into by the Borrower and the Required Lenders or by the Borrower and the Administrative Agent with the consent of the Required Lenders or in the case of the
Guarantee Agreement, the Guarantor; provided that no such agreement shall (i) increase the Commitment of any Lender without the written consent of such Lender, (ii) reduce the principal amount of any Loan or reduce the rate of
interest thereon (other than a waiver of post-default additional interest as specified in Section 2.14(a)), or reduce any fees payable to any Lender hereunder, without the written consent of each Lender adversely affected thereby,
(iii) postpone any scheduled payment of principal of any Loan, or any interest thereon (other than a waiver of post-default additional interest as specified in Section 2.14(c)), or any fees payable hereunder, or reduce the amount of, waive
or excuse any such payment, or postpone the scheduled date of expiration of any Commitment, without the written consent of each Lender adversely affected thereby, (iv) change Section 2.19(b) or (c) in a manner that would alter the
pro rata sharing of payments required thereby, without the written consent of each Lender adversely affected thereby or (v) change any of the provisions of this Section 9.02(b) or the definition of “Required Lenders”
(other than any change to the definition of “Required Lenders” necessary for any new class of Lenders to be treated on the same basis as existing Lenders) or any other provision of any Loan Document specifying the number or percentage of
Lenders required to waive, amend or modify any rights hereunder or make any determination or grant any consent hereunder, without the written consent of each Lender, without the written consent of each Lender; provided, further, that
no such agreement shall amend, modify or otherwise affect the rights or duties of the Administrative Agent hereunder without the prior written consent of the Administrative Agent. Notwithstanding any of the foregoing (A) no consent with respect
to any amendment, waiver or other modification of this Agreement or any other Loan Document shall be required of (1) any Defaulting Lender, except with respect to any amendment, waiver or other modification referred to in clause (i),
(ii) or (iii) of the first proviso of this paragraph and then only in the event such Defaulting Lender shall be affected by such amendment, waiver or other modification or (2) any Lender that receives

  
 58 

 
payment in full of the principal of and interest accrued on each Loan made by, and all other amounts owing to, such Lender or accrued for the account of such Lender under this Agreement and the
other Loan Documents at the time such amendment, waiver or other modification becomes effective and whose Commitments terminate by the terms and upon the effectiveness of such amendment, waiver or other modification and (B) any provision of
this Agreement or any other Loan Document may be amended by an agreement in writing entered into by the Borrower and the Administrative Agent to cure any ambiguity, omission, defect or inconsistency so long as, in each case, the Lenders shall have
received at least five Business Days prior written notice thereof and the Administrative Agent shall not have received, within five Business Days of the date of such notice to the Lenders, a written notice from the Required Lenders stating that the
Required Lenders object to such amendment, and (C) this Agreement may be amended to provide for Incremental Term Commitments in the manner contemplated by Section 2.22 and the extension of the Maturity Date as provided in
Section 2.23, in each case, without the consent of any Person other than as required pursuant to Section 2.22 or Section 2.23, as applicable. 

SECTION 9.03. Expenses; Indemnity; Damage Waiver. (a) The Borrower shall pay (i) all reasonable and documented out-of-pocket expenses incurred by the Administrative Agent, the Arrangers and their Affiliates, including the reasonable and documented fees, charges and disbursements of
counsel for the Administrative Agent, in connection with the syndication of the credit facility provided for herein, the preparation and administration of the Loan Documents or any amendments, modifications or waivers of the provisions hereof
(whether or not the transactions contemplated hereby or thereby shall be consummated) and (ii) all documented out-of-pocket expenses incurred by the Administrative Agent, the Arrangers or, after the occurrence of a Default or an Event of
Default or any Lender, including the reasonable fees, charges and disbursements of any counsel for the Administrative Agent or any Lender, in connection with the enforcement or protection of its rights in connection with the Loan Documents,
including its rights under this Section; provided further that the Borrower, in connection with the foregoing, shall only be required to pay the fees and expenses of (A) one counsel engaged to represent the Administrative Agent
and (B) in the case of the preceding clause (ii), (1) one joint counsel engaged to represent the Administrative Agent, the Arrangers and all Lenders (taken together), plus one additional counsel for each of the parties taken as a whole who
are similarly situated in the event any Lender shall have reasonably determined, or been advised by counsel, that there are or may be actual conflicts of interest, including situations in which one or more legal defenses available to it are
different from or in additional to those available to any other Lender, and (2) such other joint local counsel in any applicable jurisdiction engaged to represent the Administrative Agent and all Lenders as may be required in the reasonable
judgment of the Administrative Agent. 
 (b) The Borrower shall indemnify the Administrative Agent (and any sub-agent thereof), the
Arrangers and each Lender, and each Related Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and
related expenses (but limited, in the case of legal fees and expenses, to the documented 

  
 59 

 
fees, charges and disbursements of one counsel for the Indemnitees, taken as a whole, and, if necessary, one local counsel in any applicable jurisdiction plus one additional counsel (and one
additional local counsel in each applicable jurisdiction) for each of the parties taken as a whole who are similarly situated in the event any Indemnitee shall have reasonably determined, or been advised by counsel, that there are or may be
conflicts of interest, including situations in which one or more legal defenses available to it are different from or in additional to those available to any other Indemnitee, incurred by or asserted against any Indemnitee arising out of, in
connection with, or as a result of any actual or prospective claim, litigation, investigation or proceeding (regardless of whether any Indemnitee is a party thereto and regardless of whether such matter is initiated by a third party, the Borrower or
any Affiliate of the Borrower) relating to (i) the execution or delivery of any Loan Document or any agreement or instrument contemplated thereby, the performance by the parties to the Loan Documents of their obligations thereunder or the
consummation of the Transactions or any other transactions contemplated hereby, (ii) any Loan or the use of the proceeds therefrom or (iii) any actual or alleged presence or release of Hazardous Materials on or from any property currently
or formerly owned or operated by the Borrower or any of its Subsidiaries, or any Environmental Liability related in any way to the Borrower or any of its Subsidiaries; provided that such indemnity shall not, as to any Indemnitee, be available
to the extent that such losses, claims, damages, liabilities or related expenses (A) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence, bad faith or wilful
misconduct of such Indemnitee (or any Related Party of such Indemnitee) or, solely in the case of a claim initiated by the Borrower, material breach of such Indemnitee’s obligations under the Loan Documents in bad faith or (B) arise out of
disputes solely among Indemnitees and not arising out of any act or omission by the Borrower or any of its Subsidiaries (other than any disputes against the Administrative Agent or any Arranger in its capacity as such). This Section 9.03(b)
shall not apply with respect to Taxes. 
 (c) To the extent that the Borrower fails to pay any amount required to be paid by them to the
Administrative Agent (or any sub-agent thereof) or any Related Party of any of the foregoing, under paragraph (a) or (b) of this Section, each Lender severally agrees to pay to the Administrative Agent (or any sub-agent hereof) or such
Related Party, as the case may be, such Lender’s Applicable Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought), of such unpaid amount; provided that the unreimbursed expense or
indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent, in its capacity as such. 

(d) To the extent permitted by applicable law, (i) the Borrower shall not assert, or permit any of their Affiliates or Related Parties to
assert, and each hereby waives, any claim against any Indemnitee for any damages arising from the use by others of information or other materials obtained through telecommunications, electronic or other information transmission systems (including
the Internet), unless caused by such Indemnitee’s gross negligence or willful misconduct (as determined by a court of competent jurisdiction in a final and non-appealable decision) and (ii) no party hereto shall, nor shall it permit any of
its Affiliates or Related Parties to assert, and each hereby 

  
 60 

 
waives, any claim against any other party, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in
connection with, or as a result of, this Agreement or any agreement or instrument contemplated hereby, the Transactions, any Loan or the use of the proceeds thereof; provided that nothing contained in this clause (ii) will limit the
Borrower’s obligations as set forth in paragraph (b) above. 
 (e) All amounts due under this Section shall be payable promptly
after written demand therefor. 
 SECTION 9.04. Successors and Assigns. (a) The provisions of this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that (i) the Borrower may not (except as otherwise provided herein) assign or otherwise transfer any of its rights or
obligations hereunder without the prior written consent of each Lender (and any attempted assignment or transfer by the Borrower without such consent shall be null and void) and (ii) no Lender may assign or otherwise transfer its rights or
obligations hereunder except in accordance with this Section. Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby,
Participants (solely to the extent expressly provided in paragraph (e) of this Section) and the Indemnitees) any legal or equitable right, remedy or claim under or by reason of this Agreement. 

(b) Any Lender may assign to one or more commercial banks or other financial institutions all or a portion of its rights and obligations under
this Agreement (including all or a portion of its Commitment and the Loans at the time owing to it); provided that (i) each of the Borrower (except in the case of an assignment to a Lender or an Affiliate of a Lender) and the
Administrative Agent must give their prior written consent to such assignment (which consents shall not be unreasonably withheld), (ii) the amount of the Commitment of the assigning Lender subject to each such assignment (determined as of the
date the Assignment and Acceptance with respect to such assignment is delivered to the Administrative Agent), if less than the entire remaining amount of the assigning Lender’s Commitment, shall not in any event be less than $5,000,000 unless
each of the Borrower and the Administrative Agent otherwise consent, (iii) each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement,
(iv) the parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Acceptance, together with a processing and recordation fee of $3,500, and (v) the assignee, if it shall not be a Lender, shall
deliver to the Administrative Agent an Administrative Questionnaire; and provided further that (A) any consent of the Borrower otherwise required under the first proviso to this paragraph shall (1) not be required if an Event
of Default under clauses (a), (b), (h) or (i) of Article VII (with respect to the Borrower) has occurred and is continuing and (2) for any assignment, be deemed to have been given by the Borrower unless it shall object to such
assignment by written notice to the Administrative Agent within five Business Days after having first received notice thereof, and (B) notwithstanding any other provision in this paragraph (b) (including the preceding clause (A) of
this proviso), the prior written consent of the Borrower shall be 

  
 61 

 
required in the case of any assignment to a Person referred to in clause (v) of Section 9.04(e). Subject to acceptance and recording thereof pursuant to paragraph (d) of this
Section, from and after the effective date specified in each Assignment and Acceptance the assignee thereunder shall be a party hereto and, to the extent of the interest assigned by such Assignment and Acceptance, have the rights and obligations of
a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Acceptance, be released from its obligations under this Agreement (and, in the case of an Assignment and
Acceptance covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto but shall continue to be entitled to the benefits of Sections 2.16, 2.17, 2.18 and 9.03). Any
assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this paragraph shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in
accordance with paragraph (e) of this Section. 
 (c) The Administrative Agent, acting for this purpose as an agent of the Borrower,
shall maintain at one of its offices in New York, New York a copy of each Assignment and Acceptance delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitment of, and principal amount of and
stated interest on the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent
and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for
inspection by the Borrower and any Lender (as to its own interest), at any reasonable time and from time to time upon reasonable prior notice. 

(d) Upon its receipt of a duly completed Assignment and Acceptance executed by an assigning Lender and an assignee, the assignee’s
completed Administrative Questionnaire (unless the assignee shall already be a Lender hereunder), the processing and recordation fee referred to in paragraph (b) of this Section and any written consent to such assignment required by paragraph
(b) of this Section, the Administrative Agent shall accept such Assignment and Acceptance and record the information contained therein in the Register. No assignment shall be effective for purposes of this Agreement unless it has been recorded
in the Register as provided in this paragraph. 
 (e) Any Lender may sell participations to one or more banks or other entities (a
“Participant”) in all or a portion of such Lender’s rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans owing to it); provided that (i) unless the Participant is
an Affiliate or an affiliated funding vehicle of such Lender, the Borrower’s consent, in its sole discretion, shall be required for the sale of such participation, (ii) such Lender’s obligations under this Agreement shall remain
unchanged, (iii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations, (iv) the Borrower, the Administrative Agent and the other Lenders shall continue to deal solely and directly
with such Lender in connection with such Lender’s rights and obligations under this Agreement and (v) notwithstanding 

  
 62 

 
any other provision in this paragraph (e), no Lender may, without the Borrower’s prior written consent, sell participations in any Loan or Commitment to Persons (other than banks and
similar financial institutions) that are engaged in the gold or minerals business and which are designated in writing from time to time by the Borrower as Persons that are ineligible to participate in Loans and Commitments; provided
further that any consent of the Borrower otherwise required under the first proviso to this paragraph (other than any consent required under clause (v) of this paragraph) shall (x) not be required if an Event of Default under
clauses (a), (b), (h) or (i) of Article VII (with respect to the Borrower) has occurred and is continuing and (y) be deemed to have been given by the Borrower unless it shall object to such participation by written notice to the
Administrative Agent within five Business Days after having first received notice thereof. Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce the
Loan Documents and to approve any amendment, modification or waiver of any provision of the Loan Documents; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any
amendment, modification or waiver described in clause (i), (ii) or (iii) of the first proviso to Section 9.02(b) that affects such Participant. The Borrower agrees that each Participant shall be entitled to the benefits of
Sections 2.16, 2.17 and 2.18 (subject to the requirements and limitations therein, including the requirements under Section 2.18(f) (it being understood that the documentation required under Section 2.18(f) shall be delivered to the
participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section; provided that such Participant (A) agrees to be subject to the provisions of
Sections 2.19 and 2.20 as if it were an assignee under paragraph (b) of this Section; and (B) shall not be entitled to receive any greater payment under Sections 2.16 or 2.18, with respect to any participation, than its participating
Lender would have been entitled to receive. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 9.08 as though it were a Lender, provided such Participant agrees to be subject to
Section 2.19(c) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as an agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the
principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under this Agreement (the “Participant Register”); provided that no Lender shall have any obligation to disclose
all or any portion of the Participant Register to any Person (including the identity of any Participant or any information relating to a Participant’s interest in any Commitments, Loans or its other obligations under any Loan Document) except
to the extent that such disclosure is necessary to establish that such Commitment, Loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall
be conclusive absent manifest error, and such Lender shall treat each person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the
avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register. 

(f) Each Lender agrees that it will only provide to a Participant information relating to the Borrower and its Subsidiaries that (i) is
or becomes generally 

  
 63 

 
available to the public other than as a result of a disclosure by such Lender or its agents, employees or advisors or (ii) becomes available on a nonconfidential basis, in each case other
than from a source which is bound by a confidentiality agreement with the Borrower. 
 (g) Any Lender may at any time pledge or assign a
security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank or other central bank, and this Section shall not
apply to any such pledge or assignment of a security interest; provided that no such pledge or assignment of a security interest shall release a Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such
Lender as a party hereto. 
 SECTION 9.05. Survival. All covenants, agreements, representations and warranties made by the Borrower
herein, in the other Loan Documents and in the certificates or other instruments delivered in connection with or pursuant to this Agreement or any other Loan Document shall be considered to have been relied upon by the other parties hereto and shall
survive the execution and delivery of the Loan Documents and the making of any Loans, regardless of any investigation made by any such other party or on its behalf and notwithstanding that the Administrative Agent or any Lender may have had notice
or knowledge of any Default or incorrect representation or warranty at the time any credit is extended hereunder, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any fee or any other
amount payable under this Agreement is outstanding and unpaid and so long as the Commitments have not expired or terminated. The provisions of Sections 2.16, 2.17, 2.18 and 9.03 and Article VIII shall survive and remain in full force and effect
regardless of the consummation of the transactions contemplated hereby, the repayment of the Loans, the expiration or termination of the Commitments or the termination of this Agreement or any provision hereof. 

SECTION 9.06. Counterparts; Integration; Effectiveness. This Agreement may be executed in counterparts (and by different parties hereto
on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement, the other Loan Documents and any separate letter agreements with respect to fees payable
to the Administrative Agent constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Delivery of
an executed counterpart of a signature page of this Agreement by telecopy or other electronic imaging shall be effective as delivery of a manually executed counterpart of this Agreement. 

SECTION 9.07. Severability. Any provision of any Loan Document held to be invalid, illegal or unenforceable in any jurisdiction shall,
as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability without affecting the validity, legality and enforceability of the remaining provisions of such Loan Document; and the invalidity of a
particular provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction. 

  
 64 

 SECTION 9.08. Right of Setoff. If the Loans shall have become due and payable, each Lender
and each of its Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and
other obligations at any time owing by such Lender or Affiliate to or for the credit or the account of the Borrower against any of and all the obligations of the Borrower now or hereafter existing under this Agreement held by such Lender,
irrespective of whether or not such Lender shall have made any demand under this Agreement and although such obligations may be unmatured. The rights of each Lender under this Section are in addition to and shall not limit other rights and remedies
(including other rights of setoff) which such Lender may have. 
 SECTION 9.09. Governing Law; Jurisdiction; Consent to Service of
Process. (a) This Agreement shall be construed in accordance with and governed by the law of the State of New York. 
 (b) The
Borrower hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the Supreme Court of the State of New York sitting in New York County and of the United States District Court of the
Southern District of New York, and any appellate court from any thereof, in any action or proceeding arising out of or relating to any Loan Document, or for recognition or enforcement of any judgment, and each of the parties hereto hereby
irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees
that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or any other Loan Document shall affect
any right that the Administrative Agent or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Loan Document against the Borrower or its properties in the courts of any jurisdiction. 

(c) The Borrower hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection
which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan Document in any court referred to in paragraph (b) of this Section. Each of the parties
hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

(d) Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 9.01 (other
than by electronic communications or telecopy). Nothing in this Agreement or any other Loan Document will affect the right of any party hereto or thereto to serve process in any other manner permitted by law. 

  
 65 

 SECTION 9.10. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER
BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION,
SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

SECTION 9.11. Headings. Article and Section headings and the Table of Contents used herein are for convenience of reference only, are
not part of this Agreement and shall not affect the construction of, or be taken into consideration in interpreting, this Agreement. 

SECTION 9.12. Confidentiality. Each of the Administrative Agent and the Lenders agrees to maintain the confidentiality of the
Information (as defined below), except that Information may be disclosed (a) to its and its Affiliates’ directors, officers, employees and agents, including accountants, legal counsel and other advisors (it being understood that the
Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority or self-regulatory body,
(c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process (in which case, the Administrative Agent or such Lender shall, to the extent not inconsistent with applicable law or such Person’s
internal policies, use reasonable efforts to promptly inform the Borrower thereof), (d) to any other party to this Agreement, (e) in connection with the exercise of any remedies hereunder or any suit, action or proceeding relating to this
Agreement or any other Loan Document or the enforcement of rights hereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to any assignee or prospective assignee of any of its rights or
obligations under this Agreement, (g) to any direct, indirect, actual or prospective counterparty (and its advisor) to any swap, derivative or securitization transaction related to the obligations under this Agreement (it being understood that
the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (h) to any credit insurance provider relating to the Borrower and its obligations
(it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (i) with the consent of the Borrower or (j) to the
extent such Information (i) becomes publicly available other than as a result of a breach of this Section or (ii) becomes available to the Administrative Agent or any Lender on a nonconfidential basis from a source other than the Borrower
not subject (to the knowledge of the Administrative Agent or such Lender) 

  
 66 

 
to a confidentiality agreement with the Borrower. For the purposes of this Section, “Information” means all information received from the Borrower relating to the Borrower or its
business, other than any such information that is available to the Administrative Agent or any Lender on a nonconfidential basis prior to disclosure by the Borrower; provided that, in the case of information received from the Borrower after
the Effective Date, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its
obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information. 

SECTION 9.13. USA Patriot Act. Each Lender hereby notifies each Loan Party that pursuant to the requirements of the USA PATRIOT Act, it
may be required to obtain, verify and record information that identifies such Loan Party, which information includes the name, address and tax identification number of such Loan Party and other information that will allow such Lender to identify
such Loan Party in accordance with the Act. Each Loan Party shall promptly, following a request by the Administrative Agent or any Lender, provide all documentation and other information that the Administrative Agent or such Lender reasonably
requests in order to comply with its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations, including the Act. 

SECTION 9.14. Release of Newmont USA as a Guarantor. Newmont USA shall automatically be released from its obligations as a Guarantor
under the Loan Documents upon the consummation of any transaction permitted by this Agreement as a result of which Newmont USA (a) ceases to be a Subsidiary; provided that, if so required by this Agreement, the Required Lenders shall
have consented to such transaction and the terms of such consent shall not have provided otherwise, or (b) is released from its obligations under the Guarantee Agreement pursuant to the terms thereof. In connection with any termination or
release pursuant to this Section, the Administrative Agent shall execute and deliver to the Borrower, at the Borrower’s expense, all documents that the Borrower shall reasonably request to evidence such termination or release. Any execution and
delivery of documents pursuant to this Section shall be without recourse to or warranty by the Administrative Agent. 
 SECTION 9.15. No
Fiduciary Relationship. The Borrower, on behalf of itself and the Subsidiaries, agrees that in connection with all aspects of the transactions contemplated hereby and any communications in connection therewith, the Borrower and the Subsidiaries,
on the one hand, and the Administrative Agent, the Lenders and their Affiliates, on the other hand, will have a business relationship that does not create, by implication or otherwise, any fiduciary duty on the part of the Administrative Agent, the
Lenders or their Affiliates, and no such duty will be deemed to have arisen in connection with any such transactions or communications. The Administrative Agent, the Arrangers, the Lenders and their Affiliates may be engaged, for their own accounts
or the accounts of customers, in a broad range of transactions that involve interests that differ from those of the Borrower and the Subsidiaries, and none of the Administrative Agent, the 

  
 67 

 
Arrangers, the Lenders or their Affiliates has any obligation to disclose any of such interests to the Borrower or any of the Subsidiaries. To the fullest extent permitted by law, the Borrower
hereby waives and releases any claims that it or any of the Subsidiaries may have against the Administrative Agent, the Arrangers, the Lenders and their Affiliates with respect to any breach or alleged breach of agency or fiduciary duty in
connection with any aspect of any transaction contemplated hereby. 

  
 68 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their
respective authorized officers as of the day and year first above written. 
  

							
	NEWMONT MINING CORPORATION,
			
		 	by	 	 /s/ Thomas P. Mahoney

		 		 	Name:	 	Thomas P. Mahoney
		 		 	Title:	 	Vice President and Treasurer
	
	JPMORGAN CHASE BANK, N.A., individually and as Administrative Agent,
			
		 	by	 	 /s/ Gitanjali Pundir

		 		 	Name:	 	Gitanjali Pundir
		 		 	Title:	 	Vice President

 LENDER SIGNATURE PAGE TO 

THE NEWMONT MINING CORPORATION 
 TERM
LOAN CREDIT AGREEMENT 
 DATED THE DATE FIRST ABOVE WRITTEN 
  

							
	Name of Lender:
	
	Bank of Montreal, Chicago Branch 
			
		 	by	 	 /s/ Yacouba Kane

		 		 	Name:	 	Yacouba Kane
		 		 	Title:	 	Vice President
	
	Name of Lender:
	
	The Bank of Tokyo-Mitsubishi UFJ, Ltd. 
			
		 	by	 	 /s/ Mark Maloney

		 		 	Name:	 	Mark Maloney
		 		 	Title:	 	Authorized Signatory
	
	Name of Lender:
	
	Citibank, N.A.
			
		 	by	 	 /s/ Michael Vondriska

		 		 	Name:	 	Michael Vondriska
		 		 	Title:	 	Vice President

							
	Name of Lender:
	
	Credit Suisse AG, Cayman Islands Branch
			
		 	by	 	 /s/ Alain Daoust

		 		 	Name:	 	Alain Daoust
		 		 	Title:	 	Authorized Signatory
	
	For any Institution requiring a second signature line:
			
		 	by	 	 /s/ Ryan Long

		 		 	Name:	 	Ryan Long
		 		 	Title:	 	Authorized Signatory
	
	Name of Lender:
	
	HSBC Bank USA, National Association
			
		 	by	 	 /s/ Alexandra Barrows

		 		 	Name:	 	Alexandra Barrows
		 		 	Title:	 	Vice President
	
	Name of Lender:
	
	Mizuho Bank, Ltd.
			
		 	by	 	 /s/ Leon Mo

		 		 	Name:	 	Leon Mo
		 		 	Title:	 	Authorized Signatory

							
	 Name of Lender:

	
	The Royal Bank of Scotland plc, Canada Branch
			
		 	by	 	 /s/ Shehan De Silva

		 		 	Name:	 	Shehan De Silva
		 		 	Title:	 	Vice President
			
		 	by	 	 /s/ David Wright

		 		 	Name:	 	David Wright
		 		 	Title:	 	Director

  

							
	Name of Lender:
	
	Sumitomo Mitsui Banking Corporation
			
		 	by	 	 /s/ James D. Weinstein

		 		 	Name:	 	James D. Weinstein
		 		 	Title:	 	Managing Director

  

							
	Name of Lender:
	
	The Bank of Nova Scotia
			
		 	by	 	 /s/ Ray Clarke

		 		 	Name:	 	Ray Clarke
		 		 	Title:	 	Managing Director

  

							
	For any Institution requiring a second signature line:
			
		 	by	 	 /s/ Ian Stephenson

		 		 	Name:	 	Ian Stephenson
		 		 	Title:	 	Director

							
	Name of Lender:
	
	Royal Bank of Canada
			
		 	by	 	 /s/ Stam Fountoulakis

		 		 	Name:	 	Stam Fountoulakis
		 		 	Title:	 	Authorized Signatory

  

							
	Name of Lender:
	
	U.S. Bank National Association
			
		 	by	 	 /s/ Marty McDonald

		 		 	Name:	 	Marty McDonald
		 		 	Title:	 	AVP

  

							
	Name of Lender:
	
	Bank of America, N.A.
			
		 	by	 	 /s/ James K.G. Campbell

		 		 	Name:	 	James K.G. Campbell
		 		 	Title:	 	Director

							
	Name of Lender:
	
	Canadian Imperial Bank of Commerce, New York Branch
			
		 	by	 	 /s/ Dominic Sorresso

		 		 	Name:	 	Dominic Sorresso
		 		 	Title:	 	Authorized Signatory
	
	For any Institution requiring a second signature line:
			
		 	by	 	 /s/ Zhen Ma

		 		 	Name:	 	Zhen Ma
		 		 	Title:	 	Authorized Signatory
	
	Name of Lender:
	
	Commonwealth Bank of Australia
			
		 	by	 	 /s/ Greg Caione

		 		 	Name:	 	Greg Caione
		 		 	Title:	 	Executive Director, Natural Resources
	
	Name of Lender:
	
	Compass Bank
			
		 	by	 	 /s/ Michael Dixon

		 		 	Name:	 	Michael Dixon
		 		 	Title:	 	Senior Vice President

  

							
	 Name of Lender:
  

Societe Generale

			
		 	by	 	 /s/ P.E. Kavanagh

		 		 	Name:	 	P.E. Kavanagh
		 		 	Title:	 	Director

 Schedule 2.01 

Commitments 
  

					
	 Bank
	  	Term Loan Allocation	 
	 JPMorgan Chase Bank, N.A.
	  	$	40,000,000	  
	 Bank of Montreal, Chicago Branch
	  	$	40,000,000	  
	 The Bank of Tokyo-Mitsubishi UFJ, Ltd.
	  	$	40,000,000	  
	 Citibank, N.A.
	  	$	40,000,000	  
	 Credit Suisse AG
	  	$	40,000,000	  
	 HSBC Bank USA, National Association
	  	$	40,000,000	  
	 Mizuho Bank, Ltd.
	  	$	40,000,000	  
	 The Royal Bank of Scotland plc, Canada Branch
	  	$	40,000,000	  
	 Sumitomo Mitsui Banking Corporation
	  	$	40,000,000	  
	 The Bank of Nova Scotia
	  	$	30,000,000	  
	 Royal Bank of Canada
	  	$	30,000,000	  
	 U.S. Bank National Association
	  	$	30,000,000	  
	 Bank of America, N.A.
	  	$	25,000,000	  
	 Canadian Imperial Bank of Commerce, New York Branch
	  	$	25,000,000	  
	 Commonwealth Bank of Australia
	  	$	25,000,000	  
	 Compass Bank
	  	$	25,000,000	  
	 Societe Generale
	  	$	25,000,000	  
		  	  
	  
	 
	 TOTAL:
	  	$	575,000,000	  
		  	  
	  
	 

 Schedule 3.06 

Disclosed Matters 
 NWG
Investments Inc. v. Fronteer Gold Inc. 
 Further to the NWG Investments Inc. v. Fronteer Gold Inc. matter
disclosed in the most recent Form 10-K of Newmont Mining Corporation (“Newmont”), NWG served a lawsuit against NMCCL and several other entities with the same allegations contained in the New York action in Ontario, Canada. As
previously disclosed, Newmont successfully obtained dismissal of the New York matter for forum non conveniens. NWG filed a motion to appeal the dismissal in New York, but did not perfect the appeal. After filing the Ontario
action, NWG withdrew the appeal in New York. Newmont will defend the action in Ontario. 

 Schedule 3.13 

Subsidiaries 
 NEWMONT MINING
CORPORATION AND SUBSIDIARIES 
 As of March 31, 2014 
  

							
	 Name
	  	 Incorporation
	  	Ownership	 
	 Newmont Mining Corporation
	  	Delaware, USA	  			
	 Dafrico (Overseas) Ltd
	  	Cyprus	  	 	100	% 
	 Moydow Limited
	  	Ghana	  	 	100	% 
	 Newmont LaSource SAS
	  	France	  	 	17	% 
	 Euronimba Ltd
	  	Jersey	  	 	43.5	% 
	 Euronimba Liberia Limited
	  	Liberia	  	 	100	% 
	 Euronimba UK Limited
	  	United Kingdom	  	 	100	% 
	 Societe des Mines de Fer de Guinee
	  	Guinea	  	 	95	% 
	 Newmont Ghana Gold Limited
	  	Ghana	  	 	100	% 
	 Newmont Golden Ridge Limited
	  	Ghana	  	 	100	% 
	 Societe Miniere de Sabodala
	  	Senegal	  	 	50.6	% 
	 N.I. Limited
	  	Bermuda	  	 	100	% 
	 Newmont Australia Holdings Pty Ltd
	  	Victoria, Australia	  	 	100	% 
	 Newmont Australia Pty Ltd
	  	Western, Australia	  	 	100	% 
	 Newmont AP Power Pty Ltd
	  	Western Australia	  	 	100	% 
	 Newmont Capital Pty Ltd
	  	New South Wales, Australia	  	 	100	% 
	 Newmont Landco Pty Ltd
	  	Western Australia	  	 	100	% 
	 Newmont Boddington Pty Ltd
	  	South Australia	  	 	100	% 
	 Newmont Boddington Gold Pty Ltd
	  	Western Australia	  	 	100	% 
	 Kalgoorlie Lake View Pty Ltd
	  	Victoria, Australia	  	 	100	% 
	 Kalgoorlie Consolidated Gold Mines Pty Ltd
	  	Western Australia	  	 	50	% 
	 North Kalgurli Mines Pty Ltd
	  	Western Australia	  	 	100	% 
	 Newmont Yandal Operations Pty Ltd
	  	Victoria, Australia	  	 	100	% 
	 Eagle Mining Pty Ltd
	  	Western Australia	  	 	100	% 
	     Australian Metals Corporation Pty Ltd
	  	Western Australia	  	 	100	% 
	     Hunter Resources Pty Ltd
	  	Queensland, Australia	  	 	100	% 
	     Newmont Wiluna Gold Pty Ltd
	  	Queensland, Australia	  	 	100	% 
	 Newmont Mining Finance Pty Ltd
	  	Australian Capital Territory	  	 	100	% 
	 Newmont Mining Holdings Pty Ltd
	  	South Australia	  	 	100	% 
	 Newmont Exploration Pty Ltd
	  	Victoria, Australia	  	 	100	% 
	 Newmont Gold Pty Ltd
	  	Western Australia	  	 	100	% 
	     GMK Investments Pty Ltd
	  	South Australia	  	 	100	% 
	         Newmont Power Pty Ltd
	  	Western, Australia	  	 	100	% 
	         NP Kalgoorlie Pty Ltd
	  	Western, Australia	  	 	100	% 
	             Goldfields Power Pty Ltd
	  	Western Australia	  	 	50	% 
	     Newmont Gold Marketing & Finance Pty Ltd
	  	Western, Australia	  	 	100	% 
	         Australian Gold Alliance Pty Ltd
	  	Western, Australia	  	 	100	% 
	     Newmont NGL Holdings Pty Ltd
	  	Northern Territory, Australia	  	 	100	% 
	         Newmont Boddington Holdings Pty Ltd
	  	Western, Australia	  	 	100	% 
	             Newmont Boddington Investments Pty Ltd
	  	Western, Australia	  	 	100	% 
	         Newmont Kaltails Pty Ltd
	  	Victoria, Australia	  	 	100	% 
	         Newmont Pajingo Pty Ltd
	  	Western Australia	  	 	100	% 
	         Newmont Tanami Pty Ltd
	  	Western, Australia	  	 	57.39	% 
	             Otter Gold Mines Pty Ltd
	  	Victoria, Australia	  	 	100	% 
	                 Otter Gold Pty Ltd
	  	New South Wales, Australia	  	 	100	% 
	         Wirralie Gold Mines Pty Ltd
	  	Queensland, Australia	  	 	100	% 
	     Newmont Pacific Energy Pty Ltd
	  	Western Australia	  	 	100	% 
	 Newmont International Exploration Pty Ltd
	  	Western, Australia	  	 	100	% 
	     Newmont Asia Pty Ltd
	  	Western, Australia	  	 	100	% 

							
	         Kepala Burung Offshore Pty Ltd
	  	Victoria, Australia	  	 	36.11	% 
	 Newmont Mining Services Pty Ltd
	  	Western, Australia	  	 	100	% 
	     Newmont Australia Superannuation Plan Pty Ltd
	  	South Australia	  	 	100	% 
	 Newmont Tanami Pty Ltd
	  	South Australia	  	 	42.61	% 
	 Newmont Woodcutters Pty Ltd
	  	New South Wales, Australia	  	 	100	% 
	 Newmont Capital Limited
	  	Nevada, USA	  	 	88.65	% 
	 Fronteer Development (USA) Inc.
	  	Delaware, USA	  	 	89	% 
	 Fronteer Development LLC
	  	Delaware, USA	  	 	100	% 
	 Fronteer Royalty LLC
	  	Delaware, USA	  	 	100	% 
	 Nevada Eagle Resources LLC
	  	Nevada, USA	  	 	100	% 
	 Newmont USA Limited
	  	Delaware, USA	  	 	100	% 
	 Battle Mountain Resources Inc.
	  	Nevada, USA	  	 	100	% 
	 Desarollos Mineros Fresne, S. de R.L. de C.V.
	  	Mexico	  	 	50	% 
	 Dawn Mining Company LLC
	  	Delaware, USA	  	 	51	% 
	 Elko Land and Livestock Company
	  	Nevada, USA	  	 	100	% 
	     ELLC Grazing Membership LLC
	  	Nevada, USA	  	 	100	% 
	 Empresa Minera Maria SRL
	  	Bolivia	  	 	75.4266	% 
	 Hospah Coal Company
	  	Delaware, USA	  	 	100	% 
	 Idarado Mining Company
	  	Delaware, USA	  	 	80.2	% 
	     Idarado Legacy, LLC
	  	Colorado, USA	  	 	80	% 
	 Minera BMG
	  	Nevada, USA	  	 	100	% 
	     Minera Choluteca S.A. de C.V.
	  	Honduras	  	 	50	% 
	 Minera El Bermejal S. de R.L. de C.V.
	  	Mexico	  	 	44	% 
	 Minera Newmont (Chile) Limitada
	  	Chile	  	 	99.24	% 
	 Minera Penmont S. de R.L. de C.V.
	  	Mexico	  	 	44	% 
	 Newmont (Uzbekistan) Limited
	  	Cyprus	  	 	60	% 
	 Newmont Australia Investment Limited
	  	Delaware, USA	  	 	100	% 
	 Newmont Bolivia Limited
	  	Nevada, USA	  	 	100	% 
	 Newmont Canada Corporation
	  	Nova Scotia	  	 	11.7577	% 
	     PT Newmont Minahasa Raya
	  	Indonesia	  	 	80	% 
	     Silidor Mines Inc.
	  	Quebec	  	 	100	% 
	 Newmont de Mexico, S.A. de C.V.
	  	Mexico	  	 	99	% 
	 Newmont Global Employment Limited Partnership
	  	Bermuda	  	 	99	% 
	 Newmont Gold Company
	  	Delaware, USA	  	 	100	% 
	 Newmont GTR LLC
	  	Nevada, USA	  	 	100	% 
	 Newmont Indonesia Investment Limited
	  	Delaware, USA	  	 	100	% 
	 Newmont Indonesia Limited
	  	Delaware, USA	  	 	100	% 
	     Newmont Nusa Tenggara Holdings B.V.
	  	Netherlands	  	 	100	% 
	         Nusa Tenggara Partnership (VOF)
	  	Netherlands	  	 	56.25	% 
	         Nusa Tenggara Partnership B.V.
	  	Netherlands	  	 	100	% 
	             PT Newmont Nusa Tenggara
	  	Indonesia	  	 	56	% 
	     PT Bhinneka Investama Indonesia
	  	Indonesia	  	 	27.56	% 
	         PT Investama Utama Indonesia
	  	Indonesia	  	 	51	% 
	     PT Investama Utama Indonesia
	  	Indonesia	  	 	27.56	% 
	 Newmont International Services Limited
	  	Delaware, USA	  	 	100	% 
	     Newmont Global Employment Limited Partnership
	  	Bermuda	  	 	1	% 
	     PT Newmont Pacific Nusantara
	  	Indonesia	  	 	1	% 
	 Newmont Kazakhstan Gold Limited
	  	Delaware, USA	  	 	100	% 
	 Newmont Latin America Limited
	  	Delaware, USA	  	 	100	% 
	     Minera Los Tapados S.A.
	  	Peru	  	 	.0144	% 
	     Minera Newmont (Chile) Limitada
	  	Chile	  	 	.76	% 
	     Newmont de Mexico S.A. de C.V.
	  	Mexico	  	 	1	% 
	 Newmont McCoy Cove Limited
	  	Nevada, USA	  	 	100	% 
	 Newmont Nevada Energy Investment LLC
	  	Delaware, USA	  	 	100	% 
	 Newmont North America Exploration Limited
	  	Delaware, USA	  	 	100	% 
	 Newmont Nova Scotia ULC
	  	Nova Scotia	  	 	100	% 
	 Newmont Overseas Exploration Limited
	  	Delaware, USA	  	 	100	% 

							
	     PT Newmont Pacific Nusantara
	  	Indonesia	  	 	99	% 
	     Suriname Gold Company, LLC
	  	Delaware, USA	  	 	80	% 
	 Newmont Peru Limited
	  	Delaware, USA	  	 	100	% 
	     Minera Los Tapados S.A.
	  	Peru	  	 	99.9856	% 
	     Newmont Investment Holdings LLC
	  	Delaware, USA	  	 	100	% 
	         Newmont Peru S.R.L.
	  	Peru	  	 	.00026	% 
	     Newmont Peru S.R.L.
	  	Peru	  	 	99.99974	% 
	         Minera Chaupiloma Dos de Cajamarca S.R.L.
	  	Peru	  	 	40	% 
	         Minera Ninobamba S.R.L.
	  	Peru	  	 	60	% 
	     Newmont Realty Company
	  	Delaware, USA	  	 	100	% 
	 Newmont Second Capital Corporation
	  	Delaware, USA	  	 	100	% 
	     Minera Yanacocha S.R.L.
	  	Peru	  	 	51.35	% 
	     Newmont Mines Limited
	  	Delaware, USA	  	 	100	% 
	 Newmont Technologies Limited
	  	Nevada, USA	  	 	100	% 
	 New Verde Mines LLC
	  	Delaware, USA	  	 	100	% 
	 Proveedora de Equipo Fresne, S. de R.L. de C.V.
	  	Mexico	  	 	50	% 
	 Resurrection Mining Company
	  	Delaware, USA	  	 	100	% 
	 San Juan Basin Coal Holding Company
	  	Delaware, USA	  	 	100	% 
	 Santa Fe Pacific Gold Corporation
	  	Delaware, USA	  	 	100	% 
	 Waihi Gold Company Limited
	  	New Zealand	  	 	14.3	% 
	 Pittston Nevada Gold Company, Ltd.
	  	Nevada, USA	  	 	96.3473	% 
	 Newmont FH B.V.
	  	Netherlands	  	 	100	% 
	 Newmont Canada Holdings ULC
	  	British Columbia	  	 	100	% 
	 Fronteer Development (USA) Inc.
	  	Delaware, USA	  	 	11	% 
	 West Pequop LLC
	  	Nevada, USA	  	 	49	% 
	     Pequop Exploration LLC
	  	Nevada, USA	  	 	100	% 
	 Hope Bay Mining Ltd.
	  	British Columbia	  	 	99.9999	% 
	 Newmont Holdings ULC
	  	Nova Scotia	  	 	1	% 
	 Newmont Holdings ULC
	  	Nova Scotia	  	 	99	% 
	 Minera La Zanja S.R.L.
	  	Peru	  	 	47	% 
	 Newmont Canada FN Holdings ULC
	  	British Columbia	  	 	100	% 
	 Newmont Canada Corporation
	  	Nova Scotia	  	 	88.2423	% 
	 Newmont Northern Mining ULC
	  	British Columbia	  	 	100	% 
	 Miramar Northern Mining Ltd.
	  	British Columbia	  	 	100	% 
	     Con Exploration Ltd.
	  	British Columbia	  	 	100	% 
	     Hope Bay Mining Ltd.
	  	British Columbia	  	 	0.0001	% 
	     Miramar HBG Inc.
	  	Quebec	  	 	100	% 
	     Vol Mines Limited
	  	British Columbia	  	 	67	% 
	 Newmont Mining B.C. ULC
	  	British Columbia	  	 	100	% 
	     Newmont Capital Limited
	  	Nevada, USA	  	 	11.35	% 
	         Miramar Gold Corporation
	  	Nevada, USA	  	 	100	% 
	         Orcana Resources Inc.
	  	Nevada, USA	  	 	100	% 
	         Talapoosa Mining Inc.
	  	Nevada, USA	  	 	100	% 
	 NeXtech Drilling Ltd.
	  	Alberta, Canada	  	 	50	% 
	 Newmont Mining Corporation of Canada Limited
	  	British Columbia	  	 	100	% 
	 Newmont NE Holdings Subco Limited
	  	British Columbia	  	 	100	% 
	 Newmont LaSource SAS
	  	France	  	 	16.70	% 
	 Newmont Mineral Holdings B.V.
	  	Netherlands	  	 	100	% 
	 European Gold Refineries Holding SA
	  	Switzerland	  	 	60.64	% 
	 Valcambi SA
	  	Switzerland	  	 	100	% 
	 Newmont Ventures Limited
	  	Delaware, USA	  	 	100	% 
	 Newmont (Guyana) Incorporated
	  	Guyana	  	 	100	% 
	 Newmont Services U.K. Limited
	  	United Kingdom	  	 	100	% 
	 NVL (Guinee) SARL
	  	Guinea	  	 	100	% 
	 NVL (USA) Limited
	  	Delaware, USA	  	 	100	% 
	 NVL Argentina S.R.L.
	  	Argentina	  	 	5	% 

							
	 NVL Argentina S.R.L.
	  	Argentina	  	 	95	% 
	 NVL Burkina Faso SARL
	  	Burkina Faso	  	 	100	% 
	 NVL Caucasus Limited LLC
	  	Armenia	  	 	100	% 
	 NVL Cote D’Ivoire SARL
	  	Ivory Coast	  	 	100	% 
	 NVL Haiti Limited S.A.
	  	Haiti	  	 	100	% 
	 NVL PNG Limited
	  	Papua New Guinea	  	 	100	% 
	 NVL Saramacca Mining LLC
	  	Delaware, USA	  	 	100	% 
	 NVL Solomon Islands Limited
	  	Solomon Islands	  	 	100	% 
	 Saddleback Investments Pty Ltd
	  	Australia	  	 	100	% 
	 Suriname Gold Company, LLC
	  	Delaware, USA	  	 	20	% 
	 Newmont Waihi Gold Limited
	  	New Zealand	  	 	100	% 
	 Waihi Gold Company Limited
	  	New Zealand	  	 	86	% 
	 Newmont (Uzbekistan) Limited
	  	Cyprus	  	 	40	% 
	 Normandy Overseas Holding Company Sdn Bhd
	  	Malaysia	  	 	100	% 
	 Normandy Company (Malaysia) Sdn Bhd
	  	Malaysia	  	 	100	% 
	 Newmont International Group BV
	  	Netherlands	  	 	100	% 
	 Newmont LaSource SAS
	  	France	  	 	66.3748	% 
	 Pittston Nevada Gold Company, Ltd.
	  	Nevada, USA	  	 	3.6527	% 

 Schedule 6.02 

Existing Liens 
 Liens securing the
following Indebtedness are in existence on the Effective Date. 
  

	 	1.	Ahafo IFC Project Financing - $34,999,998 

  

	 	2.	PTNNT Project Financing - $555,000,000 

 EXHIBIT A 

[FORM OF] ASSIGNMENT AND ACCEPTANCE 

Reference is made to the Term Loan Credit Agreement dated as of [March 31], 2014 (as amended, supplemented, waived or otherwise modified from
time to time, the “Credit Agreement”), among Newmont Mining Corporation, the Lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent. Capitalized terms used but not defined herein shall have
the meanings specified in the Credit Agreement. 
 1. The Assignor named below hereby sells and assigns, without recourse, to the Assignee
named below and the Assignee hereby purchases and assumes, without recourse, from the Assignor, effective as of the Assignment Date set forth below, the interests set forth below (the “Assigned Interest”) in the Assignor’s
rights and obligations under the Credit Agreement, including, without limitation, the interests set forth below in the Commitments of the Assignor on the Assignment Date and the Loans owing to the Assignor which are outstanding on the Assignment
Date. The Assignor represents and warrants that it is the legal and beneficial owner of the interests being assigned by it hereunder and that such interests are free and clear of any Liens. The Assignee hereby acknowledges receipt of a copy of the
Credit Agreement. From and after the Assignment Date (i) the Assignee shall be a party to and be bound by the provisions of the Credit Agreement and, to the extent of the interests assigned by this Assignment and Acceptance, have the rights and
obligations of a Lender thereunder and (ii) the Assignor shall, to the extent of the interests assigned by this Assignment and Acceptance, relinquish its rights and be released from its obligations under the Credit Agreement. 

2. This Assignment and Acceptance is being delivered to the Administrative Agent together with (i) to the extent required, any
documentation required to be delivered by the Assignee pursuant to Section 2.18(f) of the Credit Agreement, (ii) if the Assignee is not already a Lender under the Agreement, an Administrative Questionnaire in the form provided by the
Administrative Agent and (iii) a processing and recordation fee in the amount of $3,500. 
 3. This Assignment and Acceptance shall be
governed by and construed in accordance with the laws of the State of New York. 
 Date of Assignment: 

Legal Name of Assignor: 
 Legal Name of Assignee: 

Assignee’s Address for Notices: 
 Effective Date of
Assignment (“Assignment Date”): 
  

  
 A-1 

Form of Assignment and Acceptance 

 2 
  

									
	 Facility
	  	Principal
Amount
Assigned	 	  	Percentage Assigned
of Commitment 
(set forth, to at least
8 decimals, as a
percentage of the
aggregate Commitments
of all
Lenders
thereunder)	 
	 Initial Term Loans
	  	$	    	  	  	 	    	% 
	 Incremental Term Loans
	  				  			

 The terms set forth herein are hereby agreed to: 
  

											
	
                          
                                         
                 , as Assignor,
	 		 		 	Consented to (if required)
					
		 		 		 		 	NEWMONT MINING CORPORATION,
						
	by	 	  
	 		 		 	by	 	  

		 	Name:	 		 		 	Name:
		 	Title:	 		 		 	Title:

  
 A-2 

Form of Assignment and Acceptance 

 3 
  

									
	                                   
                                         
    , as Assignee,	 		 	Consented to (if required):
				
		 		 		 	JPMORGAN CHASE BANK, N.A., as
		 		 		 	Administrative Agent
					
	by	 	  
	 		 	by	 	  

		 	Name:	 		 	Name:	 	
		 	Title	 		 	Title	 	
				
		 		 		 	Consented to (if required):
				
		 		 		 	[                     ], as
		 		 		 	an Issuing Bank
					
		 		 		 	by	 	  

					
		 		 		 	Name:	 	
		 		 		 	Title	 	

  
 A-3 

Form of Assignment and Acceptance 

 EXHIBIT B 

[FORM OF] ASSUMPTION AGREEMENT 

[name of surviving corporation], a              corporation (the
“Surviving Corporation”), the surviving corporation of the merger of Newmont Mining Corporation, a Delaware corporation (the “Company”), with and into the Surviving Corporation, hereby expressly assumes all rights,
obligations and liabilities of the Company under the Term Loan Credit Agreement dated as of [March 31], 2014 (as amended, supplemented, waived or otherwise modified from time to time, the “Credit Agreement”), among Newmont Mining
Corporation, the Lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent and any promissory notes. From and after the date hereof, all references in the Credit Agreement and any promissory notes to the Company
(except historical references in the representations and warranties which should continue to apply to the Company) shall be deemed to be references to the Surviving Corporation, which shall hereafter be a Borrower for all purposes of the Credit
Agreement and any promissory notes. 
 IN WITNESS WHEREOF, the Surviving Corporation has caused its duly authorized officer to execute and
deliver this Assumption Agreement as of              , 20[    ] which is the date of the merger referred to above. 

 

			
	[NAME OF SURVIVING
CORPORATION]
		
	By	 	  

		 	Name:
		 	Title:

  
 B-1 

Form of Assumption Agreement 

 EXHIBIT C-1 

[FORM OF] 
 U.S. TAX
CERTIFICATE 
 (For Non-U.S. Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes) 

Reference is made to the Term Loan Credit Agreement dated as of [March 31], 2014 (as amended, supplemented, waived or otherwise modified from
time to time, the “Credit Agreement”), among Newmont Mining Corporation, the Lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent. 

Pursuant to the provisions of Section 2.18 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record
and beneficial owner of the Loan(s) (as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a
10-percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, (iv) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code and (v) all
interest payments made under any Loan Document are not effectively connected with the undersigned’s conduct of a U.S. trade or business. 

The undersigned has furnished the Administrative Agent and the Borrower with a certificate of its non-U.S. person status on IRS Form
W-8BEN. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the Borrower and the Administrative Agent and (2) the undersigned
shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two
calendar years preceding such payments. 
 Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have
the meanings given to them in the Credit Agreement. 
  

			
	[NAME OF LENDER]
		
	By:	 	  

		 	Name:
		 	Title:

 Date:            
        , 20[    ] 

  
 C-1 

Form of U.S. Tax Certificate 

 EXHIBIT C-2 
  

 [FORM OF] 

U.S. TAX CERTIFICATE 
 (For
Non-U.S. Lenders That Are Partnerships For U.S. Federal Income Tax Purposes) 
 Reference is made to the Term Loan Credit
Agreement dated as of [March 31], 2014 (as amended, supplemented, waived or otherwise modified from time to time, the “Credit Agreement”), among Newmont Mining Corporation, the Lenders from time to time party thereto and JPMorgan
Chase Bank, N.A., as Administrative Agent. 
 Pursuant to the provisions of Section 2.18 of the Credit Agreement, the undersigned
hereby certifies that (i) it is the sole record owner of the Loan(s) (as well as any Note(s) evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) its partners/members are the sole beneficial owners of such
Loan(s) (as well as any Note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit pursuant to this Credit Agreement, neither the undersigned nor any of its partners/members is a bank extending credit pursuant to a loan
agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its partners/members is a 10-percent shareholder of the Borrower within the meaning of
Section 871(h)(3)(B) of the Code, (v) none of its partners/members is a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the Code, and (vi) all interest payments made under any Loan
Document are not effectively connected with the undersigned’s or its partners’/members’ conduct of a U.S. trade or business. 

The undersigned has furnished the Administrative Agent and the Borrower with IRS Form W-8IMY accompanied by an IRS Form W-8BEN from
each of its partners/members claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform the
Borrower and the Administrative Agent and (2) the undersigned shall have at all times furnished the Borrower and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year in which each
payment is to be made to the undersigned, or in either of the two calendar years preceding such payments. 
 Unless otherwise defined
herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement. 
  

			
	[NAME OF LENDER]
		
	By:	 	  

		 	Name:
		 	Title:

 Date:             
        , 20[    ] 

  
 C-2 

Form of U.S. Tax Certificate 

 EXHIBIT C-3 
  

 [FORM OF] 

U.S. TAX CERTIFICATE 
 (For
Non-U.S. Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes) 
 Reference is made to the Term Loan Credit
Agreement dated as of [March 31], 2014 (as amended, supplemented, waived or otherwise modified from time to time, the “Credit Agreement”), among Newmont Mining Corporation, the Lenders from time to time party thereto and JPMorgan
Chase Bank, N.A., as Administrative Agent. 
 Pursuant to the provisions of Section 2.18 of the Credit Agreement, the undersigned
hereby certifies that (i) it is the sole record and beneficial owner of the participation in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code,
(iii) it is not a 10-percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, (iv) it is not a controlled foreign corporation related to the Borrower as described in Section 881(c)(3)(C) of the
Code, and (v) all interest payments made under any Loan Document are not effectively connected with the undersigned’s conduct of a U.S. trade or business. 

The undersigned has furnished its participating Lender with a certificate of its non-U.S. person status on IRS Form W-8BEN. By
executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender in writing and (2) the undersigned shall have at all times furnished
such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments. 

Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit
Agreement. 
  

			
	[NAME OF LENDER]
		
	By:	 	  

		 	Name:
		 	Title:

 Date:             
        , 20[    ] 

  
 C-3 

Form of U.S. Tax Certificate 

 EXHIBIT C-4 
  

 [FORM OF] 

U.S. TAX CERTIFICATE 
 (For
Non-U.S. Participants That Are Partnerships For U.S. Federal Income Tax Purposes) 
 Reference is made to the Term Loan Credit
Agreement dated as of [March 31], 2014 (as amended, supplemented, waived or otherwise modified from time to time, the “Credit Agreement”), among Newmont Mining Corporation, the Lenders from time to time party thereto and JPMorgan
Chase Bank, N.A., as Administrative Agent. 
 Pursuant to the provisions of Section 2.18 of the Credit Agreement, the undersigned
hereby certifies that (i) it is the sole record owner of the participation in respect of which it is providing this certificate, (ii) its partners/members are the sole beneficial owners of such participation, (iii) with respect such
participation, neither the undersigned nor any of its partners/members is a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code,
(iv) none of its partners/members is a 10-percent shareholder of the Borrower within the meaning of Section 871(h)(3)(B) of the Code, (v) none of its partners/members is a controlled foreign corporation related to the Borrower as
described in Section 881(c)(3)(C) of the Code, and (vi) all interest payments made under any Loan Document are not effectively connected with the undersigned’s or its partners’/members’ conduct of a U.S. trade or
business. 
 The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by an IRS Form W-8BEN from
each of its partners/members claiming the portfolio interest exemption. By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender
and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two
calendar years preceding such payments. 
 Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have
the meanings given to them in the Credit Agreement. 
  

			
	[NAME OF PARTICIPANT]
		
	By:	 	  

		 	Name:
		 	Title:

 Date:             
        , 20[    ] 

  
 C-4 

Form of U.S. Tax Certificate 

 EXHIBIT D 

[FORM OF] 

GUARANTEE AGREEMENT dated as of March [31], 2014 (as amended, supplemented or otherwise modified from time to time,
this “Agreement”), among NEWMONT USA LIMITED (the “Guarantor”) and JPMORGAN CHASE BANK, N.A., as Administrative Agent. 

Reference is made to the Term Loan Credit Agreement dated as of March [31], 2014 (as amended, supplemented or otherwise modified
from time to time, the “Credit Agreement”), among Newmont Mining Corporation (the “Borrower”), the Lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent (the
“Administrative Agent”). 
 The Lenders have agreed to extend credit to the Borrower subject to the terms and conditions
set forth in the Credit Agreement. The Guarantor will derive substantial benefits from the extension of credit to the Borrower pursuant to the Credit Agreement and is willing to execute and deliver this Agreement in order to induce the Lenders to
continue to extend such credit. Accordingly, the parties hereto agree as follows: 
 SECTION 1. Definitions. (a) Capitalized
terms used in this Agreement and not otherwise defined herein have the meanings specified in the Credit Agreement. 
 (b) The rules of
construction specified in Section 1.03 of the Credit Agreement also apply to this Agreement. 
 SECTION 2. Guarantee.
(a) The Guarantor hereby irrevocably and unconditionally guarantees, as a primary obligor and not merely as a surety, the Obligations of the Borrower. The Guarantor further agrees that the due and punctual payment of the Obligations of the
Borrower may be extended or renewed, in whole or in part, without notice to or further assent from it, and that it will remain bound upon its guarantee hereunder notwithstanding any such extension or renewal of any Obligation. 

(b) The Guarantor waives presentment to, demand of payment from and protest to the Borrower of any of the Obligations, and also waives notice
of acceptance of its obligations and notice of protest for nonpayment. The obligations of the Guarantor hereunder shall not be affected by (i) the failure of any Lender to assert any claim or demand or to enforce any right or remedy against the
Borrower under the provisions of this Agreement, any Loan Document or otherwise; (ii) any extension or renewal of any of the Obligations; (iii) any rescission, waiver, amendment or modification of, or release from, any of the terms or
provisions of this Agreement or any Loan Document or other agreement; (iv) the failure or delay of any Lender to exercise any right or remedy against any other guarantor of the Obligations; (v) the failure of any Lender to assert any claim
or demand or to enforce any remedy under any Loan Document or any other agreement or 

  
 D-1 

Form of Guarantee Agreement 

 
instrument; (vi) any default, failure or delay, wilful or otherwise, in the performance of the Obligations; or (vii) any other act, omission or delay to do any other act which may or
might in any manner or to any extent vary the risk of the Guarantor or otherwise operate as a discharge of the Guarantor as a matter of law or equity or which would impair or eliminate any right of the Guarantor to subrogation. 

(c) The Guarantor further agrees that its guarantee hereunder constitutes a promise of payment when due (whether or not any bankruptcy or
similar proceeding shall have stayed the accrual or collection of any of the Obligations or operated as a discharge thereof) and not merely of collection, and waives any right to require that any resort be had by any Lender to any balance of any
deposit account or credit on the books of any Lender in favor of the Borrower or any Subsidiary or any other Person. 
 (d) The obligations
of the Guarantor hereunder shall not be subject to any reduction, limitation, impairment or termination for any reason other than the indefeasible payment in full in cash of the Obligations, and shall not be subject to any defense or setoff,
counterclaim, recoupment or termination whatsoever, by reason of the invalidity, illegality or unenforceability of the Obligations, any impossibility in the performance of the Obligations or otherwise. 

(e) The Guarantor further agrees that its obligations hereunder shall continue to be effective or be reinstated, as the case may be, if at any
time payment, or any part thereof, of any Obligation is rescinded or must otherwise be restored by any Lender upon the bankruptcy or reorganization of the Borrower or otherwise. 

(f) In furtherance of the foregoing and not in limitation of any other right which any Lender may have at law or in equity against the
Guarantor by virtue hereof, upon the failure of the Borrower to pay any Obligation when and as the same shall become due, whether at maturity, by acceleration, after notice of prepayment or otherwise, the Guarantor hereby promises to and will, upon
receipt of written demand by the Administrative Agent, forthwith pay, or cause to be paid, to the Administrative Agent for distribution to the applicable Lenders in cash an amount equal to the unpaid principal amount of such Obligation. 

(g) Upon payment in full by the Guarantor of any Obligation of the Borrower, each Lender shall, in a reasonable manner, assign to the
Guarantor the amount of such Obligation owed to such Lender and so paid, such assignment to be pro tanto to the extent to which the Obligation in question was discharged by the Guarantor, or make such disposition thereof as the Guarantor shall
direct (all without recourse to any Lender and without any representation or warranty by any Lender). Upon payment by the Guarantor of any sums as provided above, all rights of the Guarantor against the Borrower arising as a result thereof by way of
right of subrogation or otherwise shall in all respects be subordinated and junior in right of payment to the prior indefeasible payment in full of all the Obligations owed by the Borrower to the Lenders (it being understood that, after the
discharge of all the Obligations due and payable from the Borrower, such rights may be exercised by the Guarantor notwithstanding that the Borrower may remain contingently liable for indemnity or other Obligations). 

  
 2 

 SECTION 3. Additional Agreements. Until the Commitments have expired or terminated and the
principal of and interest on each Loan and all fees payable under the Credit Agreement have been paid in full, the Guarantor covenants and agrees with the Administrative Agent for the benefit of the Lenders that it will be bound by each of the
covenants contained in the Credit Agreement to the extent applicable to the Guarantor. 
 SECTION 4. Information. The Guarantor
assumes all responsibility for being and keeping itself informed of the Borrower’s financial condition and assets, and of all other circumstances bearing upon the risk of nonpayment of the Obligations and the nature, scope and extent of the
risks that the Guarantor assumes and incurs hereunder, and agrees that neither the Administrative Agent nor any Lender will have any duty to advise the Guarantor of information known to it or any of them regarding such circumstances or risks. 

SECTION 5. Notices. All communications and notices hereunder shall (except as otherwise expressly permitted herein) be in writing and
given as provided in Section 9.01 of the Credit Agreement. All communications and notices hereunder to the Guarantor shall be given to it in care of the Borrower as provided in Section 9.01 of the Credit Agreement. 

SECTION 6. Survival of Agreement. All covenants, agreements, representations and warranties made by the Guarantor herein and in the
certificates or other instruments prepared or delivered in connection with or pursuant to this Agreement or any Loan Document shall be considered to have been relied upon by the Administrative Agent and shall survive the execution and delivery of
this Agreement, the Loan Documents and the making of any Loans, regardless of any investigation made by the Administrative Agent or on its behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any
Default or incorrect representation or warranty at the time any credit is extended under the Credit Agreement, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any fee or any other amount
payable under any Loan Document is outstanding and unpaid and so long as the Commitments have not expired or terminated. 
 SECTION 7.
Binding Effect; Several Agreement. (a) This Agreement shall become effective when a counterpart hereof executed on behalf of the Guarantor shall have been delivered to the Administrative Agent and a counterpart hereof shall have
been executed on behalf of the Administrative Agent. 
 (b) Following the effectiveness of this Agreement, this Agreement shall be binding
upon the Guarantor and the Administrative Agent and their respective permitted successors and assigns, and shall inure to the benefit of the Guarantor, the Administrative Agent and the Lenders and their respective successors and assigns, except that
the Guarantor shall not have the right to assign or transfer any of its rights or obligations hereunder or any interest herein (and any such assignment or transfer shall be void) except as expressly contemplated by this Agreement or the Credit
Agreement. 

  
 3 

 SECTION 8. Successors and Assigns. Whenever in this Agreement any of the parties hereto is
referred to, such reference shall be deemed to include the permitted successors and assigns of such party; and all covenants, promises and agreements by or on behalf of the Guarantor or the Administrative Agent that are contained in this Agreement
shall bind and inure to the benefit of their respective successors and assigns. 
 SECTION 9. Administrative Agent’s Fees and
Expenses; Indemnification. (a) The parties hereto agree that the Administrative Agent shall be entitled to reimbursement of its expenses incurred hereunder as provided in Section 9.03 of the Credit Agreement. 

(b) The Guarantor agrees to indemnify the Administrative Agent and the other Indemnitees against, and hold each Indemnitee harmless from, any
and all losses, claims, damages, liabilities and related expenses (but limited, in the case of legal fees and expenses, to the documented fees, charges and disbursements of one counsel for the Indemnitees, taken as a whole, and, if necessary, one
local counsel in any applicable jurisdiction plus one additional counsel (and one additional local counsel in each applicable jurisdiction) for each of the parties taken as a whole who are similarly situated in the event any Indemnitee shall have
reasonably determined, or been advised by counsel, that there are or may be conflicts of interest, including situations in which one or more legal defenses available to it are different from or in addition to those available to any other
Indemnitee), incurred by or asserted against any Indemnitee arising out of, in connection with, or as a result of, the execution, delivery or performance of this Agreement or any claim, litigation, investigation or proceeding relating to any of the
foregoing or to any agreement or instrument contemplated hereby, whether or not any Indemnitee is a party thereto (and regardless of whether such matter is initiated by a third party or the Borrower or any Affiliate of the Borrower); provided
that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (i) are determined by a court of competent jurisdiction by final and nonappealable judgment to
have resulted from the gross negligence or wilful misconduct of such Indemnitee (or any Related Party of such Indemnitee) or, solely in the case of a claim initiated by the Borrower, material breach of such Indemnitee’s obligations under this
Agreement in bad faith or (ii) arise out of disputes solely among Indemnitees and not arising out of any act or omission by the Borrower or any of its Affiliates (other than any disputes against the Administrative Agent in its capacity as
such). 
 (c) Any such amounts payable as provided hereunder shall be additional Obligations. The provisions of this Section 9 shall
remain operative and in full force and effect regardless of the termination of this Agreement or any Loan Document, the consummation of the transactions contemplated hereby, the repayment of any of the Obligations, the invalidity or unenforceability
of any term or provision of this Agreement or any Loan Document, or any investigation made by or on behalf of the Administrative Agent or any Lender. All amounts due under this Section 9 shall be payable on written demand therefor. 

  
 4 

 SECTION 10. APPLICABLE LAW. THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND
GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. 
 SECTION 11. Waivers; Amendment. (a) No failure or delay by the
Administrative Agent or any Lender in exercising any right or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a
right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the Administrative Agent and the Lenders hereunder and under the Loan Documents are cumulative and are not
exclusive of any rights or remedies that they would otherwise have. No waiver of any provision of this Agreement or consent to any departure by the Guarantor therefrom shall in any event be effective unless the same shall be permitted by
paragraph (b) of this Section 11, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. No notice or demand on the Guarantor in any case shall entitle the Guarantor to any
other or further notice or demand in similar or other circumstances. 
 (b) Neither this Agreement nor any provision hereof may be waived,
amended or modified except pursuant to an agreement or agreements in writing entered into between the Administrative Agent and the Guarantor with respect to which such waiver, amendment or modification is to apply, subject to the consent of the
Required Lenders. 
 SECTION 12. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE
LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, ANY LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER
THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND
(B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

SECTION 13. Severability. In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a
particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties shall endeavor in good-faith negotiations to replace the invalid, illegal or
unenforceable provisions with 

  
 5 

 
valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions. 

SECTION 14. Counterparts. This Agreement may be executed in counterparts, each of which shall constitute an original but all of which
when taken together shall constitute a single contract, and shall become effective as provided in Section 7. Delivery of an executed signature page to this Agreement by facsimile transmission or other electronic means shall be as effective as
delivery of a manually signed counterpart of this Agreement. 
 SECTION 15. Headings. Section headings used herein are for
convenience of reference only, are not part of this Agreement and are not to affect the construction of, or to be taken into consideration in interpreting, this Agreement. 

SECTION 16. Jurisdiction; Consent to Service of Process. (a) The Guarantor hereby irrevocably and unconditionally submits, for
itself and its property, to the exclusive jurisdiction of the Supreme Court of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof,
in any action or proceeding arising out of or relating to this Agreement or any Loan Document, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect
of any such action or proceeding may be heard and determined in such New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or any Loan Document shall affect any right that the Administrative Agent or any Lender may otherwise
have to bring any action or proceeding relating to this Agreement or any Loan Document against the Guarantor or its properties in the courts of any jurisdiction. 

(b) The Guarantor hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection
which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement or any Loan Document in any court referred to in paragraph (a) of this Section 16. Each of the parties
hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

(c) Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section 5. Nothing in
this Agreement or any Loan Document will affect the right of either party to this Agreement to serve process in any other manner permitted by law. 

SECTION 17. Termination; Release of Guarantor. (a) This Agreement and the guarantees set forth herein shall terminate when all the
Obligations have been paid in full and the Lenders have no further commitment to lend under the Credit Agreement. 

  
 6 

 (b) In the event that (i) all the equity interests in the Guarantor are sold, transferred or
otherwise disposed of to a Person other than the Borrower or its Subsidiaries in a transaction permitted under the Credit Agreement or (ii) the Guarantor shall no long guarantee any Material Indebtedness of the Borrower, the Administrative
Agent shall, in each case, at the Borrower’s expense, promptly take such action and execute such documents as the Borrower may reasonably request to terminate the guarantee of the Guarantor hereunder. 

SECTION 18. Right of Setoff. If an Event of Default shall have occurred and be continuing, each Lender and each of its Affiliates is
hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held and other obligations at any time
owing by such Lender or Affiliate to or for the credit or the account of the Guarantor against any of and all the obligations of the Guarantor now or hereafter existing under this Agreement held by such Lender, irrespective of whether or not such
Lender shall have made any demand under this Agreement and although such obligations may be unmatured. The rights of each Lender under this Section 18 are in addition to other rights and remedies (including other rights of setoff) which such
Lender may have. 

  
 7 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year
first above written. 
  

					
	 NEWMONT USA LIMITED,

			
		 	by	 	  

		 		 	Name:
		 		 	Title:
	
	JPMORGAN CHASE BANK, N.A., as Administrative Agent,
			
		 	by	 	  

		 		 	Name:
		 		 	Title:

 EXHIBIT E 

[FORM OF] 
 MATURITY DATE
EXTENSION REQUEST 
 [Date] 
 JPMorgan Chase Bank, N.A. 

500 Stanton Christiana Road, 3/Ops2 
 Newark, DE 19713 

Fax No. (302) 634-4712 
 Attention: Rea Seth 

Ladies and Gentlemen: 
 Reference is made to the
Term Loan Credit Agreement dated as of [March 31], 2014 (as amended, supplemented, waived or otherwise modified from time to time, the “Credit Agreement”), among Newmont Mining Corporation, the Lenders from time to time party
thereto and JPMorgan Chase Bank, N.A., as Administrative Agent. Capitalized terms used but not defined herein shall have the meanings specified in the Credit Agreement. In accordance with Section 2.23 of the Credit Agreement, the undersigned
hereby requests [(i)] an extension of the [insert applicable Class] Maturity Date from [—], 20[—] to [—], 20[—], [(ii) the following changes to the Applicable Rate to be applied in determining the interest payable on [insert applicable Class]
Loans of, and fees payable hereunder to, Consenting Lenders in respect of that portion of their [insert applicable Class] Commitments extended to such new Maturity Date, which changes shall become effective on [—], 20[—]] [and] [(iii) the amendments to the terms of the Credit Agreement set forth below, which amendments shall become effective on [—], 20[—]]. 
  

					
	NEWMONT MINING CORPORATION, as Borrower,
			
		 	By:	 	  

		 		 	Name:
		 		 	Title:

  
 E-1 

Form of Maturity Date Extension Request 

 The undersigned consents to the requested amendments to the terms of the Credit Agreement and the
requested extension of the [insert applicable Class] Maturity Date. The maximum amount of the [insert applicable Class] Commitment of the undersigned with respect to which the undersigned agrees to the amendments to the terms of the
Credit Agreement and the extension of the [insert applicable Class] Maturity Date is set forth under its signature. 
  

					
	Name of Institution:
	
	  

			
		 	by	 	  

		 		 	Name:
		 		 	Title:

 For any Institution requiring a second signature line: 

 

					
			
		 	by	 	  

		 		 	Name:
		 		 	Title:

  
 E-2 

Form of Maturity Date Extension Request

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]